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Abstract 
This study aims to design and develop effervescent proliposomes that could disintegrate 
in water and liberate liposomes, and to investigate the potential suitability of liposomes 
generated for aerosolization to target paranasal sinuses. 
Novel effervescent proliposomes prepared with Soya phosphatidylcholine (SPC) and 
Dipalmitoylphosphatidylcholine (DPPC) successfully generated stable liposomes with an 
improved disintegration time of less than 5 min. Differences in lipid composition were 
found to influence liposome size and drug entrapment of the hydrophobic drug 
Beclometasone dipropionate (BDP). Mannitol-based formulations developed with 
DPPC:Chol (1:1) produced liposomes of 7.54±0.15 µm with a drug entrapment efficiency 
of 82.15±8.29%. Addition of the mucoadhesives alginic acid or chitosan to effervescent 
proliposomes made with SPC was found to hamper BDP entrapment in liposomes. 
Effervescent proliposomes produced SPC:Chol liposomes that also proved beneficial for 
entrapment of the hydrophilic drug Xylometazoline hydrochloride (XH). 
The Pari Sinus (pulsating aerosol technology) and Pari Sprint (non-pulsating technology) 
nebulizers were used for liposome delivery to a nasal cast. Choice of carrier did not affect 
the liposome’s ability to withstand shearing. A novel system of a Sar-Gel® (water 
indicating paste) coated clear nasal cast fixed to a two-stage impinger system was set up 
to analyze drug deposition within the nasal cast cavity. Sinus drug deposition with 
effervescent mannitol, DPPC:Chol formulation was observed to be highest at 48.45±2.75 
cm2 with pulsation compared to deposition of 35.52±11.11 cm2 without pulsation. Drug 
distribution studies indicated that the Pari Sinus deposited 10.47±2.9% drug, while the 
Pari Sprint deposited only 4.6±1.4%. The degree of drug loss was higher with 
conventional liposomes in the Pari Sinus nebulizer, indicating that the degree of bilayers 
disruption depended on formulation. 
  
4 
 
Table of Contents 
DEDICATION  ............................................................................................................. 1 
ABSTRACT  ............................................................................................................. 3 
TABLE OF CONTENTS ................................................................................................ 4 
LIST OF TABLES ........................................................................................................... 8 
LIST OF FIGURES ........................................................................................................ 9 
ACKNOWLEDGEMENTS ......................................................................................... 13 
LIST OF ABBREVIATIONS ....................................................................................... 15 
CHAPTER 1 INTRODUCTION ........................................................................... 16 
1.1. Nasal Drug Delivery .................................................................................................... 17 
1.2. Anatomy of Nasal Cavity............................................................................................. 18 
1.3. Para Nasal Sinuses (Sinuses) ....................................................................................... 21 
 Sinuses and sinusitis .............................................................................................21 
 Prevalence .............................................................................................................22 
 Anatomy of sinus ..................................................................................................22 
 Pathophysiology ...................................................................................................24 
 Complications of sinusitis.....................................................................................25 
 Treatment for sinusitis ..........................................................................................27 
1.4. Nasal Drug Delivery Devices ...................................................................................... 31 
 Aerosol drug delivery to sinus ..............................................................................32 
 SinuNeb™ device .................................................................................................33 
 RinoFlow™ nasal aerosol delivery device .............................................................34 
 PARI Vibrent™ device .........................................................................................34 
 Pari Sinustar ™ device .........................................................................................35 
 Pari Sinus ™ device pulsating aerosol system .....................................................36 
1.5. Liposomes .................................................................................................................... 40 
 An overview of liposomes and proliposomes .......................................................40 
 Historical background of liposomes .....................................................................42 
 Characterisation of liposomes ...............................................................................42 
1.6. Advantages and Disadvantages of Liposomes ............................................................. 44 
 General advantages of liposomes .........................................................................44 
 Liposomes as drug carriers ...................................................................................44 
 Drawbacks of liposomes .......................................................................................46 
 Proliposomes ........................................................................................................46 
 Nasal delivery of liposomes ..................................................................................48 
5 
 
 Nasal delivery of drugs through aerosolised proliposomes ..................................49 
1.7. Effervescent Formulations for Nasal Drug Delivery ................................................... 50 
 Introduction to effervescent formulations .............................................................50 
 Effervescent liposomes .........................................................................................52 
1.8. Model Drugs for the Study Couples with Effervescent Liposomes ............................. 54 
 Beclometasone dipropionate (hydrophobic) .........................................................54 
 Xylometazoline Hydrochloride (XH) ...................................................................55 
1.9. Aim of this thesis ......................................................................................................... 57 
1.10. Element of Originality: ............................................................................................ 59 
CHAPTER 2 METHOD AND MATERIALS ....................................................... 60 
2.1. Materials ...................................................................................................................... 61 
2.2. Preparation of proliposomes ........................................................................................ 62 
 Preparation of particulate-based proliposomes .....................................................62 
 Sucrose based conventional liposomes (SPC based) with hydrophobic drug ......62 
 Mannitol based conventional liposome (SPC based) with hydrophobic drug ......63 
 Mannitol based conventional liposomes (DPPC based) with hydrophobic drug..64 
 Mannitol based conventional liposomes (SPC based) with hydrophilic drug ......64 
2.3. Characterisation of liposomes ...................................................................................... 65 
 Particle size analysis: ............................................................................................65 
 Zeta potential (surface charge) analysis: ..............................................................65 
 Surface morphology using scanning electron microscopy (SEM) .......................65 
2.4. Entrapment studies ....................................................................................................... 67 
 High –performance liquid chromatography (HPLC studies) for drug 
beclometasone dipropionate (BDP) ......................................................................67 
 Separation of entrapped and un-entrapped drug ...................................................67 
 High –performance liquid chromatography (HPLC) analysis of beclomethasone 
dipropionate (BDP) ...............................................................................................68 
 High –performance liquid chromatography (HPLC) analysis of xylometazoline 
hydrochloride (XH) ..............................................................................................68 
2.5. Effervescent proliposome formulations ....................................................................... 71 
 Preparation of effervescent formulations ..............................................................71 
 Effervescent proliposome formulation (Mannitol based and Salt based) .............73 
 Disintegration time for both BDP and XH drugs ..................................................74 
2.6. Nebulization of liposomal formulations ...................................................................... 75 
 Nebulization of the effervescent formulation of drugs and liposomes for drug 
BDP ......................................................................................................................75 
6 
 
 Determination of nebulization time and generation of deliverable liposome from 
proliposomes for drug BDP ..................................................................................75 
 Determination of Aerosol size: Volume median diameter (VMD), Span, Fine 
particle fraction (% < 5.4µm) ...............................................................................76 
 Mass output of nebulized aerosols ........................................................................76 
 Determination of drug entrapment before and after Nebulization ........................76 
2.7. Nasal cast and Impinger studies ................................................................................... 78 
 Developing the novel system for Aerosol deposition analysis to sinus ................78 
 Deposition pattern analysis for nasal cavity and sinuses of the nasal cast ...........81 
 Determination of BDP deposition profile in the nasal cast- twin impinge model 
using HPLC ..........................................................................................................83 
 Data analysis .........................................................................................................84 
CHAPTER 3 CHARACTERISATION AND ENTRAPMENT STUDIES OF 
EFFERVESCENT LIPOSOMES ................................................................................ 85 
3.1. Introduction .................................................................................................................. 86 
3.2. Aims of the chapter ...................................................................................................... 89 
3.3. Results and Discussion ................................................................................................ 91 
 Characterisation of Sugar and Mannitol-based Liposomes (conventional) 
manufactured with SPC lipid ................................................................................91 
 Scanning electron microscopy (SEM) for conventional liposome .....................102 
 Effervescent BDP proliposome using SPC phospholipid ...................................103 
 SEM picture of Effervescent proliposomes (Mannitol and salt-based) ..............113 
 HPLC Results of BDP loaded effervescent Samples ..........................................114 
 Mucoadhesives in SPC formulations ..................................................................118 
 Characterisation of DPPC based empty liposomes .............................................125 
 SEM images of DPPC proliposomes ..................................................................135 
 Disintegration time of DPPC and SPC effervescent proliposome formulations 137 
 HPLC analysis of DPPC formulations................................................................138 
3.4. Conclusion for characterisation of BDP loaded liposomes with both SPC and DPPC     
liposomes ........................................................................................................................... 141 
3.5. Effervescent proliposomes formulations for xylometazoline hydrochloride (XH) with 
SPC 143 
 Characterisation of mannitol and salt-based liposomes loaded with XH ...........145 
 Size distribution of liposomes generated from mannitol and salt-based liposomes      
148 
 Characterisation of zeta potential mannitol and salt-based liposomes ...............151 
 HPLC results of effervescent samples for XH drug (sonicated) .........................154 
 Conclusion for xylometazoline hydrochloride (hydrophilic drug) .....................157 
7 
 
3.6. Conclusion for characterisation of effervescent liposomes ....................................... 158 
 
CHAPTER 4 DELIVERY OF EFFERVERCENT PROLIPOSOMES VIA 
PARI SINUS NEBULIZER ........................................................................................ 160 
4.1. Introduction ................................................................................................................ 161 
4.2. Aims of the chapter .................................................................................................... 163 
4.3. Results and Discussion .............................................................................................. 164 
 Nebulization of BDP loaded SPC liposomes using Pari Sinus nebulizer ...........164 
 Nebulization of BDP drug loaded with DPPC based formulations using Pari 
Sinus Nebulizer ...................................................................................................182 
4.4. Conclusion for nebulization ....................................................................................... 195 
CHAPTER 5 DRUG DEPOSTION STUDY IN NASAL CAST AND 
IMPINGER SYSTEM ................................................................................................ 198 
5.1. Introduction ................................................................................................................ 199 
5.2. Specific Aims ............................................................................................................. 202 
5.3. Results and discussion ............................................................................................... 203 
 Nebulization deposition patterns of BDP loaded liposomes with DPPC based 
formulations ........................................................................................................203 
 Regional drug deposition analysis of Pari Sinus and Pari Sprint Nebulizers .....212 
5.4. Conclusion ................................................................................................................. 220 
CHAPTER 6 GENERAL CONCLUSION .......................................................... 222 
6.1. General conclusions ................................................................................................... 223 
 Carrier choice for effervescent proliposomes .....................................................223 
 SPC based effervescent proliposomes (BDP and XH loaded) ............................223 
 DPPC lipid based effervescent proliposomes (BDP loaded) ..............................226 
 Xylometazoline hydrochloride loaded effervescent proliposomes .....................227 
 Nebulization of BDP loaded effervescent liposomes with Pari Sinus nebulizer 229 
 Nasal cast and impinger studies using Pari Sinus and Pari Sprint nebulizer ......232 
6.2. Future studies ............................................................................................................. 235 
CHAPTER 7 REFERENCES .............................................................................. 236 
7.1. Reference ................................................................................................................... 237 
 
 
 
 
 
 
 
 
8 
 
List of Tables 
Table 2-1: Chemicals and Supplier ............................................................................. 61 
Table 2-2: Non effervescent particulate based formulations investigated .................. 62 
Table 2-3 : Gradient profile of Xhylometazoline hydrocholordie HPLC method ........ 68 
Table 2-4: Accuracy of the HPLC method for the concentration range 5– 40 ng/ml . 70 
Table 2-5:     Precision of the HPLC method after 10 measurements of XH sample ...... 70 
Table 2-6:    Effervescent ingredients used for preparation of effervescent  
proliposomes .............................................................................................. 71 
Table 2-7:  Effervescent proliposome formulations tested for drug delivery  
to sinuses .................................................................................................... 72 
Table 3-1:  Dispersion time analysis of SPC based effervescent proliposomes ......... 110 
Table 3-2:  Drug entrapment efficiency for BDP loaded liposomes (%) in  
water and D2O ........................................................................................ 114 
Table 3-3:  Characterization of non-effervescent and effervescent mannitol-based 
liposomes made with SPC, coated with mucoadhesive alginic acid  ...... 119 
Table 3-4:  Characterization of non-effervescent and salt-based effervescent  
liposomes with alginic acid ..................................................................... 121 
Table 3-5:  Characterization of BDP-loaded effervescent liposomes coated with 
mucoadhesive chitosan ............................................................................ 124 
Table 3-6:  Size, Span and Zeta charge of liposomes made with SPC and DPPC  
as phospholipids prepared with cholesterol and cholesterol-free form  
by slurry method ...................................................................................... 130 
Table 3-7:  Disintegration Time for DPPC based effervescent proliposome 
formulations ............................................................................................. 137 
Table 3-8:  Comparison of Entrapment efficacies by HPLC for effervescent 
proliposomes with BDP formulations, with lipids SPC and DPPC......... 140 
Table 4-1:  Nebulization time and aerosol characteristics for effervescent  
formulations prepared using SPC as a lipid for nebulization  
via the Pari-Sinus nebulizer ..................................................................... 167 
Table 4-2:  Characterisation of SPC based liposomes before and after  
nebulization .............................................................................................. 180 
Table 4-3:  Nebulization data for effervescent formulations prepared using  
DPPC as a lipid using Pari-Sinus nebulizer ........................................... 185 
Table 4-4:  Characterisation of DPPC based liposomes before and after  
nebulization with Pari Sinus nebulizer .................................................... 193 
Table 5-1:  Deposition area analysis of effervescent liposomal formulations in  
the nasal cast (overall) and the sinuses region when nebulized via  
the Pari Sinus and Pari Sprint Nebulizers , n=3 ..................................... 206 
 
 
  
9 
 
List of Figures 
Figure 1-1:  Anatomy of the upper respiratory system ................................................... 19 
Figure 1-2:  Anatomy of nasal mucosa  ......................................................................... 20 
Figure 1-3:  Sinus and Sinustis Rinuses|Sinusitis|Rhinosinusitis ................................... 23 
Figure 1-4:  PARI Sinus™ Pulsating Aerosol System .................................................... 37 
Figure 1-5:  Pari Sinus nebulizer aerosol delivery to sinus with snake like aerosol 
movement ................................................................................................... 38 
Figure 1-6:  Mechanism of liposome formation ............................................................. 40 
Figure 1-7:  Structure of liposomes ................................................................................ 41 
Figure 1-8:  Types of basic structures and liposome size. .............................................. 43 
Figure 1-9:  Acceptance of liposome into cell ................................................................ 45 
Figure 1-10: Chemical structure of beclomethasone dipropionate (BDP) ..................... 54 
Figure 1-11: Chemical structure of xylometazoline hydrochloride (XH) ....................... 56 
Figure 2-1:  Blank sample assayed by the HPLC method .............................................. 69 
Figure 2-2:  Xhylometazoline hydrocholirdie sample assayed by the HPLC method .... 69 
Figure 2-3: Calibration curve of prednisolone for the concentration 0 – 50 µ/L ......... 69 
Figure 2-4:  Effervercent BDP loaded proliposome production .................................... 73 
Figure 2-5:  Pari Sinus mouth pieces that was changed in Pari Sprint  ........................ 78 
Figure 2-6:  Pari Sprint nebulizer .................................................................................. 79 
Figure 2-7:  Pari Sinus nebulizer ................................................................................... 80 
Figure 2-8:  Change in nasal cast colour is attributed to the coating with Sar 
Gel.,
 ........................................................................................................................ 
 ............. Non-effervescent DPPC:Chol liposomes using mannitol as carrier  
following nebulization via the Pari Sinus nebulizer. .................................. 82 
Figure 2-9:  The deposition pattern is demonstrated in pixels. DPPC:Chol, non-
effervescent liposomes made with mannitol carrier and nebulized  
via the Pari Sinus nebulizer. ....................................................................... 82 
Figure 2-10: Twin stage impinge and Nasal cast system to analyze aerosol  
deposition in nasal and sinus regions ........................................................ 83 
Figure 3-1:  Sucrose and mannitol based liposomes 1:5 w/w lipid to carrier  
ratio, size (µm) and span analysis of empty liposomes .............................. 92 
Figure 3-2:  Sucrose and mannitol based liposomes 1:5 w/w lipid to carrier ratio,  
zeta Potential (mV) analysis of empty liposomes ....................................... 93 
Figure 3-3:  Sucrose and mannitol based liposomes (1:5 w/w lipid to carrier ratio) 
loaded with 2.5 mol % BDP, liposome size distribution (µm) analysis  
and span of BDP loaded liposomes ........................................................... 94 
Figure 3-4:  Sucrose and mannitol based liposomes 1:5 w/w lipid to carrier ratio 
loaded with 2.5 mol % BDP, liposome zeta potential (mV) analysis  
of BDP loaded liposomes ........................................................................... 96 
Figure 3-5:  Mannitol Liposomes 1:5 w/w lipid to carrier ratio made with ethanol  
as a solvent, 2.5 mol% BDP, Liposome zeta potential (mV) of  
empty and BDP loaded liposomes ............................................................. 97 
10 
 
Figure 3-6: Mannitol Liposomes 1:5 w/w lipid to carrier ratio made with ethanol  
as a solvent, loaded with 2.5 mol% BDP. Liposome sizes (µm) and  
span analysis of empty and BDP loaded liposomes ................................... 97 
Figure 3-7:  Mannitol based liposomes 1:10 w/w lipid to carrier ratio with  
2.5 mol% BDP, liposome size (µm) and Span analysis of empty and BDP 
loaded liposomes ........................................................................................ 99 
Figure 3-8:  Mannitol based liposomes 1:10 w/w lipid to carrier ratio with  
2.5 mol% BDP, liposomes zeta potential (mV) of empty and BDP  
loaded liposomes ........................................................................................ 99 
Figure 3-9:  Mannitol based liposomes 1:10 w/w lipid to carrier ratio with  
5 mol% BDP, Liposome size (µm) and span analysis of empty  
and BDP loaded liposomes ...................................................................... 101 
Figure 3-10: Mannitol based liposoems 1:10 w/w lipid to carrier ratio, with 5 mol % 
BDP, liposome zeta charge (mV) of empty and BDP loaded liposomes .. 101 
Figure 3-11: Sucrose-based proliposomes. A typical observation of three different 
experiments .............................................................................................. 102 
Figure 3-12: Sucrose-based proliposomes particles with 2.5mol % BDP drug and 
Sucrose-based proliposomes. A typical observation of three different 
experiments .............................................................................................. 102 
Figure 3-13: Mannitol-based proliposomes particles at (50μm with 2.5mol % BDP drug 
and proliposomes ..................................................................................... 103 
Figure 3-14: Mannitol -based proliposomes particles (200μm) with 2.5mol % BDP drug 
and proliposomes ..................................................................................... 103 
Figure 3-15: Liposome size of SPC lipid based effervescent formulations,  
5 mol % BDP loaded ................................................................................ 105 
Figure 3-16: Liposome span analysis of SPC lipid based effervescent formulations, 
 5 mol % BDP loaded ............................................................................... 106 
Figure 3-17: Zeta potential (mV) analysis of effervescent liposome formulations  
of SPC lipid based formulations, 5 mol % BDP loaded liposomes ......... 106 
Figure 3-18: Location of cholesterol molecules within phospholipids bilayer. ............ 108 
Figure 3-19: Appearance of mannitol - based effervescent liposome sample (more 
foam), milky appearance .......................................................................... 112 
Figure 3-20: Appearance of Salt -based effervescent liposome sample (more foam) 
milky appearance ..................................................................................... 112 
Figure 3-21: Appearance of mannitol and salt –based effervescent liposome samples 
together, foam goes down after a while giving both the samples similar 
appearance ............................................................................................... 112 
Figure 3-22: SEM picture of salt-based sample without cholesterol ............................ 113 
Figure 3-23: SEM picture of mannitol-based sample without cholesterol .................... 113 
Figure 3-24: SEM picture salt -based sample withcholesterol ..................................... 113 
Figure 3-25: SEM picture of mannitol-based sample with cholesterol ......................... 113 
Figure 3-26: Microscopy investigation of BDP crystal sedimentation of effervescent 
Mannitol based with cholesterol formulation 40X ................................... 117 
Figure 3-27: Microscopy investigation of BDP crystal sedimentation of effervescent 
Mannitol based without cholesterol formulation 40X .............................. 117 
11 
 
Figure 3-28: Microscopy investigation of BDP crystal sedimentation of effervescent  
Salt based with cholesterol 40X ............................................................... 117 
Figure 3-29:  Size (µm), analysis of 5 mol% BDP loaded effervescent liposomes  
and non-effervescent liposomes made with DPPC lipid .......................... 127 
Figure 3-30:  Span value, analysis of 5 mol% BDP loaded effervescent liposomes  
and non-effervescent liposomes made with DPPC .................................. 129 
Figure 3-31:  Zeta potential, analysis of 5 mol% BDP loaded effervescent liposomes 
and non-effervescent liposomes made with DPPC .................................. 134 
Figure 3-32: SEM picture of mannitol based effervescent proliposomes with SPC ..... 136 
Figure 3-33: SEM picture of mannitol based effervescent proliposomes with DPPC .. 136 
Figure 3-34: SEM picture of salt - based effervescent proliposomes with SPC ........... 136 
Figure 3-35: SEM picture of salt - based effervescent proliposomes with DPPC ........ 136 
Figure 3-36: SEM picture of mannitol based non- effervescent proliposomes  
with DPPC ............................................................................................... 136 
Figure 3-37: SEM picture of mannitol based non- effervescent proliposomes  
with SPC ................................................................................................... 136 
Figure 3-38: Preparation of effervescent liposomes with hydrophilic drug. ................ 144 
Figure 3-39: Size (µm), analysis of XH loaded effervescent liposomes SPC based 
formulations before sonication ................................................................ 146 
Figure 3-40: Size (µm), analysis of XH loaded effervescent liposomes SPC based 
formulations after sonication ................................................................... 146 
Figure 3-41: Span, analysis of XH loaded effervescent liposomes SPC based 
formulations before sonication ................................................................ 150 
Figure 3-42: Span, analysis of XH loaded effervescent liposomes SPC based 
formulations after sonication ................................................................... 150 
Figure 3-43: Zeta potential, analysis of XH loaded effervescent liposomes SPC  
based formulations before sonication ...................................................... 153 
Figure 3-44: Zeta potential, analysis of XH loaded effervescent liposomes SPC  
based formulations after sonication ......................................................... 153 
Figure 3-45: Drug entrapment analysis of XH loaded effervescent liposomes  
SPC based formulations ........................................................................... 156 
Figure 4-1:  Determination of drug output (%) of SPC based liposomes from  
Pari Sinus nebulizer. ................................................................................ 177 
Figure 4-2:  Entrapment efficiency of DPPC based formulations loaded with BDP 
before and after nebulization ................................................................... 190 
Figure 5-1:  Deposition area of full nasal cavity as a percentage nebulized via Pari 
Sinus and Pari Sprint nebulizers , n=3 .................................................... 207 
Figure 5-2:  Regional drug deposition study via Pari Sinus nebulizer ........................ 218 
Figure 5-3:  Regional drug deposition study via Pari Sprint nebulizer ....................... 218 
 
  
12 
 
Acknowledgments 
First, I would to thank my supervisor Dr Abdelbary Elhissi for supporting me during the 
past three years, for his continuous encouragement and patience during the whole time. I 
would especially like to thank him for helping me, even from Qatar, and for always being 
kind. I would also like to thank my supervisor Dr Mohamed Alhnan for his scientific 
advice and knowledge and for always taking the time to help with the HPLC studies and 
nasal cast work. I am also very grateful to Professor Waqar Ahmad for his advice and 
guidance. I am grateful to Professor Jaipaul Singh for helping me from day one through 
to the end with advice and encouragement. Thank you also to Clare Altham from the 
graduate research school for making my journey at UCLAN an easy one. A hearty thank 
you also goes to the technicians and staff of UCLAN. 
I am thankful to Dr Basel Arafat for teaching me how a good senior graduate student 
should be and thank him for all the help with spray tec studies. I must also not forget to 
thank Maryam Gotly, and I was lucky to have friends who were more than just colleagues, 
Sneha Subramanian, Dr Iftikhar Khan, Sakib Yousaf, Tanem Garanti, Dr Huner Gardy 
and Dr Nozad Khurmalaee for encouraging me, sharing their liposomes knowledge and 
helping me with problem solving. I am thankful to everyone in rooms MB 226 and MB 
212 for being friendly, kind, and for all of the good times we shared. 
I would like to acknowledge Lipoid, Germany for supplying me with Soya 
phosphatidylcholine. I am also thankful to Pari GmbH, Germany for supplying me with 
the Pari SinusTM nebulizer. I would also like to thank the University of Central Lancashire 
for financial support with the international scholarship given to me that helped me to 
pursue a Ph. D. 
I especially want to thank Dr Damodaran from my undergraduate days for believing in 
me and encouraging me towards getting a Ph. D degree. I would also like to thank my 
friends Chandrika and Himaja for helping me with editing my abstracts. I am grateful to 
13 
 
my friends in the UK for not letting me feel homesick, especially Sneha and Ifthi and my 
friends Erandi, Ruma, Natasha, Susanne, Shobha, Ishanka, and Navindi for encouraging 
me. 
My deepest gratitude goes to my parents for their generous support, encouragement and 
for believing in me. I must thank my grandmother who called me daily and sent me lots 
of Sri Lankan food so I would not miss home. I would also like to thank my brother 
Gamika for encouragement. I will not forget to thank Aunty Sudarshi and Uncle 
Chandrasena for their continued support and encouragement. Lastly, I must thank my 
fiancé Chathum for being my rock throughout my Ph.D. studies — thank you for always 
listening and being patient, and for helping; without your love and encouragement this 
would have not been possible. Thank you.  
 
 
 
 
 
 
 
 
 
 
  
14 
 
List of Abbreviations 
Aeroneb Go (Mesh):  Aeroneb Go vibrating-mesh nebulizer 
Aeroneb Pro (Large mesh):  A customized (8 μm-aperture) Aeroneb Pro  
ANOVA: Analysis of variance  
AUC: Area under the curve 
BDP: Beclometasone dipropionate 
Chol: Cholesterol 
CT: computer tomography 
D2O: Deuterium oxide 
Dryness:  Status where no aerosols are seen for at least 30 s 
DLPC: Dilauroylphosphatidylcholine 
DLVO: Derjaguin-Landau-Verwey-Overbeek 
DMPC:  Dimyristoylphosphatidylcholine 
DMPG: Dimyristoylphosphatidylglycerol 
DPI: Dry powder inhaler 
DPPC: Dipalmitoylphosphatidylcholine 
DPPG: Dipalmitoylphosphatidylglycerol 
DTPA: Diethlyentraminepentaacetic acid 
EE: Drug entrapment efficiency  
EF: Effervescent  
FPF: Fine particle fraction  
GR: Glucocoritcoid receptor 
HPLC: High-performance liquid chromatography 
HSPC: Hydrogenated Soya phosphatidylcholine 
Impinger: Two-stage (twin) impinger 
LUV: Large unilamellar vesicle 
15 
 
MRI: magnetic resonance imaging  
MLV: Multilamellar vesicle 
MVL: Multivesicular liposome 
MS: Maxillary sinus 
NAMCS: National ambulatory medical care survey 
NO: Nitric oxide 
NON-EF: Non-effervescent  
NSAID: Non-steroidal anti-inflammatory drug 
OLV: Oligolamellar vesicle 
OMC: Ostiomeatal complex 
Omron (Mesh): Omron Micro Air NE-U22 vibrating-mesh nebulizer 
P:  Probability value 
Pari Sinus: Pari Sinus™ Pulsating Aerosol System 
 
Pari Sprint: Pari LC® Sprint Nebulizer attached to a PARI Turboboy®SX compressor) 
 
PC: Phosphatidylcholine 
RE: Retained entrapment 
SD: Standard deviation 
SEM: Scanning electron microscopy 
Span: (90% undersize-10% undersize)/ 50% undersize 
SPC: Soya phosphatidylcholine 
SUV: Small unilamellar vesicle 
TEM: Transmission electron microscopy 
Tm: Main phase transition temperature 
VMD: Volume median diameter (50% undersize) 
XH: Xylometazoline hydrochloride 
16 
 
CHAPTER 1  
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1.1. Nasal Drug Delivery  
The nasal drug delivery route has been exploited for decades in the administration of 
systemic drugs and has been used as an alternative to oral drug delivery (Touitou and 
Illum, 2013). The nasal route of drug delivery was conventionally used for treatment of 
local diseases such as nasal infections, congestions and allergies. However, more recently 
the nasal route has shown promising results in drug delivery of small molecular weight, 
such as polar drugs, peptides, proteins, and other drugs (Illum, 2003). Nasal drug delivery 
is a significant mode of transport for drugs that need a rapid onset of action, such as in 
case of crisis treatment in  pain management (Illum, 2002; Pires et al., 2009).  
There are number of advantages for the use of nasal drug delivery, such as increased levels 
of drug absorption, fast therapeutic effect, non-invasiveness and the provision of a large 
surface area for drug absorption. Moreover, the permeable endothelial membranes in the 
nose and the rich blood flow within the nasal mucosa may provide a unique opportunity 
for a wide range of drugs to be absorbed and escape the first pass hepatic metabolism 
(Pires et al., 2009; Türker et al., 2004). High total blood flow per cm3, easy accessibility, 
and possibility of drugs to be delivered straight to the brain along olfactory nerves also 
make the nasal drug delivery an attractive substitute to the parenteral route (Illum, 2002; 
Ridley et al., 1995). 
Other benefits, such as the need for lower doses than traditional oral formulations, help 
decrease the side effects caused by the delivery of the drugs directly into the blood stream. 
Drugs delivered via nasal administration can either act locally within the nose, such as 
nasal decongestants, or systemically, such as anti-migraine drugs, hormonal treatments, 
etc. (Jadhav et al., 2007). Nasal delivery is also a needle-free (i.e. non-invasive) approach 
for drug administration (Djupesland, 2013). Nasal delivery may improve patient 
compliance compared to the parenteral route of drug administration, offering avoidance 
of harsh conditions (e.g. unsuitable pH levels) such as that of the gastrointestinal tract. 
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Respiratory infections such as influenza (nasal influenza vaccine from Berna Biotech 
(CH)) are now being tackled through the use of nasal cavity vaccinations (Illum, 2002). 
Initiation of secondary immune responses at a distant mucosal site and direct delivery of 
vaccines to lymphatic tissue are also positives of the nasal drug delivery (Jadhav et al., 
2007). 
Despite the number of advantages there are a few limitations of nasal drug delivery, 
mainly the epithelium barrier, rapid mucociliary clearance, mucosal barrier, and 
enzymatic activity. Poor contact of formulations in nasal mucosa is one of the major 
drawbacks of nasal delivery. Nasal mucociliary clearance is principally responsible for 
the lack of absorption of certain drugs, and the resident time of the drugs are furthermore 
reduced due to mucociliary clearance (Marttin et al., 1998). Nasal drug delivery is also 
hampered during a diseased condition, resulting in impaired absorption (Jain, 2008). 
Diseased conditions in the nose could amplify or diminish mucociliary clearance or 
absorption of drugs. This could have significant consequences for drugs with narrow 
therapeutic index; therefore, lack of reproducibility can be observed in nasal delivery. 
Nasal drug delivery might be inconvenient, leading to nasal irritation (Rahisuddin et al., 
2011). Poor delivery of the drug across the nasal epithelium is also one of the limitations 
of nasal drug delivery (Davis and Illum, 2003).  
1.2. Anatomy of Nasal Cavity 
The nostrils and the external nose consist of long dual chambers (one third of nasal 
cavity), which are 5 cm high and 10 cm long, while the total surface area of the nasal 
cavity is approximately 150 cm2 with a total volume of 15 ml (Baroody, 1997). The 
primary function of the nasal cavity is to warm, filter air, and give moisture to the air 
entering the lungs, while filtering out the dust and small particles from entering the body 
by trapping it in hair and a mucus layer (Lang, 1989). Both nasal cavities have a septal 
wall and lateral wall; the vertical fin (nasal septum) divides the nasal cavity in two. 
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Temperature and humidity of the air is regulated by inferior, middle, and superior 
turbinates, which also dominates a major part of the nasal cavity (Figure 1-1). 
 
 
Figure 1-1: Anatomy of the upper respiratory system (source:  http://antranik.org/the-
respiratory-system/). 
 
The inferior, middle (and superior) meatus are located under and lateral to the turbinates; 
inferior and middle meatus function as the opening to the nasolacrimal duct and the 
paranasal sinuses (Mygind and Dahl, 1998). The small orifices called ostia connect the 
paranasal sinuses to the nasal cavity. The nasal cavity contains columnar epithelial cells, 
which are ciliated or non-ciliated (Figure 1-2). Columnar cells also have microvilli, which 
increases area of absorption. Cilia beats 700–1000 times per minute,  transporting mucus 
containing trapped particles to the throat (Clarke and Pavia 1980).  
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Figure 1-2: Anatomy of nasal mucosa (source: Clarke and Pavia 1980). 
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1.3. Para Nasal Sinuses (Sinuses) 
 Sinuses and sinusitis 
Sinuses are also referred to as paranasal sinuses, which are pockets or cavities of air 
present in the cranial bones. They connect the nose and the facial part of the skull, which 
helps air pass and mucus drain. Sinuses are lined with mucus; they filter and humidify the 
air and improve vocal resonance (Fagnan, 1998). The hollow pockets of sinus lighten the 
weight of the skull (the head). Vital functions of our heads are protected by the air pockets 
in sinuses in trauma situations by acting as crumple zones. The ostiomeatal complex acts 
as the common drainage pathway for frontal, maximal sinuses, and anterior ethmoid (Rao 
and El-Noueam, 1998).  
Paranasal sinuses are of a complex nature due to their range of pneumatization and bony 
variants (Ogle et al., 2012). Inflammation of the paranasal sinuses is known as sinusitis.  
Sinusitis is caused by several reasons, such as allergies, infections (bacterial, viral, or 
fungal), or autoimmune diseases. Sinusitis can be divided into four groups according to 
the duration of the disease. These are acute (less than four weeks), sub-acute (four to eight 
weeks in duration), chronic sinusitis (symptoms lasting longer than eight weeks), and 
recurrent acute sinusitis (three or more episodes per year lasting more than two weeks) 
(Slavin et al., 2005). The infection may be caused by bacteria such as Streptococcus 
pneumoniae, Haemophilus influenza or Moraxella catarrhalis for acute sinusitis (Leung 
and Katial, 2008) while Staphylococcus aureus (Brook et al., 2008) with a combination 
of aerobic and anaerobic bacteria  (Brook and Frazier, 2005) was detected in chronic 
sinusitis. 
Breathing is vital for all animals, and the nasal pathway is the main airway. Air volume 
of 20-30 l/min is inhaled and exhaled during sleep, rest, and mild exercising (Cole, 1996). 
Paranasal cavities range from 5–30 ml (Tarhan et al., 2005). Ostia is the opening that 
connects the sinus to the nasal passage; it ranges from 1–3 mm in diameter and has 10–
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15 mm length narrow ducts, that  help the paranasal cavities transit the nasal passage 
(Tarhan et al., 2005) 
 Prevalence  
Diagnosing sinusitis from common respiratory infections such as the common cold and 
influenza occurring from bacterial infections is challenging due to both conditions sharing 
similar symptoms. However, in 1990, antibiotics were prescribed for 92% of patients  in 
the United Kingdom, and 85–98% of patients in the United States for upper respiratory 
and sinus infections (Ashworth et al., 2005; Hickner et al., 2001). In the United Kingdom, 
in 2002–2003, 73000 beds were taken by patients having chronic sinusitis).    
A summary of health statistics of US adults reported in 2012 in their national health 
survey that 28.5 million (12.1%) of non-hospitalized adults were diagnosed with sinusitis 
(Vital and Health Statistics, series 10, number 260, 2012). In 2009, the National 
Ambulatory Medical Care Survey (NAMCS) reported 11.7 million patients being 
diagnosed with chronic sinusitis (Vital and Health Statistics, series 10, number 260, 
2012). 
 Anatomy of sinus  
Paranasal sinus development is closely linked to facial bone development. Initially, 
sinuses develop as evaginations of mucosa in the third and fourth months of foetal 
development (Anderhuber et al., 1992). By the age of 12, the child's sinuses are developed 
to adult size (Fujioka and Young, 1978). Rapid development in stages of the maxillary 
sinuses is observed between the ages of 2–3 years and then a slower development is 
observed until the age of 7–8 years (Eggesbø, 2006). Kaliner et. al., in 1997 stated that 
the paranasal sinuses’ final structure is as exclusive as a set of finger prints (Kaliner et 
al., 1997). 
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Sinuses could be divided into four pairs:   
 Frontal sinuses, which are situated just above the eyes in the centre of the forehead on 
both right and left sides.  
 Maxillary sinuses, which are positioned behind the cheekbones, near the upper jaws. 
Maxillary sinuses are considered the largest of the sinuses.  
 Sphenoid sinuses, which are located in the sphenoid bone. Sphenoid sinuses are in close 
proximity to the optic nerve and pituitary glands.  
 Ethmoid sinuses, which are a collection of 6–12 small cavities independent of the nasal 
cavity. These sinuses are not single sacs like the other sinuses.  
 
 
 
  
Figure 1-3: Sinus and sinustis rinuses|sinusitis|rhinosinusitis. (Source: 
http://healthstalk.blogspot.co.uk/2012/01/sinusitis.html) 
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 Pathophysiology  
Sinusitis (Figure 1-3) is a condition when sinus drainage is obstructed and normal mucus 
transport is reduced with diminished ventilation in the sinuses. Inflammation of the 
sinuses usually leads to obstruction of sinus ostium, resulting in reduced mucus drainage.  
Bacterial infections in the sinuses lead to a decrease in cilia beating down to 300 beats 
per min-1; normal ciliary beat frequency is 1000–1500 beats per min. Ciliated columnar 
cells (30%) experience metaplastic changes to mucus secreting goblet cells during an 
inflammation. Sinus blockage results in an environment in which bacteria could thrive, 
due to reduced pH and diminished oxygen tentions (Loevner, 2008). 
There are number of factors predisposing people to sinusitis, such as allergic and non-
allergic rhinitis, anatomic variations similar to septal deviation, choanal atresia, dental 
infections, trauma, immunodeficiency (e.g. IgA deficiency), adenoid hypertrophy, 
hormonal conditions and factors, nasal dryness, upper respiratory infections, inhalation 
of irritants, and acquired immune deficiency (Eggesbø, 2006; Tomassen et al., 2011; 
Winstead, 2003). Acute sinusitis is the most common form of upper respiratory tract 
infections, which are usually viral in origin. Acute sinusitis can also be caused by a 
blockage of ostia. Maxillary and anterior sinuses in particular are the most common 
sinuses seen in both acute and chronic sinusitis (Hamilos, 2000). Inflammation of the 
sinuses leads to thickening of mucosal lining, hyperplasia, and oedema. Normal 
thickening of a healthy sinus is known to be around 4 mm. Mucosal thickening of 
maxillary sinuses is often observed with asymptomatic patients (Eggesbø et al., 1999; 
Zinreich et al., 1988).  
Ciliated cells in sinuses move mucous against gravity due to lateral and inferior 
positioning of the sinuses. Cilia in each of the cells beat in different diffractions in each 
sinus, resulting in mucosa being moved from sinuses to the choanae, with a unique 
mucous flow pattern (Hilding, 1966). When different flow patterns of different sinuses 
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meet, stagnation occurs; long immobilization will also result in sinusitis, especially in 
ostiomeatal complex (OMC). Mechanical obstructions of OMC also interferes with 
mucociliary clearance (Eggesbø, 2006).  
The recruitment of inflammatory mediators and production of mucosa is increased by 
nasal mucosa in response to viruses, which leads to future congestion and swelling. 
Interleukin-1 beta, Interleukin-6 and Interleukin-8 play a major role in acute sinusitis. 
Interleukin-3 supports inflammatory mediators in chronic sinusitis (Rudack et al., 1998). 
Nitric oxide (NO) is observed in high concentrations in the sinuses, produced by epithelial 
cells in the sinuses. NO functions by the sterilization of sinuses and improving ciliary 
motility. Decreases in nitric oxide amounts are observed in sinusitis (Jain et al., 1993). 
Chronic sinusitis is triggered by mucosal swelling, loss of cilia, sinus obstruction, and 
bacterial and viral infections. In addition, cystic fibrosis, ciliary dyskinesia, and chronic 
conditions of sinusitis are due to impaired mucociliary clearance. Asthma, rhino-sinusitis, 
and other upper respiratory diseases may also lead to chronic sinusitis (Bachert et al., 
2006).  
 Complications of sinusitis  
Treatment is given to relieve the patient’s pain and pressure in the sinuses and to clear up 
the infection. Treatment helps to improve the discharge of mucus and decrease the sinus 
swelling. Preventing permanent damage to the tissue lining of the sinus and scar tissue 
formation is also one of the main objectives of sinusitis treatment. If not treated, acute 
sinusitis could cause toxic shock syndrome and acute local effect. Cellulitis, proptosis, 
chemosis, and ophthalmoplegia can also be caused by acute sinusitis. Furthermore, orbital 
cellulitis, subperiosteal abscess, and orbital abscess are also complications that can arise 
from acute sinusitis. Acute sinusitis often leads to flare-ups of asthma. Acute sinusitis 
sometimes occurs along with ear infections.  
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The main three areas that result in complications of the sinuses are in the orbital (60–
75%), intracranial (15–20%), and bony area (5–10%) of the sinuses. The orbital area of 
the sinuses are the most commonly involved complication site (Bailey et al., 2006). 
Preseptal cellulitis, orbital cellulitis, subperiosteal abscess, orbital abscess, and cavernous 
sinus thrombosis all occur in the orbital site, sometimes even co-currently (Hassan and 
Ramadan, 2014) (Agayev and Yilmaz, 2008). The intracranial area of sinus complication 
is most commonly observed in male teenagers rather than children, due to their developed 
frontal and sphenoid sinuses. Meningitis, cavernous, sagittal, venous sinus thrombosis, or 
intracerebral, subdural, and epidural abscess are the major intracranial complications 
observed as a consequence of sinusitis (Achilles and Mösges, 2013; Bailey et al., 2006; 
Hicks et al., 2011; Ramachandran and Ramachandran, 2009). Bony sinus complications 
are relatively rare (Raja et al., 2007). There are reports of only 20–25 cases of bony sinus 
complications in the post-antibiotic era, with  reports of 50 paediatric cases or less in 10 
years of study (Blumfield and Misra, 2011). Furthermore, osteitis and osteomyelitis are 
also bony sinus complications that arise from dental issues. Pott’s puffy tumour also often 
results from inflammation of the frontal sinuses and is also a bony sinus complication.   
Long-lasting sinusitis that persists for more than eight weeks can lead to chronic sinusitis. 
Superimposed acute sinusitis is the most common complication of chronic sinusitis. 
Nasopharynx pus causing adenoiditis is seen commonly in paediatric chronic sinusitis 
patients. A high percentage of paediatric patients suffer from pus in the nasopharynx, 
which can later develop into secondary serious or purulent otitis media. When acute 
sinusitis is not resolved, it can lead to mucosal hyperplasia and possible development of 
nasal polyps. Chronic sinusitis can also lead to meningitis, an infection that spreads to the 
lining of the brain causing vision problems through infection of the eye sockets that could 
lead to permanent blindness or reduced vision. In children, dacryocystitis and laryngitis 
are also common complications of chronic sinusitis. Untreated chronic sinusitis can even 
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lead to life-threatening conditions such as cystic fibrosis (Sharma et al., 1994). If not 
treated, sinusitis could cause the need for surgery to drain the mucus (Sharma et al., 1994). 
If the infection is not treated at an early stage, it could disseminate further to the bones 
and brain, leading to osteomyelitis, infection of the eye socket, blood clot, and brain 
infection (Rosenfeld et al., 2007). 
 Treatment for sinusitis  
1.3.6.1. Topical and systemic therapy for sinusitis treatment  
Topical decongestants, oral decongestants, intranasal corticosteroids, topical steroids, 
antibiotics, nasal saline, antihistamines, changes in diet, topical cromolyn, or mucolytics 
are used for relieving the symptoms of sinusitis. Nasal saline wash and steam inhalation 
are also used, along with other treatments to help humidify dry secretions, reducing 
inflammation of the mucosal lining and minimizing viscosity of the mucus. Physicians 
often suggest some of the above-mentioned non-drug therapies, along with antibiotic 
therapies for tackling sinusitis. These adjunctive therapies, even though never 
investigated for their effectiveness, are believed to help recover ciliary functions, 
decrease inflammations, and improve sinus draining (Mabry, 1993; Zeiger, 1992).  
Decongestants to relive nasal congestion are available in the form of tablets, nasal sprays, 
nasal drops, and liquids. Decongestants work by reducing the inflammation of the mucous 
membrane by constricting the blood vessel in the mucous membrane. The reduced blood 
supply results in a decrease of congestion and blockage. Nasal decongestants do not cure 
sinusitis but offer temporary relief of the symptoms (Lalwani, 2011). Nasal decongestants 
mainly affect the nasal blood supply, unlike oral decongestants, but a drawback of nasal 
decongestants is rebound congestion. Long-term use of nasal decongestants can result in 
swelling of the sinus membranes as the decongestants wear off, leading to additional 
congestion. Nasal and oral decongestants act on alpha1 and alpha2 adrenoceptors (Malm, 
1994). 
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First-line treatment for acute sinusitis is often antibiotics, usually amoxicillin (for two 
weeks) or amoxicillin-clavulanate (AugmentinTM). Antibiotics prescribed for the 
treatment of sinusitis typically cover S. pneumoniae, H. influenzae, and M. catarrhalis. 
Antibiotics targeting beta-lactamase inhibitors are also used for H. influenzae and M. 
catarrhalis (Sinus and Allergy Health Partnership, 2000). Patients who are allergic to 
Beta-lactams usually obtain prescriptions for trimethoprim-sulfamethoxazole 
(BactrimTM), clarithromycin (BiaxinTM), or azithromycin (ZithromaxTM) as a substitute. 
When first-line treatment is not showing promising results, an alternative broad spectrum 
of antibiotics is prescribed. The third to fifth most common diagnosis with antibiotic 
prescriptions in Nordic countries was for sinusitis  (André et al., 2002).  It was estimated 
that 15–21% of antibiotic prescriptions in outpatient care were for sinusitis patients (The 
Cochrane Collaboration, 1996).  
Chronic sinusitis treatment usually involves broad-spectrum antibiotics (four to six 
weeks), and topical intranasal steroids (Spector et al., 1998). Antibiotics used for the 
treatment of chronic sinusitis are amoxicillin-clavulanate, cefpodoxime proxetil, 
moxifloxacin, and levofloxacin, to cover organisms that are observed in acute sinusitis, 
but also cover Staphylococcus species and anaerobes. Short courses of oral steroids are 
also used for extreme cases of mucosal thickening and congestion treatment (Fagnan, 
1998). However, according to Fagnan (1998), treatment with antibiotics for chronic 
sinusitis often leads to limited benefit. 
1.3.6.2. Surgical treatment for sinusitis  
Surgical treatment for sinusitis is considered when all other medical therapy fails. 
Surgical treatment is also carried out in the case of endocranial complications, septic 
complications, orbital complications, and malignant growth. (Bachert et al., 2003). 
Sinus surgery is considered along with a nasal endoscopy, and ostiomeatal complex along 
with an endoscopically guided culture. Sinus surgery helps to clear the sinus of chronic 
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infections, edema, and polyps. Unlike older days, where open surgery was performed for 
chronic sinus diseases, now a much safer and simpler operation of endoscopic sinus 
surgery is performed with local anaesthesia (Slavin et al., 2005). Aspiration is also one of 
the simpler surgical treatments for sinusitis. Drainage is used for acute frontal sinusitis 
treatment, resorting to mucociliary clearance and improving ventilation of the sinuses 
(Stammberger, 1994). The most commonly practiced sinus surgery is functional 
endoscopic sinus surgery.  Affected parts of mucosa are separated, which helps drainage 
and ventilation when the wounds are healed. Sense of smell, mucociliary clearance and 
nasal respiration, and quality of life overall are improved in the patient’s post-surgery.  
However, surgery does have drawbacks of potential injuries to orbits and dura 
(Cumberworth et al., 1994). 
1.3.6.3. Difficulty in targeting paranasal sinuses  
Current oral and intravenous antimicrobials and corticosteroids have significant side 
effects. A high number of sinus surgeries is an indication of need for better treatment 
methods and delivery methods of oral, topical, and systemic drugs (Schappert and 
Rechtsteiner, 2008). Therefore, direct delivery of drugs to the site of action has been 
considered. Topical drug delivery at the nasal cavity and sinuses has many advantages, 
namely acting straight on the site of inflammations, avoiding systemic side effects with 
high concentrations of drug being localized at the target area, and an increased rate of 
response to therapy.  
Nasal irrigation, douches, neti pots, and different saline concentrations (isotonic and 
hypertonic) are often used for removal of sinusitis causing factors such as pollutants, 
irritants, inflammatory products, bacteria, mucus, and antigens (Achilles and Mösges, 
2013). However, these procedures result in a high volume and high pressure (leading to 
shearing forces for removal of mucous and inflammatory products from the sinuses). This 
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mechanism is not appropriate for drug delivery where longer mucosal contact, local 
absorption, and minimal clearance is expected for better drug delivery.  
Topical drug delivery to a sinus is difficult as paranasal sinuses are hollow cavities that 
are non-ventilated and perfused. Sinuses are also highly protected by a particular filtration 
process (Sahin-Yilmaz and Naclerio, 2011). In vivo and in vitro studies have shown that 
even though paranasal sinuses are poorly ventilated there is low deposition of the 
nebulized drug in the affected areas. Therefore, finding improved methods to increase the 
drug delivery to the sinuses is important for the treatment of chronic sinusitis (Moeller et 
al., 2009). Furthermore, flow and pressure fluctuation between nasal passage and the 
sinus cavity increases airflow, therefore aiding in ventilation of the sinuses (Krüner et al., 
2013). 
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1.4. Nasal Drug Delivery Devices  
Drug delivery to the sinuses through aerosols offers many advantages over the invasive 
means of drug delivery and oral drug delivery. Corticosteroids and antibiotics have been 
delivered to the nasal cavity through various methods, such as nasal drops, nasal sprays, 
nebulized aerosols, and irrigation, but not all of these methods are suitable for targeting 
the sinuses. Due to the location of the sinuses, nasal drops, nasal sprays, or irrigation are 
not necessarily suitable for drug delivery. However, nebulization has recently been 
exploited for drug delivery to the sinuses with results indicating possible success. Nasal 
irrigation is a suitable method for the removal of inflammatory cells, reducing 
inflammation, increasing mucociliary clearance, and even drug delivery post-sinus 
surgery. Irrigation as described previously is not suitable for drug delivery before surgery 
(Albu, 2012). 
Nasal spray pumps generate large droplets of 50–100 µm in diameter with deposition of 
70–150 µl per puff (Albu, 2012). Currently, different formulations of saline, 
decongestants, mucolytics, and steroids have been used along with nasal sprays. 
However, nasal sprays do not cause appreciable deposition of formulation on the sinuses. 
A major part of deposition upon using nasal sprays is the anterior part of the nose; these 
sprays are not suitable for sinus targeting (Möller et al., 2011).  
Another nasal drug delivery device on the market is the breath-actuated bidirectional 
delivery devices (OptiMist™; OptiNose AS, Oslo, Norway). OptiMist™ has a breath–
actuation mechanism along with a conventional spray pump that gives out droplets around 
the size of 43 µm. Comparison of OptiMist™ with nasal sprays has demonstrated that 
OptiMist™ causes a large deposition of the drug in the upper posterior sector (in the 
middle meatus and sinus ostia) and lower depositions in the anterior segments of the nose 
(Djupesland et al., 2006).  
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Medical nebulizers are inhalation devices that deliver aerosols from an aqueous 
formulation. Characteristics of aerosols generated are dependent on the operating 
principle and design of the nebulizer as well as the properties of the formulation. There 
are three main types of medical nebulizers: air jet, ultrasonic, and vibrating-mesh 
nebulizers. Small droplet sizes generated by nasal nebulizers have been observed to be 
superior for drug deposition when compared to spray pumps (Suman et al., 1999). 
 
 Aerosol drug delivery to sinus 
For efficient aerosol transport to the sinus, it is required that aerosols are deposited in the 
posterior nasal cavity. Recently, few nasal devices have been developed to produce 
different size aerosols (in diameter) with different flow patterns, such as ‘pulsating’, 
‘sonic’, ‘acoustic’, as well as utilizing pressure differences to target the sinuses.  Aerosols 
that can penetrate to the posterior nasal cavity is of an aerodynamic diameter below 5 μm 
(ICRP Publication 66, 1994). In conditions such as sinusitis the normal deposition of drug 
within the nose is blocked. Therefore, the flow rate should be regulated at moderate level. 
New technologies such as ViaNase (Kurve Technology Inc., Lynnwood, WA, US) and 
the OptiNose (OptiNose AS, Oslo, Norway) do not use a pulsating drug delivery system, 
but may promote the awareness for the need of new aerosol delivery devices with more 
efficient mechanisms to maximize deposition in the nasal sinuses. Using conventional 
nasal devices, deposition in the nasal sinuses is unlikely due to the large size of the 
particles generated (>10 μm). This is further proven due to the lack of ventilation in the 
sinuses, and studies done with nasal casts using these devices  (Möller et al., 2008; Sato 
et al., 1981).  
Pulsating aerosol technology was introduced with the use of  resonance conditions for gas 
exchange in secondary spaces and surrounding spaces; this was first suggested by 
Hermann Von Helmholtz (Keller et al., 2010). Guillerm and colleagues discovered the 
basics of pulsating aerosols in studies for sinus drug delivery (Guillerm et al., 1959). Kauf 
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studied model cavities and the aerosol’s ability to pass to secondary spaces such as sinuses 
cavities. Human cadavers and a nasal cast were used by Sato and co-workers, as well as 
Hyo and co-workers, for continuations of Kauf's studies, confirming deposition 
efficiencies to be between 1–4% (Kelleret al., 2010). The first commercial pulsating 
aerosol technology produced was developed by La Diffusion Technique Francaise 
(Atomisor Automatic Manosonique Aerosol, DTF, Saint Etienne, France).  
 SinuNeb™ device 
The SinuNeb™ (PARI Respiratory Equipment, Inc., Midlothian, VA) is a passive 
diffusion nebulizer producing smaller, particle-sized aerosols delivered in a constant 
direction with a slower velocity. Aerosols generated by SinuNeb™ are around 3 μm in 
diameter and are used for the delivery of antibiotics and anti-fungal formulations to the 
sinuses (Albu, 2012). Aerosols are transported to the sinuses through a hollow tube with 
two perforations at one end, through which the liquid is aspired transnasally. In spite of 
that, a review by Aetna (2002, p. 593) suggests an insufficient amount of clinical studies 
are seen to support the claims of the manufacturer, which state that the drug can be 
nebulized directly into the lining of the sinuses to increase the rate of response, 
effectiveness, and reduction of infection. Manufacturers of SinuNeb™ also claim fewer 
side effects are observed by using SinuNeb™ when compared to side effects seen with 
oral delivery or intravenous administration.  
A study published by Schuschnig et al. (2009) compares the nebulization efficiency of 
the AeroNeb Go (Aerogen, Galway, Ireland), the SinuNeb™ (Sinus Pharmacy, 
Carpinteria, CA), the Atomisor AMSA and Atomisor Sonique Box (both DTF, St. 
Etienne, France), and the VibrENT™ prototype (PARI Pharma, Munich, Germany) to the 
sinuses using a novel nasal cast model developed by PARI. The study concluded that only 
VibrENT™ (in pulsating mode) deposited a significant amount of drug (19% of the label 
claim = LC) to the sinuses. Standard nebulizers only managed to deliver less than 0.06% 
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of the drug to the artificial nasal cast model developed by PARI Researchers, this  lower 
depositions explain that pulsation and pressure fluctuations constitute to the key principle 
behind drug deposition in the nasal sinuses (Schuschniget al., 2009).  
 RinoFlow™ nasal aerosol delivery device 
The RinoFlow™ nasal aerosol delivery device (Respironics, Inc., Cedar Grove, NJ) 
deposits aerosols in the size range of 20–30 μm in a controlled flow directly into the 
sinuses (Ranade et al., 2003). Volunteers were used in a study where technetium Tc99m 
was nasally administrated by the subjects using the Politzer Manoeuvre. Three out of the 
five subjects had inconsistent deposition in the frontal and maxillary sinuses. The sample 
size was too small to recognize the significance and the healthy volunteer group did not 
have blockages; therefore, future investigations should involve patients with sinusitis. 
However, Negley et al. (1999) have concluded that the results are promising (Negley et 
al., 1999). Another study has compared the distribution of nasal irrigation isotonic 
solution on eight volunteers using three irrigation techniques. The deposition was 
analyzed using computer tomography imaging. Three irrigation techniques, positive-
pressure irrigation (Sinus Rinse™), negative-pressure irrigation (inhalation through 
sniffing), and passive diffusion (RinoFlow™) were tested. In that study, the RinoFlow 
nebulizer was found unsuccessful in ethmoid penetration. However, ethmoid penetration 
was observed in the other two cases (Albu, 2012).   
 PARI VibrENT™ device 
The PARI VibrENT™ is a modified electronic nebulizer that generates aerosols through 
a perforated vibrating membrane. The nebulizer operates using the PARI eFlow 
technology with an amendable pulsation (flow pulsation at 25 Hz) to generate aerosols 
with a diameter of 3 μm and a flow rate of about 3 l/min (Kelleret al., 2010). Three healthy 
male non-smoking volunteers were recruited for the study by Keller et al. (2010). 81mKr-
gas gamma camera imaging along with 99mTc-DTPA aerosols were delivered through a 
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Pari Vibrent nebulizer to analyze the deposition of the aerosol solution by pulsating air 
flow and nasal pump spray (Kelleret al., 2010; Möller et al., 2010). Results indicated 
successful sinus deposition using the Pari Vibrent, while no deposition occurred into the 
sinuses using the nasal pump. Resident time of the drug was also observed to be threefold 
longer with the Pari Vibrent system, showing 71±17% total  deposition in the nasal cavity 
and 6.5±2.5% deposition in the sinuses (Möller et al., 2010).  
Another study investigates the deposition and nebulization effect using a novel nasal cast, 
developed by PARI GmbH (Munich, Germany). Budesonide solution was nebulized and 
deposition was measured by a high-performance liquid chromatography (HPLC). 15.9% 
was deposited in the paranasal cavity while 57.7% of the total volume was deposited in 
the nasal cavity. Deposition in each sinus cavity ranged from 0.1 to 7%. The highest 
deposition was observed in the ostium diameters from 1.5 to 3 mm  (Schuschnig et al., 
2008).  
 Pari Sinustar™ device 
The Pari SinustarTM is an FDA-approved device used for aerosol delivery to the upper 
respiratory airways and for the treatment of sinusitis. The Pari SinustarTM produces 
aerosols with a size of 2.9 µm and total output of 180 ml/min. The total percentage of 
aerosols under the size of 5 µm are around 79% (Scheinberg and Otsuji, 2002). Pari 
SinustarTM was compared to Ayr, Afrin, and Zicam nasal spray devices to investigate the 
deposition profile in sinuses (Kundoor and Dalby, 2010). The study indicated that the 
inhaled flow rate did not have a significant effect on the deposition pattern, while the 
Afrin nasal spray and Pari SinustarTM nebulizer did have a significant difference in 
deposition when compared; the nebulizer covered a greater deposition area compared to 
the nasal spray. The Pari SinustarTM nebulizer deposited aerosols on a greater surface 
compared to the spray pumps investigated in the study.  
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 Pari Sinus ™ device pulsating aerosol system  
The Pari Sinus™ Pulsating Aerosol System (PARI GmbH, Starnberg, Germany) (Figure 
1-4) was developed in Germany in 2003 by PARI GmbH. The Pari Sinus nebulizer is 
supplied with a pulsating aerosol system that provides a vibrating pulse. The aerodynamic 
size of the aerosol droplets generated by this nebulizer results in direct delivery to the 
sinuses. ICRP Publication 66 (1994) states that the aerodynamic diameter of aerosols 
should be below 3 µm with a moderate flow rate to reach the posterior nasal cavity. Pari 
Sinus is currently being marketed for the treatment of upper respiratory airway diseases 
such as chronic sinusitis, rhinitis, and nasal allergies.  
A Pari Sinus consists of a Pari LC star jet nebulizer, with a pulsation of 44 Hz (Lass et 
al., 2006). This nebulizer has been reported to deposit a significant proportion of the 
aerosolized medication in the sinus cavities when the jet flow was set up at 6 l/min and 
the temperature of the surrounding environment was 23 °C. The ‘snake-like’ movement 
of the aerosols flow helps the aerosols reach the hidden pockets of the sinus cavities 
(PARI Respiratory Equipment, Inc., 2012) (Figure 1-5).  
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Figure 1-4: PARI Sinus™ Pulsating Aerosol System (PARI GmbH, Starnberg, 
Germany). (Source: 
http://www.medema.co.uk/pari_sinus_nebuliser__efficient_medication_deposition
_in_the_nasal_cavities) 
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The Pari Sinus nebulizer is used for delivery by attaching the LC® Sprint Sinus Nebulizer 
with nasal adapter to one nostril at a time while keeping the other nostril closed with a 
nose plug. During the delivery, the soft palate should be kept closed. This directs the 
aerosols to the second output nostril from the delivery nostril. These protocols help 
aerosols to be deposited in the lung more efficiently. To ensure that optimal pressure 
transduction to the sinuses is achieved, it is vital that the output resistor and closure of the 
soft palate is done (Keller et al., 2010; Möller et al., 2011; 2010) 
 
 
The Pari Sinus nebulizer has been compared to the nasal spray in order to understand its 
capacity of  aerosol deposition into the nasal sinus cavities (Schuschnig et. al, 2006). It 
was observed that significantly higher drug doses were deposited by the use of Pari Sinus 
compared to nasal sprays. It is expected that due to greater deposition, less medication 
would be required, possibly resulting in reduced side effects.  
Figure 1-5: Pari Sinus nebulizer aerosol delivery to sinus with snake-like aerosol 
movement. (Source: 
http://www.pari.com/products/sinus/product/detail/info/sinus_pulsating_aerosol_
system.html) 
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The efficiency of Pari Sinus was further explored by Valentine et al. (2008) where the 
sinonasal penetration of nasal douching and the Pari pulsed nebulizer were tested on a 
highly dissected cadaver model. Methylene blue stained solutions were used in the 
nebulizers and douching and sinuses deposition was observed. Significant increases in 
the intensity of the deposition pattern, percentage, and circumference of the stain were 
noted for the Pari Sinus nebulizer, compared to the nasal douching. Regular ethmoid sinus 
staining was observed by the Pari Sinus, while the other sinuses were variably reached 
when sinuses were analyzed individually for deposition. The  frontal sinus had a 
deposition of  43%; maxillary sinus 46%, and sphenoid 54% (Valentine et al., 2008).   
Five healthy volunteers were used to investigate sinus ventilation using 81mKr-gas gamma 
camera imaging and 99mTc-DTPA radiolabel aerosols in order to investigate retention 
time over a 24-hour period. Nasal pump sprays and pulsating aerosols were used. Results 
indicated no deposition when the nasal pump was sprayed in the sinuses. Deposition was 
around 6.5% for the pulsating airflow within the sinuses, with a slow reduced clearance 
of the deposited material. Residence time of the drug deposited via pulsating aerosols was 
also observed to have increased threefold compared to the nasal spray in the nasal cavity  
(Möller et al., 2010).  
A study was conducted using nasal casts and healthy volunteers to recognize sinus 
ventilation and paranasal deposition using a pulsating airflow. The study demonstrated a 
promising result of an 8% increase in the nasal deposition of the drug within the sinuses 
using pulsating aerosols compared to nasal pump sprays. The study also demonstrated 
that the retention kinetics of the aerosols were longer in the nose when using the pulsating 
airflow (Möller et al., 2011). 
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1.5. Liposomes 
 An overview of liposomes and proliposomes  
Liposomes are phospholipid bilayer vesicles used for the encapsulation of drugs and 
nutrients (Li et al., 2015). Phospholipids are naturally occurring, or synthetic amphipathic 
lipids (Figure 1-7). Liposomes are vesicles having self-closed structures of lipid bilayers 
due to their thermodynamic phase and self- assembling characteristics of the amphipathic 
molecules (Chrai et al., 2002) (Figure 1-6). Vesicles are shaped through self-assembly, a 
spontaneous process of phospholipids that change into ‘closed-up’ structures when 
dispersed in aqueous media. Phospholipid molecules arrange themselves into bilayer 
sheets that lower unfavourable interaction between the aqueous medium and the long 
hydrocarbon fatty acid chains. This state leads to low energy and maximum stability; 
bilayer sheets then start folding to form the sealed bilayer vesicles (Figure 1-6).   
 
Figure 1-6: Mechanism of liposome formation. (Source: Sharma V. K et al., 2010) 
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Water-soluble drugs and lipid-soluble drugs can be effectively entrapped in liposomes. 
Lipophilic drugs are entrapped among the bilayers while hydrophilic drugs are entrapped 
within the aqueous spaces of the liposomes (Sharma, 2009) (Figure 1-7). Liposomes are 
also used as carriers of unstable compounds, such as antimicrobials, and antioxidants for 
applications in cosmetic, pharmaceutical, food, and farming industries. Liposomes 
protect the functionality of the unstable molecules until they reach the designated site by 
shielding them from decomposition (Akbarzadeh et al., 2013). Hydration temperature, 
choice of phospholipid, nature of membrane additives, size reduction technique, addition 
of kinetic energy, and the nature of the drug all can affect the physical nature of liposome 
formulation, and the stability and entrapment of the drug included (Surender Verma et 
al., 2010). 
 
 
Figure 1-7: Structure of liposomes. (Source: 
http://www.medscape.com/viewarticle/734055_3) 
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 Historical background of liposomes  
Liposomes were first discovered in 1961 by Dr A. Bangham (Bangham and Horne, 1964). 
Bangham and co-workers discovered that phospholipids tend to curl and form unilamellar 
or multilamellar vesicles in the presence of appropriate solvents.  
In the modern era from 1985 until today, liposomes have been used in various fields such 
as mathematics, chemistry, colloid science, biology, and other fields. The first liposomal 
product marketed for medicinal use was Ambisome TM, a parenteral Amphotericin B 
formulation that is given intravenously for the treatment of systemic fungal infections.  
Doxorubicin, Daunorubicin, Amikacin, and Hepatitis A vaccine have all emerged as 
liposomal-based products in the market  (Sharma Vijay et al., 2010).  
 Characterization of liposomes  
Liposomes can be classified according to the number of lipid bilayers they have in 
multilamellar vesicles (MLV), small unilamellar vesicles (SUV), giant unilamellar 
vesicles (GUV), and large unilamellar vesicles (LUV) (Storm and Crommelin, 1998) 
(Figure 1-8). Liposomes can also be categorized according to their size (small, 
intermediate, or large) or based on their manufacturing methods such as reverse phase 
evaporation vesicles and thin film hydrated (hand-shaken) vesicles, etc.  Unilamellar 
vesicles consist of a single lipid bilayer with a size range of 50–250 nm (Immordino et 
al., 2006). The size and surface properties of liposomes may affect their biological half-
life following intravenous administration. The number of liposome bilayers could also be 
a deciding factor of the entrapment efficiency of drugs incorporated into liposome 
formulations. Unilamellar liposomes are mainly used for the delivery of water-soluble 
drugs due to their large aqueous cores. Multilamellar vesicles consist of many bilayers 
arranged in an onion-skin-like arrangement and are large in size (1–5 μm).  Lipid-soluble 
drugs are usually entrapped for delivery in MLV liposomes due to their high lipid content 
(Sharma and Sharma, 1997).  
43 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 Figure 1-8: Types of basic structures and liposome size. 
 (Source: http://www.hindawi.com/journals/jdd/2011/863734/fig1/) 
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1.6. Advantages and Disadvantages of Liposomes  
 General advantages of liposomes  
There are many advantages for using liposomes. For example, liposomes provide a 
controlled and sustained drug delivery. They could be designed to be a targeted carrier. 
They are biodegradable, and may increase the therapeutic effect of the encapsulated drug. 
Moreover, they can carry both water-soluble and lipid-soluble drugs and protect them 
against instability caused by the surrounding in vivo environment (Goyal et al., 2005). 
Storm and Crommelin (1998) summarized the answer to the question of why to use 
liposomes, simply by stating ‘Direction, Duration, Protection, Internalization and 
Amplification’. 
 Liposomes as drug carriers  
Entrapment of drugs in liposomes improves the solubility of lipophilic and amphiphilic 
drugs (Amphotericin B, some peptides, anthracyclines) and the passive targeting of the 
immune system cells, resulting in the potential for use as carriers of vaccines, 
immunomodulators,  and antimonials (Akbarzadeh et al., 2013). Liposomes also help 
improve drugs by protecting them from the surrounding environment and allowing 
sustained release (systemically and locally). Biocompatibilities, biodegradability, non-
toxicity, and the multidisciplinary nature of their use all have made liposomes highly 
suitable for drug delivery and targeting. The ‘milieu interne’ phenomenon (lipophilic and 
aqueous environment in one system) gives liposomes a unique advantage of being able 
to transport hydrophobic, amphipathic, and hydrophilic drugs. Liposomes have also been 
used to offer site-avoidance in cases such as Doxorubicin and Amphotericin B, which 
constitute the bases for drug targeting (Akbarzadeh et al., 2013).  
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Site-specific targeting of liposomes has been used with anti-inflammatory, anti-cancer, 
and anti-infection drugs to reduce side effects and improve the therapeutic outcome. 
Mucoadhesive properties of liposomes also help improve penetrations of the encapsulated 
drug molecules into the tissues (e.g. corticosteroids, anaesthetics, and insulin) 
(Akbarzadeh et al., 2013)  (Figure 1-9). Liposomes also have the ability to be formulated 
in suspension such as an aerosol, gel, cream, or lotion (Sipai et al., 2012). Liposomes can 
be generated from dry powder precursors (i.e. proliposomes) for hydration prior to 
administration. Liposomes have been used for most routes of drug administration such as 
pulmonary, oral, intramuscular, nasal, topical, subcutaneous, and intravenous (Sipai et 
al., 2012).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1-9: Acceptance of liposome into cell. (Source: Sampathkumar et al., 
2012) 
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The versatile nature of liposomes has allowed entrapment of small molecules and 
macromolecules (haemoglobin, interleukin-2) (Akbarzadeh et al., 2013; Kapoor et al., 
2014; Surender Verma et al., 2010). Encapsulation of toxic drugs in liposomes may help 
reduce exposure of sensitive tissues to toxic drugs. Liposomes have also been flexible in 
coupling with site-specific ligands to improve targeting of the encapsulated drug in cases 
of anti-cancer and anti-microbial therapy (Sipai et al., 2012).  
 Drawbacks of liposomes   
Drawbacks of liposomes include the liability of liposomal phospholipids to oxidation and 
hydrolysis, as well as the tendency of the liposome dispersions to microbial 
contamination during storage because phospholipids are natural food components (Omri 
and Ravaoarinoro, 1998). Other drawbacks of liposomes include the possibility of losing 
drug encapsulation due to chemical decomposition. Another disadvantage is that 
liposome production is expensive (Anwekar et al., 2011).  
One major drawback of liposomes is their rapid elimination from the blood. Reticulo-
endothelial system cells, mainly the liver, capture liposomes and clear them from the 
blood (Torchilin, 2005). This drawback has now been addressed by the development of 
long–circulating liposomes by changing lipid composition, size, and charge of the vesicle. 
The most significant changes in liposomes were achieved by coating the vesicles with 
polyethylene glycol polymer to improve blood circulation and reduce the uptake by the 
mononuclear phagocyte system (stealth liposomes). This modification has improved the 
ability of liposomes to encapsulate active molecules, and target high efficiency and 
activity (Immordino et al., 2006).  
 Proliposomes   
Payne and co-workers (1986) designed an alternative to the direct formation of liposomes 
in order to offer an approach to overcoming the problems of conventional liposome 
instabilities. Liposomes can be made via passive loading and active loading methods. 
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Passive loading can be divided into three categories: mechanical dispersion method, 
solvent dispersion method, and detergent removal method (Huang et al., 2014). 
Proliposomes are stable, powdered phospholipid formulations that generate liposomes by 
the addition of an aqueous phase (Payne et al., 1986). Thus, a lot of liposome drawbacks 
could be overcome by the use of particulate-based proliposomes as an approach to 
generate liposomes.  
The most common method of proliposomes manufacture includes film deposition on the 
carrier method, the spray drying method, the fluidized bed method, and supercritical anti-
solvent method (Shaji and Bhatia, 2013). The film deposition on carrier method is done 
via deposition of a film of drugs and phospholipid onto water-soluble carrier material. 
Volatile organic solvent is introduced dropwise via a feed tube to the rotary evaporator 
flask on to the bed of carrier in the flask (Shaji and Bhatia, 2013). The solvent is then 
evaporated under a vacuum. The spray drying method involves a single step of both 
particle formation and drying. The spray drying method can be used on both aqueous and 
non-aqueous systems (Shaji and Bhatia, 2013). The fluidized bed method uses particle-
coating technology and is used for large-scale production of proliposomes. The 
supercritical anti-solvent method uses apparatuses with a supercritical carbon dioxide 
(sCO.2) fluid state held at or above its critical temperature and pressure to prepare 
proliposomes (Shaji and Bhatia, 2013). 
Liposomes are vesicles composed of phospholipid bilayers. Drawbacks of liposomes 
include their liability to oxidation and hydrolysis, and the tendency of the liposome 
dispersions to become microbially contaminated during storage because phospholipids 
are natural food components (Eichman and Robinson, 1998; Omri and Ravaoarinoro , 
1998). There is also the possibility of losing drug encapsulation due to chemical 
decomposition of the lipids in the formulation. A lot of these drawbacks could be 
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overcome by the use of particulate-based proliposomes by being available in dry form, 
making it easy to store, distribute, transfer, and measure (Shaji and Bhatia, 2013).  
 Nasal delivery of liposomes  
Sustained delivery of drugs to specific sites in the body achieved by carriers such as 
liposomes have attracted great interest. While the use of liposomes has been studied 
extensively in nasal delivery (Illum, 2003; Ravouru et al., 2013)  liposomes in nasal drug 
delivery especially have proven advantages by causing decreased mucociliary clearance 
due to formulation viscosity. Efficient and increased drug absorption is noted through the 
opening of ‘new pores’ in the paracellular tight junctions in phospholipid membranes of 
nasal mucosa, which helps with liposome incorporation (Mainardes et al., 2006). 
Nifedipine-bearing MLV liposomes given via nasal delivery have been successful in 
achieving a sustained plasma concentration and decreases in mucociliary clearance 
(Mainardes et al., 2006). A study done on a liposomal formulation of levonorgestrel, 
coupled with mucoadhesive polymers such as carbopol and chitosan for nasal delivery, 
has demonstrated increased drug bioavailability, increased contact time of the drug, and 
enhanced absorption through decreased mucociliary clearance (Shahiwala and Misra, 
2004a). The study by Shahiwala and Misra (2004b) also states that using liposomes with 
colloidal carriers leads to decreased drug-dosing frequencies and decreased systemic side 
effects by maintaining blood concentrations from 6–60 hours (Shahiwala and Misra, 
2004b). Many other studies support the use of liposomes in nasal delivery (Heurtault et 
al., 2010; Mainardes et al., 2006; Türker et al., 2004).  
Permeability of liposomes with insulin entrapped and insulin solution (with and without 
treatment of sodium glycocholate) have been studied on the nasal mucosa of a rabbit. 
Results indicated that insulin loaded on to liposome solution has superior permeability to 
insulin solution (Maitani et al., 1992). Desmopressin-loaded liposomes were investigated 
on nasal mucosa. Researchers state positively charged liposomes had the most superior 
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nasal permeability, while negatively charged liposomes demonstrated less permeability 
compared to positive liposomes but superior permissibility compared to solution of 
desmopressin without liposomes (Law et al., 2001). 
 Nasal delivery of drugs through aerosolized proliposomes  
Drug delivery to the pulmonary or nasal systems via nebulized aerosols may need a carrier 
system, especially when water solubility of the drug is poor. Liposomes may entrap drugs 
and when delivered intranasally they can enhance the uptake of the drug by the nasal 
mucosa. This approach has been exploited for nasal delivery of vaccines (Heurtault et al., 
2010). However, the poor stability of liposomes is a serious obstacle since phospholipids 
are liable to oxidation and hydrolysis when present in aqueous formulations. 
Proliposomes are carbohydrate carrier particles coated with phospholipids using simple 
techniques, offering enhanced formulation stability. Nasal delivery is a needle-free 
approach, comprising a comfortable and painless mode of drug delivery for the treatment 
of local and systemic diseases.  
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1.7. Effervescent Formulations for Nasal Drug Delivery 
 Introduction to effervescent formulations   
Effervescence is a reaction that happens in water and results in the liberation of carbon 
dioxide as a result of acid-base reactions. For nearly 200 years, effervescent formulations 
were mainly used in oral delivery (Eichman and Robinson, 1998) but only a limited 
number of studies have been published on the use of effervescent formulations in nasal 
and pulmonary delivery (Ely et al., 2007; Katare et al., 1995, 1990; Wei et al., 2013; Zhao 
et al., 2010). As a general context of preparation, effervescent formulations (containing 
carbonates, acid substance, or hydrogen carbonates) are made to permit the occurrence of 
an acid-base reaction in water, resulting in tablet/granule disintegration with subsequent 
liberation of the drug from the solid compact. The shaking provided via effervescence 
(because of the liberated carbon dioxide) helps to dissolve the drug that was originally 
included in the formulation. Effervescent tablets are also uncoated, so when water is 
present the reaction takes place immediately and carbon dioxide is released ( Lindberg 
and Hansson, 2006). European Pharmacopeia 5 state, Effervescent granules should 
typically disintegrate or its medicinal ingredients dissolve in less than 5 min (Council of 
Europe, 2004, p. 606)  
Effervescent formulations may offer a means of enhancing the dissolution of the 
incorporated drug, and hence its absorption through biological membranes can be 
improved (Coletta and Kennon, 1964). Effervescent granules also modify the releases and 
are designed to control the rate of release of the drug and delay the active component 
from releasing too quickly (Aulton and Taylor, 2013).  
Effervescent formulations, apart from containing acids/acid salts, bicarbonates/carbonate 
salts, also contain fillers, binders, sweeteners, flavours, and lubricants. These products 
are then mixed in to effervescent formulations tableted by  either wet granulations, fusion 
method, fluid-bed granulation, or direct compression (Aslani and Jahangiri, 2013). The 
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key benefit of effervescent solid formulations is its ability for the solid formulations to 
disperse in water and quickly be available in liquid formulation. This property of 
effervescent formulations has been used in many industries (dental hygiene, household 
cleaners, medicines, food supplements, detergents, etc.) with a market value thought to 
be in multibillions ( Lindberg and Hansson, 2006).  
Effervescent tablets, granules, and powders are mentioned in pharmacopeia and in 
medical products in the current market ( Lindberg and Hansson, 2006). Effervescent 
formulations are often available in the market in tablet form. Currently, the most 
commonly used effervescent table is the aspirin tablet (Palanisamy et al., 2011). 
Effervescent oral tablets have many advantages over conventional solid dosage forms, 
namely, improved palatability, sparkling solution, portability, help for patients who 
cannot swallow tablets, and the stability of products that are unstable in liquid form, 
which are often stable as effervescent tablets. Effervescent liquid also address issues 
related to dissolution (absorption rate and extent of bioavailability). However, there are 
drawbacks, such as expensive manufacturing due to needing large amounts of excipients 
and special facilities to produce effervescent products. Effervescent products also need 
special packaging to minimize contact with moisture and air (Prabhakar and Krishna, 
2011). Effervescent tablets are also bulky compared to conventional solid dosage form 
tablets. Effervescent formulations are sensitive to moisture and temperature; therefore, a 
relative humidity of 25% or less and a temperature of 25 °C are needed for manufacturing 
(Prabhakar and Krishna, 2011).  
Drugs formulated as effervescent tablets are often drugs difficult to digest or that cause 
disruption in the stomach, pH-sensitive drugs (amino acids and antibiotics), and drugs 
requiring a large dose. The typical effervescent tablet is 1 in in diameter with a weight of 
5 g in total. If the dose is larger, effervescent granules could be available in sachet form 
(Prabhakar and Krishna, 2011).  
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Laxative effervescent suppositories that release carbon dioxide have been researched and 
have been available on the Swedish market for many years (Hakata et al., 1993). 
Effervescent vaginal suppositories have also been studied (Kurobe et al., 1983). A 
pulsatile and gastric floating drug delivery system based on a reservoir system consisting 
of effervescent core and polymeric coating have been investigated (Krögel and Bodmeier, 
1999). 
 Effervescent liposomes  
Very limited studies have been done on effervescent formulations coupled with 
liposomes. Effervescent Ibuprofen proliposomes were first investigated for systermic 
administration by Katare and co-workers. Soya bean lecithin, Stearylamine, and 
cholesterol were incorporated into effervescent formulations, which produced regular- 
and uniform-sized (1–4 µm) liposomes with high drug encapsulation efficiency (Katare 
et al., 1990). Phospholipids in uniform liposomes were protected by an inert umbrella 
product that helped with the hydration of lipids by the high shear pressure given off by 
the effervescence reaction.  
A study was carried out by the same research group in 1995 to explore the potential of 
indomethacin effervescent proliposomes. The liposomes were studied for their anti-
inflammatory activity following systermic delivery using experimental rats, which 
confirmed superior anti-inflammatory activity of the liposomal formulation of the drug 
compared to a conventional drug preparation (Katare et al., 1995). More recent studies 
have demonstrated that effervescent proliposomes were used with docetaxel (composed 
of docetaxel/Tween-80/Phospholipon 90H/cholesterol/citric acid) for pulmonary drug 
delivery. The formulations were produced using a solid dispersion technique, which 
produced liposomes of 1 µm, negatively charged with a favourable lung-targeting effect. 
Following the addition of the aqueous phase, the formulation’s composition was 
docetaxel, Tween-80, Phospholipon 90H, cholesterol, and citric hydrated in 
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NaHCO3 solution (Zhao et al., 2010). Wei Y et al. (2013) studied liposomes made with 
Phospholipon 90H and Tween-80 for delivery of paclitaxel to the lung in rabbits. 
Liposomes were 8.166±0.459 µm in size, negatively charged with high drug entrapment 
efficiency, indicating that effervescent proliposomes are a promising drug delivery 
system (Wei et al., 2013). 
The paclitaxel liposomes drug delivery system was prepared by solid dispersion and 
effervescent techniques targeting the lung (Zhao et al., 2011). Liposomes contained 
between 80/HSPC/cholesterol (0.03 : 3.84 : 3.84, mol/mol), containing paclitaxel and 
lipids (1 : 40, mol/mol). Liposomes were found to have a mean size of 0.5±15.43 µm, a 
span of 0.28±0.02, zeta potential of −20.93±0.06 mV, and a drug entrapment of 
95.17±0.32%, Liposomes were found to be stable for least three months at 6±2 °C. It was 
observed that paclitaxel liposomes had a drug concentration of 15 fold higher than of 
paclitaxel injection at 2h in the lung (Zhao et al., 2011). Research concluded that 
liposomes loaded with drug was an effective drug carrier system.  
The lung-targeting injectable liposome formulation consisting of particles or powder 
loaded with medicine for solid phase and effervescent has been studied. In this study, 
proliposomes and effervescent were packed separately and mixed together in an 
effervescent dispersion technique before administration of the injection(Yu et al., 2010). 
Research on pulmonary delivery to the lung with the use of effervescent formulations was 
conducted by Ely et al., (2007) using formulations of dry effervescent powders for 
pulmonary delivery. Spray drying of effervescent drug powder was made by 
incorporating polybutylcyanoacrylate nanoparticles and ciprofloxacin. The effervescent 
powder was made with the aim of generating the effervescence within the pulmonary 
system. As yet, the delivery of effervescent proliposomal formulations via nebulizers to 
treat sinusitis has not been investigated. 
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1.8. Model Drugs for the Study of Couples with 
Effervescent Liposomes 
 Beclometasone dipropionate (hydrophobic)  
Beclometasone dipropionate (BDP) (Figure 1-10) is a glucocorticoid steroid that is 
insoluble in water (i.e. hydrophobic) and has an anti-inflammatory effect, reducing the 
ability to produce immune reactions. BDP acts on the body by inhibiting inflammatory 
cells such as mast cells, eosinophils, basophils, lymphocytes, macrophages, and 
neutrophils. BDP also prevents the release of inflammatory mediators such as histamine, 
leukotrienes, and cytokines. Monoester 17 and monopropionate (17-BMP) are activated 
by hydrolysis in vivo by BDP demonstrating binding affinity for humans’ glucocorticoid 
receptor (GR), resulting in anti-inflammatory effects (Wang et al., 2011).  All 
corticosteroids can cause side effects, associated with adrenaline inhibition and 
significant bone density decrease) (Wilson et al., 1997).  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1-10: Chemical structure of beclomethasone dipropionate (BDP). 
(Source: 
http://upload.wikimedia.org/wikipedia/commons/2/21/Beclometasone_dipropionat
e.png) 
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Long-term use of this drug orally causes serious side effects, such as a cough, oral 
candidiasis, bad mouth odour, hoarseness, nasal congestion, pain, headache, and visual 
changes. Thus, the formulation of this drug as effervescent proliposomes will not only 
enhance its solubility but may also shorten the course of therapy by enhancing the drug 
absorption (Messerli et al., 1975; Mygind, 1973).  
 Xylometazoline hydrochloride (XH) 
Xylometazoline hydrochloride (XH) (Figure 1-11) is a hydrophilic (i.e. water-soluble) 
drug, usually used as a topical nasal decongestant (Eccles et al., 2008). The typical 
concentration of the drug given to an adult is around 0.1% w/v XH and 0.05% for children 
under 12 years. XH works by constricting the blood vessels and increasing nasal airflow. 
Nasal congestion happens due to the inflammation of the large veins in the nose and/ or 
infections or inflammation due to nasal allergy. XH also causes constriction of smaller 
arteries. Due to the constriction, nasal airflow increases and blockage of the nose is 
reduced, resulting in easier breathing for the patient (Castellano and Mautone, 2002).  
XH mimics the molecular shape of adrenaline and is a derivative of imidazole which 
binds to alpha-adrenergic receptors in nasal mucosa. XH results in sympathomimetic 
effects and is not for patients with heart issues and high blood pressure. Long-term use of 
XH will decrease the effectiveness of the drug and result in an increased tolerance of the 
drug by decreasing in the number of drug receptors. Chronic congestion is also one of the 
side effects of XH, known as rebound congestion. Degeneration of the nasal mucosa 
membrane can also be a side effect of the long-term use of XH. 
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Figure 1-11: Chemical structure of xylometazoline hydrochloride (XH). (Source: 
http://upload.wikimedia.org/wikipedia/commons/8/8a/Xylometazoline_Structural_
Formulae_V_2.png) 
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1.9. Aim of This Thesis 
The aim of this thesis is to design and develop an effervescent proliposomes formulation 
that could disintegrate in water and liberate liposomes in a matter of minutes by 
improving its disintegration time compared to conventional proliposomes. This will 
potentially help to improve dosing and produce liposomes available for immediate 
administration. The suitability of effervescent liposomes in terms of their characteristics, 
entrapment, and suitability for delivery through a nebulizer will be compared with the 
conventional liposomes. The hydrophobic model drug Beclometasone dipropionate 
(BDP), and also in some formulations the hydrophilic drug Xylometazoline 
hydrochloride, have been investigated in this study. The formulations of effervescent 
proliposomes were prepared using the slurry method. Mannitol was used as a sugar-based 
carrier and formulations were tested with or without cholesterol. Dipalmitoyl 
phosphatidylcholine (DPPC) and Soya phosphatidylcholine (SPC) lipids were chosen as 
the candidate lipids for this experiment to understand the impact of cholesterol in different 
types of lipids in the presence of effervescent ingredients. All formulations contained 
effervescent ingredients (bicarbonate, sodium benzoate, and citric acid). Formulations 
were also tested for their ability to produce stable liposomes in the presence of 
effervescent salts alone, without the sugar-based carrier (sugar-free). Mucoadhesive 
polymers, such as alginic acid or chitosan, were incorporated to improve the bioadhesive 
properties. The inclusion was then investigated for its suitability in effervescent 
liposomes. This study also aims to investigate the potential suitability of liposomes for 
aerosolization to target the parasinuses using a nebulizer. The Pari Sinus nebulizer and 
the Pari Sprint nebulizer were then compared on the basis of their ability to deliver 
aerosols to the nasal cavity and sinuses using a unique system that was developed by 
incorporating a nasal cast (transparent nasal cast model) coated with Sar-Gel® (water 
indicating paste) to an impinger. The deposition patterns of nebulized formulations were 
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photographed and images were analyzed using Adobe® Photoshop, and pixels were 
counted and then converted into cubic centimetres. The ability of the Pari Sinus and Pari 
Sprint nebulizers to deposit aerosols into the full nasal cavity and sinuses alone were then 
compared.  The final outcome of this thesis is to develop a liposomal effervescent 
formulation that is more efficient, with reduced disintegration time suitable for the 
delivery of drugs to the sinuses compared to conventional liposomes via a nebulizer.   
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Aim of thesis in schematic graph 
1.10. Element of Originality:  
Novelty aspects of the project are:  
1) the design of Beclometasone dipropionate effervescent formulations for the treatment of 
sinusitis; 
2) employment of proliposomes technology in designing nanotechnology systems to target 
the parasinuses; 
3) understanding how the presence of cholesterol in effervescent liposomes affect different 
lipids used for the formulation;  
4) the employment of the Pari Sinus nebulizer to deliver effervescent nanotechnology-based 
formulations; 
5) the investigation of the suitability of effervescent liposomes in delivering hydrophilic 
drugs by loading Xylometazoline hydrochloride;  
6) the development of a novel HPLC method to determine drug entrapment for 
Xylometazoline hydrochloride;  
7) the development of a unique system with a twin impinger and a transparent nasal cast 
model coated with Sar-Gel® (water indicating paste) to study the deposition area of 
nebulized aerosols in the upper respiratory tract.  
To my best knowledge, the potential of effervescent formulations of Beclometasone 
dipropionate has not yet been explored, and proliposome technology has not been 
investigated for targeting the parasinuses. Moreover, very little research has been 
conducted on the novel Pari Sinus nebulizer. So far, the sinuses have not been targeted 
with effervescent liposomal formulations. This project is specifically designed to develop 
effervescent formulations in the form of proliposome granules that could disintegrate in 
water and liberate liposomes with the model drugs for delivering aerosols that can target 
the parasinuses via the Pari Sinus nebulizer.  
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CHAPTER 2  
METHOD AND 
MATERIALS 
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2.1. Materials 
 
  
Table 2-1: Chemicals and Supplier 
Chemicals Suppliers 
Soya Phosphatidylcholine (Lipoid S-100) A gift from Lipoid, Switzerland 
Dipalmitoyl Phosphatidylcholine (DPPC)  Lipoid, Switzerland 
Sodium bicarbonate Sigma-Aldrich, UK 
Cholesterol (Sigma grade, ≥99%), Sigma-Aldrich, UK 
Citric acid Sigma-Aldrich, UK 
Sodium benzoate  Sigma-Aldrich, UK 
Xylometazoline hydrochloride (XH) Sigma-Aldrich, UK 
Deuterium oxide (For NMR, 99.8% atom %D)  Acros Organics, UK 
Beclomethasone dipropionate Acros Organics, UK 
Deuterium oxide (For NMR, 99.8% atom %D) Acros Organics, UK  
HPLC water (HPLC gradient grade) Fisher Scientific, UK 
Methanol (HPLC grade) Fisher Scientific, UK 
Ethanol (99.8+% absolute duty free for HPLC 
certified HPLC 
Fisher Scientific, UK 
Chloroform  Fisher Scientific, UK 
Sar-Gel® Sartomer, US 
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2.2. Preparation of proliposomes  
 Preparation of particulate-based proliposomes  
The following method was used for proliposome preparation. All proliposome 
formulations were made using the same method. The samples are as follows: 
Table 2-2: Non-effervescent particulate-based formulations investigated 
Formulations 
(Lipid:Carrier) 
Carrier Lipid Solvent 
Drug 
(mol%) 
Drug 
1:5w/w Sucrose SPC Chloroform  Drug-free 
1:5 w/w Sucrose SPC Chloroform 2.5 mol% BDP 
1:5 w/w Mannitol SPC Chloroform - Drug-free 
1:5 w/w Mannitol SPC Chloroform 2.5 mol% BDP 
1:5 w/w Mannitol SPC Ethanol - Drug-free 
1:5 w/w Mannitol SPC Ethanol 2.5 mol% BDP 
1:10 w/w Mannitol SPC Ethanol - Drug-free 
1:10 w/w Mannitol SPC Ethanol 2.5 mol% BDP 
1:10 w/w Mannitol SPC Ethanol 5 mol % BDP 
1:10 w/w Mannitol DPPC Ethanol - Drug-free 
1:10 w/w Mannitol DPPC Ethanol 5 mol % BDP 
1:10 w/w Mannitol SPC Ethanol 5 mol % XH 
 
 
 Sucrose-based conventional liposomes (SPC-based) with hydrophobic 
drug 
The following is a detailed explanation of the preparation of the first sample. The same 
method has been applied for all samples with changes of weights and ingredients as 
described in Table 2-1. For preparation of (Table 2-2) 1:5 w/w lipid to sucrose (carrier) 
ratio empty proliposomes, sucrose was ground in a ball mill rotated on a rotating roll 
mixer. The resulting powder was then sieved and the fraction of the sucrose particles 
between the sizes of 300–500 µm was collected for the manufacture of proliposomes with 
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a 1:5 w/w phospholipids to carrier ratio. Sucrose particles (1.25 g) were placed in a pear-
shaped 100 ml flask and attached to a customized rotary evaporator (Büchi Rotavapor R-
114, Büchi, Switzerland, Büchi, Switzerland) and the temperature of the water bath was 
set at 40° C. A chloroformic solution of Soya phosphatidylcholine (SPC, 60 mg/ml) and 
cholesterol were dissolved and poured on to the sucrose inside the round bottom flask. 
The round bottom flask was attached to the rotavapor and negative pressure continued for 
two hours to remove the solvent and generate dried proliposomes. The vacuum was 
released to collect the proliposomes and store them in a glass vial at -18 °C.  
For drug-loaded formulations (Table 2-2): This procedure was repeated by inclusion of 
2.5 mol% Beclometasone dipropionate in the lipid phase for 1:5 w/w lipid to sucrose 
proliposomes with 2.5 mol% drug. Hydration of the proliposomes for non-effervescent 
liposomes, the samples was vortexed for 2 min (Stuart, SA8). The proliposomes were 
stored and annealing of the manufactured liposomes was carried out just prior to further 
testing.  
The same procedure was repeated for all mannitol formulations with different ingredients 
as in Table 2-1. When preparing mannitol-based proliposomes, grinding was not 
necessary but the same procedure as the method as section 2.2.2 was repeated by 
substituting sucrose with mannitol. 1:5 w/w phospholipid to carrier ratio formulation with 
mannitol, 1.25 g of mannitol was placed in a 100 ml pear-shaped flask attached to a 
customized rotary evaporator (Büchi Rotavapor R-114, Büchi, Switzerland). 
 Mannitol-based conventional liposome (SPC-based) with hydrophobic 
drug 
The following is a detailed explanation of the preparation of the first sample for mannitol 
non-effervescent formulations (Table 2-2). The same procedure was repeated for all 
mannitol formulations with different ingredients as in Table 2-1. When preparing 
mannitol-based proliposomes, grinding was not necessary but the same procedure as the 
method in section 2.2.2 was repeated by substituting sucrose with mannitol. 1:5 w/w 
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phospholipid to carrier ratio formulation with mannitol, 1.25 g of mannitol was placed in 
a 100 ml pear-shaped flask attached to a customized rotary evaporator (Büchi Rotavapor 
R-114, Büchi, Switzerland). Soya phosphatidylcholine (SPC, 60 mg/ml) and cholesterol 
dissolved in chloroforming solution was poured in to the pear-shaped flask.   The round 
bottom flask was attached to the rotavapor and negative pressure continued for two hours 
to remove the solvent and generate dried proliposomes. The vacuum was released to 
collect the proliposomes and store them in a glass vial at -18 °C.  
The same procedure was carried out for drug-loaded liposome formulations with the 
addition of 2.5 mol% drug BDP in lipid phases for 1:5 w/w lipid to mannitol proliposome 
ratio. For hydration, proliposomes were dissolved in water and vortexed for 2 min. 
Proliposomes were stored and annealing of formulations was done just prior to testing.  
 Mannitol-based conventional liposomes (DPPC-based) with hydrophobic 
drug  
When preparing DPPC lipid-based samples (Table 2-2.), the method mentioned in section 
2.2.3 was used to produce SPC-based liposomes was substituted with DPPC lipid. The 
round bottom flask in the rotary evaporator (Büchi Rotavapor R-114, Büchi, Switzerland) 
was used and the temperature of the water bath was set up at 55° C instead of 40° C. 
 Mannitol-based conventional liposomes (SPC-based) with hydrophilic 
drug  
Xylometazoline hydrochloride, drug-loaded liposome formulations (Table 2-2) were 
made with SPC according to section 2.2.3 with the exception of drug loading at lipid 
phase. The hydrophilic drug was loaded to the liposomes at the hydration phase, instead 
of adding the drug in the lipid phase. The drug was added along with the proliposomes at 
the hydration phase. Proliposomes were stored at 18 °C, until annealing and drug were 
loaded at hydrating and vortexed for 2 min. Purification step of XH is mentioned in details 
at section 2.4, and section 2.42.  
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2.3. Characterization of Liposomes  
 Particle size analysis 
Particles are passed through a beam of laser light and the scatters of the incident light are 
focused onto a Fourier lens. The Fourier lens in turn focuses the scattered light onto a 
detector array and the range of the particle sizes is calculated from the collected diffracted 
light data with the use of an inversion algorithm. Liposomes were placed in the dispersion 
unit of the Malvern Mastersizer 2000 (Malvern Instruments Ltd, UK) followed by 
measurement of the volume median diameter (VMD) and span to represent the size and 
size distribution respectively. The VMD represents the 50% undersize while span = (90% 
undersize – 10% undersize)/ VMD.  The polydisperse mode was chosen with a stirring 
speed of 1360 rpm for analysis.  
 Zeta potential (surface charge) analysis 
The zeta potential of liposomes may indicate how they behave in vivo and also help to 
identify any changes that would be made on the surface of the liposomes upon inclusion 
of certain materials. The zeta potential also provides information of stability of the 
particles in a suspension. Calculation of the zeta potential is automatic with the correlation 
of electrophoretic mobility when using the zeta sizer instrument (Malvern Instruments, 
UK). The zeta potential cell was thoroughly washed with deionized water to minimize 
possible cross-contamination. The cell was carefully loaded with the sample to avoid the 
creation of bubbles that may interfere with the measurements. The right software options 
were selected and measurement was performed.  
 Surface morphology using scanning electron microscopy (SEM)  
A scanning electron microscope (SEM) (EMITECH, UK) is operated by generating an 
image of the specimen by scanning it with a beam of electrons. The scan is done in a 
raster pattern. When the electrons from the microscope interact with the atoms of the 
specimen they produce signals that give out information about the composition of the 
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specimen and its surface topography and also other characteristics such as the electrical 
conductivity of the specimen. The SEM is an instrument that can produce highly 
magnified images that can go down to the nanometre size range of particles.  
Proliposome particles using a range of carrier size fractions, such as 300–500 μm using 
SPC or SPC:Chol (1:1), molar ratio were air-dried onto an SEM stub (TAAB Laboratories 
Equipment Ltd., UK). Samples were gold-coated for 5 min in a EMITECHK550 sputter 
coater (EMITECH, UK). The samples were then viewed, photographed, and video-
printed using the Philips XK 20 SEM. The same procedure was repeated for all samples.  
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2.4. Entrapment Studies  
 High-performance liquid chromatography (HPLC studies) for drug 
Beclometasone dipropionate (BDP) 
To investigate the HPLC entrapment of liposomes, the separation of liposomes was 
achieved by centrifugation. Liposomes and BDP crystals have a different density that 
helps with separation. Centrifugation results in sediments of suspended particles sinking, 
while liposomes tend to float. Batavia 2001 also investigated if the density difference of 
water and deuterium oxide help the separation of liposomes from the unincorporated BDP 
crystals. 
 Separation of entrapped and unentrapped drug   
Prior to the HPLC, studies of the hydrophobic drug BDP were carried out for all 
proliposomes formulations. 30 mg/ml of each formulation was dissolved for separation. 
Each sample was centrifuged (bench centrifuge: Jencons-PLS, Spectrafuge 24D) at the 
speed of 13000 rpm (15300 relative centrifugal force) for 90 min and liposomes (in D2O 
the floating layer) were removed using a Pasteur pipette. Liposomes were dissolved by 
the addition of methanol in order to release the drug for subsequent analysis by HPLC. 
Methanol was also added to the BDP spot that contained the unentrapped drug to 
determine the unentrapped drug fraction. A mobile phase was added to dissolve the 
plasma membrane just before HPLC analysis. To analyze the separations of liposomes 
and crystals, the spot that appears in the centrifuge tube was investigated using a light 
microscope to establish they were BDP crystals. 
The hydrophilic drug XH samples did not need suspension in D20. 30 mg/ml of each 
formulation was dissolved for separation in HPLC gradient water. Each sample was 
centrifuged at the speed of 13000 rpm (15300 relative centrifugal force) for 90 min. The 
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liposomal layer deposited in the bottom was removed with a Pasteur pipette and a mobile 
phase was added to dissolve the plasma membrane just before HPLC analysis.  
 High-performance liquid chromatography (HPLC) analysis of 
Beclomethasone dipropionate (BDP) 
An Agilent system, 1200 Serious USA, HPLC machine was used and HPLC analysis was 
conducted at room temperature using a high chrome ODS (4.6 x 250 mm) Eclipse XDB-
C18, 4.6 x 150 mm, Agilent, UK column. The following method was adapted from 
Batavia and co-workers (2001). HPLC grades of methanol and water were used in a 3:1 
ratio to constitute the mobile phase. The mobile phase was set to have a flow rate of 2 
ml/min. The sample injection volume was set at 50 µl, and UV detection at 238 nm was 
employed. A calibration curve was constructed using ascending drug concentrations in 
methanol. 
 High –performance liquid chromatography (HPLC) analysis of 
Xylometazoline hydrochloride (XH) 
Xylometazoline hydrochloride samples were analyzed by using HPLC Agilent 
Technologies. XH was assayed using a Synergie 4U MAX 250 x 4.60 mm column 
(Agilent, UK column). The mobile phase, consisting of acetonitrile and water was eluted 
at a flow rate of 1 ml/min with this specific gradient profile (Table 2-3) 
 
Table 2-3 : Gradient profile of Xylometazoline hydrochloride HPLC method  
Step. No. Time (min) Water (%) Acetonitrile (%) 
1 0.00 85 15 
2 11.00 50 50 
3 11.01 85 15 
4 14.00 85 15 
 
The injection volume was 50 µl and the fluorescence detector employed an absorbance 
wavelength of 225.4 nm signal and reference of 360,100. Stop time for each sample was 
8 min. Under these conditions, the retention time for prednisolone was 10.3 min. 
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Specificity  
The specificity of our method was proved by comparison of a blank sample consisting of 
mobile phase, acetonitrile, water, 1:1 (Figure 2-1) and prednisolone sample in that mobile 
phase (Figure 2-2).  
Figure 2-1: Blank sample assayed by the HPLC method. 
 
 
Figure 2-2: Xylometazoline hydrochloride sample assayed by the HPLC method. 
Linearity  
An acceptable linearity was established in the concentration range of 0 – 40 µg/ml 
(R2=0.9945) (Figure 2-3). 
 
Figure 2-3: Calibration curve of prednisolone for the concentration 0–50 µ. 
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Accuracy and Precision 
The HPLC method was also tested for accuracy and precision. Table 2-4 shows accuracy 
evaluation for the concentration range of 5–40 ng/ml, and precision is shown in Table 2-
5. 
 Table 2-4: Accuracy of the HPLC method for the concentration range 5–40 ng/ml 
 
Average actual 
concentration 
(µg/L) 
Average calculated 
concentration 
(µg/L) 
Average accuracy SD 
5.45 5.24 99.14 0.17 
10. 12 10.01 100.29 5.41 
15.94 14.99 98.14 2.67 
20.99 20.98 100.07 1.05 
25.31 24.45 99.76 3.71 
30.40 29.93 96.99 6.40 
35.21 34.94 100.50 2.98 
40.05 39.24 101.94 2.18 
 
Table 2-5: Precision of the HPLC method after 10 measurements of XH sample 
Concentration of  
XH (µg/l) 
Average AUC of 10 
measurements 
SD SD % 
40.02 2278.03 0.63 0.19 
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2.5. Effervescent Proliposome Formulations  
 Preparation of effervescent formulations  
Granules were prepared within the rotary evaporator. Both SPC and DPPC lipids were 
used for formulations and mannitol added or exempted to understand how it impacted on 
liposomes.  
Cholesterol was also included or exempted to understand the interaction with different 
careers and lipids 
Table 2-6: Effervescent ingredients used for preparation of effervescent proliposomes 
 
  
Name Effervescent content Amounts (mg) 
Beclomethasone dipropionate Drug 5.75 mg 
Mannitol Carrier 1250 mg 
SPC Phospholipid 83.33 mg 
Cholesterol Cholesterol 41.6 mg 
Sodium bicarbonate Carbonate source 1705 mg 
Citric acid anhydrous Acid Source 1375 mg 
Sodium benzoate Lubricant 110 mg 
Ethanol Binder 25 ml 
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Table 2-7: Effervescent proliposome formulations tested for drug delivery to sinuses 
 
 
Lipid: 
Carrier 
ratio 
Carrier  
Cho
leste
rol  
Lipid  Solvent  
Drug 
(mol%) 
Drug  
1:10 w/w 
Mannitol with 
effervescent salts  
Yes  SPC Ethanol - Drug-free 
1:10 w/w 
Mannitol with 
effervescent salts 
Yes  SPC Ethanol 5 mol% BDP 
1:10 w/w 
Effervescent salts 
alone  
Yes  SPC Ethanol - Drug-free 
1:10 w/w 
Effervescent salts 
alone  
Yes  SPC Ethanol 5 mol% BDP 
1:10 w/w 
Mannitol with 
effervescent salts  
No SPC Ethanol - Drug-free 
1:10 w/w 
Mannitol with 
effervescent salts 
No SPC Ethanol 5 mol% BDP 
1:10 w/w 
Effervescent salts 
alone  
No SPC Ethanol - Drug-free 
1:10 w/w 
Effervescent salts 
alone  
No SPC Ethanol 5 mol% BDP 
1:10 w/w 
Mannitol with 
effervescent salts 
Yes  SPC Ethanol 5 mol% XH 
1:10 w/w 
Effervescent salts 
alone  
Yes  SPC Ethanol 5 mol% XH 
1:10 w/w 
Mannitol with 
effervescent salts 
No SPC Ethanol 5 mol% XH 
1:10 w/w 
Effervescent salts 
alone  
No SPC Ethanol 5 mol% XH 
1:10 w/w 
Mannitol with 
effervescent salts  
Yes  DPPC Ethanol - Drug-free 
1:10 w/w 
Mannitol with 
effervescent salts 
Yes  DPPC Ethanol 5 mol% BDP 
1:10 w/w 
Effervescent salts 
alone  
Yes  DPPC Ethanol - Drug-free 
1:10 w/w 
Effervescent salts 
alone  
Yes  DPPC Ethanol 5 mol% BDP 
1:10 w/w 
Mannitol with 
effervescent salts  
No DPPC Ethanol - Drug-free 
1:10 w/w 
Mannitol with 
effervescent salts 
No DPPC Ethanol 5 mol% BDP 
1:10 w/w 
Effervescent salts 
alone  
No SPC Ethanol - Drug-free 
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 Effervescent proliposome formulation (mannitol-based and salt-based)  
The following method was used to manufacture 1:10 w/w lipid to carrier (mannitol or 
salt) ratio with 10 mol% BDP (5.75 mg) loaded with effervescent proliposome granules 
with ethanol as a solvent. 1:5 w/w phospholipid (SPC or DPPC) to carrier ratio (mannitol 
:1250 mg or effervescent salts), sodium bicarbonate (1705 mg), citric acid (1375 mg), 
and sodium benzoate (110 mg) were weighed and placed in a pear-shaped 250 ml round 
bottom flask. Phospholipid (83.33 mg) and cholesterol (41.6 mg) (2:1 ratio) were 
dissolved in 25 ml of ethanol and added to the ingredients. The flask was then attached 
to the rotary evaporator (Büchi Rotavapor R-114, Büchi, Switzerland) with water 
adjusted to 35 °C for SPC formulations or 50 °C for DPPC formulations (Figure 2-4). 
The sample was then left under vacuum for two hours until the solvent evaporated and 
dried proliposome granules were obtained. The proliposome granules were scraped from 
the bottom and stored in glass vials at -18 °C. Hydration of the proliposomes and 
annealing of the manufactured liposomes were carried out prior to further testing by 
adding 30 mg of effervescent proliposomes in 1 ml of water. Slat-based effervescent 
samples were made in the same manner omitting mannitol the sugar-based carrier. For 
samples without cholesterol, the same procedure was continued omitting cholesterol. 
Liposomes were characterized according to the methods described in sections 2.2 and 2.3 
after incorporating the effervescent constituents to the samples. Characterization of 
proliposomes with and without the effervescent property was compared.   
 
 
 
 
 
Figure 2-4: Effervescent BDP-loaded proliposome production. 
Made via slurry method  
Mannitol (1250mg) and/or effervecnt salts 
Sodium Bicarbonate (1705mg) 
Citric acid (1375mg) 
Sodium benzoate (110 mg) addd to flask 
Drug 
BDP 
added in 
lipid 
phase 
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2.5.2.1. Effervescent liposomes coated with mucoadhesive 
Effervescent liposomes were made as described in section 2.5.2. Effervescent 
proliposomes (150 mg) were hydrated in 5 ml alginic solution or chitosan solutions. Both 
mucoadhesive alginic acid and chitosan solutions 0.2 W/V % and 1 W/V% were used. 
Mucoadhesive solutions (5 ml) were used for the hydration of 150 mg of effervescent 
proliposomes. 
2.5.2.2. Effervescent liposomes with hydrophilic drug XH  
Effervescent liposomes were made as described in section 2.5.2. however, drug loading 
was done at the hydration phase for the hydrophilic drug by dissolving the drug alone in 
water and hydrating the effervescent granules (150 mg in 5 ml). Samples were then 
characterized before and after sonication according to sections 2.2 and 2.3. Sonicated 
samples were done for 20 sec to downsize the liposome size. Each sample was then 
centrifuged at a speed of 13,000 rpm for 5 min. The bottom layer of debris was removed 
from the liposome sample prior to characterization for the sonicated samples.   
 Disintegration time for both BDP and XH drugs  
The time taken for the samples to disperse was analyzed by using the same amount of 
distilled water (5 ml), and the concentration of proliposome granules used in the aqueous 
phase was 30 mg/ml for all samples. Granules were dispersed in the water and the time 
taken for dispersed (disintegration) was measured for BDP.  The XH drug was weighed 
and dissolved in distilled water of 5 ml for the 30 mg/ml proliposome sample. Each 
sample was measured three times by timing it with a stop watch. Samples were taken as 
dispersed when no solid particles were seen in the bottom. A three second shake was 
given as soon as the solute was added to the solvent. A mannitol non-effervescent 
proliposome formulation was used as a control to demonstrate the disintegration of non-
effervescent proliposomes and compared time taken to the effervescent sample. 
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Dispersion time is somehow subjective but it was necessary to check in the initial stages 
of making an effervescent formulation. 
2.6. Nebulization of Liposomal Formulations  
 Nebulization of the effervescent formulation of drugs and liposomes for 
drug BDP 
The effervescent granules (30 mg/ml) were allowed to disintegrate in a beaker by the 
addition of 5 ml of deionized water. Following the completed disintegration of the 
samples and generation of liposomes from the proliposomes, the resultant dispersion was 
placed into a Pari Sinus nebulizer reservoir. The following studies have been carried out 
for both SPC- and DPPC-based effervescent formulations made as previously described 
in section 2.4.1.  
The nebulization took place in front of a vacuum line and the time taken for achievement 
of ‘dryness’ (i.e. when aerosol generation completely ceased) was determined. The 
amount of the formulation that was not to be aerosolized was then measured by washing 
all the parts of the nebulizer with deionized water. The drug fraction delivered from the 
nebulizer was quantified using HPLC. 
 Determination of nebulization time and generation of deliverable liposome 
from proliposomes for drug BDP 
A volume of 6 ml of deionized water was used to hydrate 180 mg of effervescent powder. 
Sugar-based and salt-based formulations were tested separately. A volume of 5 ml of 
water was placed in a Pari Sinus nebulizer with its mouthpiece being directed towards the 
round bottom flask. The nebulizer was not shaken prior to nebulization. When nebulized 
to ‘dryness’, sputtering time is recorded when a few minutes of erratic and intermittent 
nebulization is noted. The sputtering nebulizer was gently hand-tapped to maximize the 
aerosol output. When aerosol generation was ceased for at least 30 s the time taken for 
dryness was calculated.  
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 Determination of aerosol size: volume median diameter (VMD), span, and 
fine particle fraction (% < 5.4 µm)  
Aerosol size, span, and fine particle fractions were all analyzed using the Spraytec 
instrument (i.e. by utilizing laser diffraction to analyze the size distribution of aerosol 
particles). Each sample was nebulized for 2 min, which was the time at which the 
nebulizer was directed towards the laser beam of the Spraytec.   
 Mass output of nebulized aerosols   
To calculate the mass output (%), the weight of the nebulizer was weighed before and 
after nebulization to dryness for the collection of the aerosol. The aerosol mass output is 
calculated by (mass nebulized–residual volume)/mass nebulized *100.   
 Determination of drug entrapment before and after nebulization  
The entrapment efficiency of the model drugs was determined by placing the liposomes 
in centrifuge tubes and measuring the unentrapped amount of the drug (i.e. the drug 
amount that was left in the supernatant) using HPLC. The entrapment efficiency of the 
drug was calculated as the percentage proportion of the entrapped drug (within the 
liposome pellet) over the total amount of the drug originally included in the proliposome 
sample.  
To investigate the entrapment of drug in liposomes, separation of liposomes was achieved 
by centrifugation. Liposomes and BDP crystals have different densities; this was helpful 
for effective separation via centrifugation, resulting in sedimentation of the suspended 
drug crystals (i.e. unentrapped drug fraction), while liposomes (with the entrapped drug 
fraction) was floating on the surface. Batavia et al. (2001) have investigated if deuterium 
oxide may help the separation of liposomes from unincorporated BDP crystals. Therefore, 
in this study we investigated if effervescent proliposomes, both mannitol-based and salt-
based, would make a difference when suspended in H2O and D2O. A proliposome 
concentration of 30 mg/ml was used for separation. Microscopic study and HPLC 
analysis were conducted on the liposome formulations. After preparation of the samples, 
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each sample was centrifuged for 90 min and liposomes (in D2O the floating layer) were 
removed using a Pasteur pipette. This procedure was adapted from the preliminary work 
conducted within Dr Elhissi’s research group ( Khan et al., 2014) to effectively separate 
the entrapped drug from the unentrapped fraction (i.e. the free BDP crystals). A light 
microscope was used to observe the BDP crystals sedimented as a white spot upon 
centrifugation. HPLC analysis of the Beclometasone dipropionate was conducted at room 
temperature using the procedure explained in sections 2.5, 2.51, and 2.52.  
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2.7. Nasal Cast and Impinger Studies  
 Developing the novel system for aerosol deposition analysis to sinus  
           A unique system was developed to investigate the effectiveness of deposition in the nasal 
cavity and sinuses. Existing methods have several limitations due to the location of hidden 
pockets of sinuses and the fact that parasinuses are non-ventilated nasal pockets. A twin 
impinger and a transparent nasal cast model coated with Sar-Gel® (water indicating paste) 
(Figure 2-8 and Figure 2.9) were fixed on to the vacuum of 60 ml/l to mimic active 
breathing (Figure 2-10). A balloon was used to fix the nasal cast to the impinger and 
wrapped with cling film. Air was passed through the nasal cast and impinger while 
liposomes formulations were nebulized.   
 
 
Figure 2-5: Pari Sinus mouth pieces that were changed in Pari Sprint (only 
the white diverted part that will be fixed to nostril). 
(Source: http://nebology.com/pari-sinus-pulsating-aerosol-compressor-
system.html) 
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The Pari Sinus nebulizer (Pari LC ® Sprint SinusTM nebulizer attached to a Pari Sinus® 
compressor) (Figure 2-7) and Pari Sprint nebulizers (Pari LC ® Sprint Nebulizer attached 
to a PARI Turboboy®SX compressor) (Figure 2-6) (adapted with the parasinus 
mouthpiece to target the sinuses, Figure 2-4) were used and 20 ml of each sample was 
nebulized. A nose plug was used to close up one of the nose openings in the nasal cast 
and nebulized to mimic actual nebulization.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2-6: Pari Sprint nebulizer. 
(Source: 
http://nebology.com/media/catalog/product/cache/1/image/500x500/9df7
8eab33525d08d6e5fb8d27136e95/v/i/vios-pro-system.png) 
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Figure 2-7: Pari Sinus nebulizer. 
(Source: http://www.pulmomed.com.au/parisinus.html) 
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 Deposition pattern analysis for nasal cavity and sinuses of the nasal cast 
Twenty ml of effervescent proliposome formulations (30 mg/ml) and a control non-
effervescent liposomal formulation (based on mannitol with cholesterol and water) were 
hydrated and nebulized by the Pari Sinus and Pari Sprint nebulizers. A novel system was 
developed to study the deposition patterns in the nasal cavity and sinuses cast model using 
a paste Sar-Gel® that turns purple upon contact with water (Figure 5-3). This system 
contains the two-stage impinger that is connected to the nasal cast, which will allow 
analysis of both upper and lower respiratory drug deposition in one system. The Pari 
Sprint nebulizer was modified by replacing the mouth piece of the nebulizer with the 
nosepiece of the Pari Sinus; thus, aerosols can be directed into the ‘nostril’ of the nasal 
cast. Effervescent BDP proliposomes (DPPC: Chol coated onto mannitol or salt carrier 
particles) were hydrated with 20 ml of water (how much lipid concentration) and then 
nebulized towards the ‘nostril’ of the cast. A nose plug was used to close up one of the 
‘nostrils’; hence, permitting efficient deposition via a single nostril to mimic the actual 
nebulization to the patient. All parameters were kept the same in terms of distance 
between the nosepiece and nostril, and height of the nasal cast. Nebulization was 
performed to ‘dryness’ and nebulization deposition patterns were then photographed and 
images quantified using Adobe® Photoshop (n=3). The pixels were counted and then 
converted into cubic centimetres for both the full nasal cavity including the sinuses and 
the sinuses alone. Deposition patterns for both the nasal cavity and sinus for each 
formulation using both nebulizers were studied (Figure 5-4). Deposition of aerosols 
generated by the Pari Sinus nebulizer and Pari Sprint devices were compared on the basis 
of their ability to deliver aerosols to the nasal cavity and specifically the sinuses. 
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Figure 2-8: Change in nasal cast colour is attributed to the coating with 
Sar Gel. Non-effervescent DPPC:Chol liposomes using mannitol as 
carrier following nebulization via the Pari Sinus nebulizer.  
Figure 2-9: The deposition pattern is demonstrated in pixels. DPPC:Chol, 
non-effervescent liposomes made with mannitol carrier and nebulized via the 
Pari Sinus nebulizer.  
83 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Determination of BDP deposition profile in the nasal cast twin impinge 
model using HPLC  
Effervescent mannitol-based DPPC:Chol proliposomes were hydrated to generate 
liposomes (30 mg/ml), which were compared with the corresponding non-effervescent 
liposomes. Twenty 5 ml of each for four times, a total of 20 ml of formulation was 
nebulized via the Pari Sinus or Pari Sprint nebulizers until ‘dryness’ status was reached. 
The nasal cast was not coated with Sar-Gel® this time, and the deposited contents were 
collected and analyzed for regional drug deposition within each compartment of the 
system (nebulizer reservoir, nasal cast, upper stage, and lower stage of the impinger). 
Collection of the contents was accomplished by washing the nasal cast with 5 ml of HPLC 
grade water using a pipette, making sure all areas of the cast were washed including the 
Figure 2-10: Twin stage impinge and nasal cast system to analyze aerosol 
deposition in nasal and sinus regions. 
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sinus cavities. The same water was used over again until all parts of the nasal cast were 
washed thoroughly, then HPLC analysis was conducted as described in section 2.4. 
Aerosolized formulations to the upper and lower stage of the impinger were separately 
collected after washing, also for performing HPLC analysis. HPLC analysis was also 
carried out for residual volume of the nebulizer reservoir. Regional drug deposition was 
then calculated by quantifying the drug within each compartment divided by the total 
quantity of drug in all compartments to understand the percentage of regional drug 
deposition. Regional drug deposition was calculated for the nebulizer reservoir, nasal 
cast, upper stage, and lower stage of the impinger.  
 Data analysis  
All values were expressed as the mean of three readings from three different experiments 
and the standard deviations (SD) were calculated. The statistical significance was 
assessed using the students’ t-tests for comparing two groups, and analysis of variance 
(ANOVA) for comparing three groups or more. When P values were lower than 0.05 (i.e. 
<0.05) the difference between the groups was considered statistically significant. 
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CHAPTER 3  
CHARACTERIZATION 
AND ENTRAPMENT 
STUDIES OF 
EFFERVESCENT 
LIPOSOMES 
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3.1. Introduction 
Liposomes are vesicles used for the delivery of drugs and nutrients. They are made 
artificially and consist of lipid bilayers. Liposomes were first discovered in 1961 by Dr 
A. Bangham (Bangham and Horne, 1964). There are many advantages in using 
liposomes. They provide a controlled and sustained drug delivery, are site-specific and 
targeted, biodegradable, increase the therapeutic effect of drugs, are able to carry both 
water and lipid-soluble drugs, and protect against oxidation (Goyal et al., 2005). 
The drawbacks of liposomes include the tendency of phospholipids to oxidize and 
hydrolyze, and the susceptibility of liposomes to microbial contamination during storage 
(Sangare et al., 1998). Hence, stable powdered phospholipid formulations were 
introduced; these were referred to as proliposomes (Payne et al., 1986). Since 
proliposomes are solid formulations, the rate of phospholipid hydrolysis and oxidation is 
expected to be much lower, offering unique advantages in liposome technology. 
Effervescence is an acid-based reaction occurring in water, resulting in the production of 
carbon dioxide. Effervescent formulations have been used in oral delivery for nearly 200 
years (Eichman and Robinson, 1998). Effervescent granules are typically uncoated 
multiparticulate entities containing carbonates, acid substance, or hydrogen carbonate, 
which disperse at a rapid rate when they contact water, resulting in carbon dioxide 
liberation. Effervescent granules disintegrate or dissolve their ingredients and drugs in 
water, usually within five minutes. Modified release effervescent granules are designed 
to control the rate of drug release, target the desired areas, and delay the active substance 
from being released too quickly (Aulton and Taylor, 2013). 
Effervescent Ibuprofen proliposomes produced with Soya bean lecithin, Stearylamine, 
and cholesterol were investigated by Katare et al. (1990). They discovered that liposomes 
produced from effervescent granules were regular and uniform in size (1–4 µm) with high 
drug encapsulation efficiency (Katare et al., 1990). High shear force produced by 
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effervescence gave uniform liposomes, by facilitating the hydration of lipids. 
Furthermore, Indomethacin effervescent proliposomes were investigated in vivo using 
rats, which confirmed the superior anti-inflammatory activity of liposomal indomethacin 
compared to plain drug administration (Katare et al., 1995). 
Effervescent proliposomes containing docetaxel for delivery to the lung were produced 
by solid dispersion technique with docetaxel/Tween-80/Phospholipon 
90H/cholesterol/citric, hydrated in NaHCO3 solution (Zhao et al., 2010). Liposomes 
loaded with docetaxel were approximately 1 µm, negatively charged and had favourable 
lung-targeting effect. A similar study by Wei et al. (2013) using paclitaxel, also involved 
formulations targeted the lung. Liposomes composed of 90H and Tween-80 had a particle 
size of 8.166±0.459 µm and high drug entrapment efficiency and negative surface charge. 
These studies demonstrated that effervescent proliposomes are promising drug carriers 
(Wei et al., 2013). 
Conventional proliposomes require vortex or vigorous shaking to disperse in water in 
order to form liposomes. The aim of this study was to design and compare effervescent 
proliposome formulations that would disintegrate in water and liberate liposomes in a 
matter of minutes. This would improve dosing and produce liposomes available for 
immediate administration. Beclometasone dipropionate (BDP) is a glucocorticoid steroid 
that is insoluble in water. BDP has anti-inflammatory properties that are effective in 
hindering inflammatory cells such as mast cells, eosinophils, basophils, lymphocytes, 
macrophages, and neutrophils production in the human body to produce an immune 
reaction. BDP also inhibits the release of inflammatory mediators such as histamines, 
leukotrienes, and cytokines. Monoester, 17 monopropionate (17-BMP) is activated by 
hydrolysis in vivo by BDP and is demonstrated by its binding affinity for humans’ 
glucocorticoid receptor (GR), resulting in anti-inflammatory effects (Wang et al., 2011). 
BDP has serious side effects during long-term oral use that could lead to headaches and 
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visual changes. Thus, formulation of this drug as effervescent proliposomes will not only 
enhance its solubility but may also shorten the therapy course by enhancing the drug’s 
mucoadhesiveness and absorption (Mygind, 1973; Messerli et al., 1975). The hydrophilic 
drug Xylometazoline hydrochloride is used for the treatment of sinusitis. XH is a topical 
nasal decongestant that constricts blood vessels of the nose, resulting in reduced 
inflammation within the nose. However, long-term use of the drug causes side effects 
such as rebound effect; therefore, preparation of XH in liposomes may reduce the 
therapeutic dose of the drug and sustain its release, thus reducing the dosing frequency 
(Castellano and Mautone, 2002). It could also be useful to investigate if effervescent 
liposomes are capable of entrapping high proportions of XH. 
Dipalmitoyl phosphatidylcholine (DPPC) and Soya phosphatidylcholine (SPC) lipids 
were chosen to prepare separate formulations. Moreover, proliposomes based on 
effervescent salt carriers have not previously been investigated. In this project, 
effervescent proliposome formulations with sugar carrier or salt carrier were developed 
and compared.   
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3.2. Aims of the Chapter  
The aim of this chapter is to investigate the suitability of carbohydrate carriers (e.g. 
sucrose and mannitol) by characterizing empty and BDP-loaded liposomes in terms of 
vesicle size, span, zeta potential, and morphology.  
This chapter also explores the suitability of ethanol and chloroform as solvents during 
proliposome preparation by characterizing the resultant liposomes in terms of size, span, 
and zeta potential.  
The chosen carbohydrate carrier (mannitol) and solvent (ethanol) were then used for 
preparation of effervescent proliposomes. Effervescent proliposomes were compared to 
conventional liposomes by investigating the disintegration time, and characterizing 
liposomes in terms of size, span, zeta potential, and vesicle morphology using drug-free 
and BDP-loaded formulations. SPC or DPPC were used for producing effervescent 
liposomes.  
Effervescent liposomes were made with mannitol and effervescent salts alone (with SPC 
or DPPC). Liposomes produced were investigated for disintegration time and then 
characterized using BDP-loaded or drug-free liposomes. 
All effervescent formulations made were tested with and without cholesterol to 
understand the influence of cholesterol on effervescent liposomes. All effervescent 
liposomes made with either a sugar-based carrier or salt-based carrier (with or without 
cholesterol) were made with SPC or DPPC and then studied for ability to entrap BDP 
using HPLC.  
Alginic acid and chitosan were used for coating the effervescent BDP-loaded liposomes 
made with SPC, with or without cholesterol, followed by characterization and drug 
entrapment studies to understand whether the incorporation of mucoadhesive would be 
beneficial for improving the drug entrapment.  
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The hydrophilic drug XH was incorporated into the effervescent liposomes made with the 
sugar-based carrier (mannitol) or effervescent salt-based (effervescent salts alone) and 
using SPC with or without cholesterol.  All formulations were studied in terms of 
disintegration time and liposome properties (size, span, and zeta potential).  
A novel HPLC method was developed to investigate the entrapment of XH within 
effervescent liposomes. At the end of this chapter the most suitable carrier is decided, and 
the potential of effervescent salts was explored for the production of stable liposomes.  
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3.3. Results and Discussion  
 Characterization of sugar- and mannitol-based liposomes (conventional) 
manufactured with SPC lipid  
3.3.1.1. Characterization of particulate-based empty liposomes (1:5 w/w lipid to 
carrier) 
Particulate-based proliposomes were made using the slurry method as explained in 
method section 2.2. Sugar or mannitol particles were coated with SPC (1:5 w/w lipid to 
carrier), and following hydration, the resultant liposomes were characterized in terms of 
size, span, and zeta potential.  
Drug-free and drug-loaded proliposomes were compared (Figure 3-1) and results 
indicated that liposomes generated from sucrose-based proliposomes had a VMD 
measurement of 6.21+0.81 µm. These results correlate with previous findings by Elhissi 
and Taylor (2005) and Elhissi et al. (2006). Empty mannitol-based liposomes had a size 
of 6.82±0.44 µm. No statistically significant difference was detected for VMD between 
sucrose- and mannitol-based proliposomes.  
The span was at 2.54±0.360 for sucrose-based proliposomes and 2.21±0.79 for mannitol-
based proliposomes (Figure 3-1), with a (P≤0.05) significant difference between the two 
formulations.  
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Figure 3-1: Sucrose- and mannitol-based liposomes 1:5 w/w lipid to carrier ratio, size 
(µm), and span analysis of empty liposomes. 
 
Elhissi (2005) stated that SPC:Chol (1:1) span, when using sucrose carrier particles, was 
1.68±0.21, correlating with the results obtained with sugar-based proliposomes in the 
present report. Elhissi et al. (2006) employing particulate-based proliposomes with 
dimyristoyl phosphatidylcholine (DMPC) reported the span was 0.99±0.06; hence, 
different phospholipids and different methods of producing proliposomes may cause a 
difference in the span of the resultant liposomes.  
The zeta potential for both formulations are presented in Figure 3-2. Liposomes generated 
from sucrose-based proliposomes showed a slightly more negative charge of  
-2.24±0.08 mV, while mannitol-based proliposomes have generated liposomes having a 
zeta potential measurement of -1.40±0.19 mV. A statistical significance (P≤0.05) was 
observed between the two formulations. Phospholipids used in the preparation of 
liposomes are neutral, but liposomes observed in both formulations were slightly 
negative, which may be due to impurities in SPC or sugar carriers. Literature by 
Yandrapati (2012) demonstrated phosphatidylcholine lipid with different concentrations 
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produced highly negative liposomes that were stable. Sharma and Sharma (1997) have 
stated that the negative surface charge of liposomes may cause them to exhibit greater 
uptake by the cells via endocytosis. The negatively charged liposomes were also cleared 
rapidly after systemic administration, helping with the release of the drug. Sharma 
(2009a) and Sharma et al. (2010) have also reported that positively or negatively charged 
liposomes tend to be taken up by the reticulo-endothelial system to greater extents, 
compared to neutral liposomes. Moreover, neutral liposomes tend to aggregate more than 
charged liposomes; therefore, having negative liposomes may help reduce liposome 
aggregation, and improve physical stability of the formulation. 
 
 
Figure 3-2: Sucrose- and mannitol-based liposomes 1:5 w/w lipid to carrier ratio, zeta 
potential (mV) analysis of empty liposomes. 
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3.3.1.2. Characterization of particulate drug-loaded 2.5 mol% liposomes 1:5 ratio 
(lipid to carrier) 
Both carriers were investigated with inclusion of BDP (2.5 mol %). Drug-loaded sucrose 
liposomes showed a VMD of 5.94±0.94, whereas mannitol-based liposomes 
demonstrated a VMD of 6.92±1.05, with no statistically significant difference between 
the two formulations. However, when compared with empty liposomes, it was observed 
that the size of the sucrose liposomes has slightly decreased, while mannitol-based 
liposomes showed a slight size increase.  
No statistically significant difference was seen between empty and drug-loaded liposomes 
for both sucrose- and mannitol-based formulations. Elhissi et al. (2006) have stated that 
liposomes generated from sucrose-based proliposomes had a VMD of 5.23±0.10 and a 
span of 1.09±0.01 when incorporated with 2.5 mol% BDP, correlating with the results 
obtained in this study. 
The span for sucrose-based liposomes (2.5 mol% BDP) was 2.13±0.22 whereas mannitol-
based proliposomes had a span of 2.69±0.40 and the differences were insignificant 
(Figure3-3). 
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Figure 3-3: Sucrose and mannitol based liposomes (1:5 w/w lipid to carrier ratio) 
loaded with 2.5 mol% BDP, liposome size distribution (µm) analysis and span of BDP 
loaded liposomes. 
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The zeta potential of liposomes was also investigated. The surface charge for sucrose-
based drug-loaded liposomes was -2.57+ 0.98 mV while mannitol-based liposomes had 
a charge of -1.29+ 0.11 mV (Figure 3-4). Sucrose-based liposomes were slightly more 
negative than mannitol-based liposomes for drug-containing formulations; this was also 
observed in non-effervescent proliposome formulations.  
Considering all of the above results between the two carriers, drug-loaded and empty, 
mannitol was more appropriate as a carrier, since after loading the drug, liposome size 
was increased only slightly. It is also widely known that mannitol gives a cooling effect; 
patients with ‘hot’ inflamed sinuses would probably feel more comfortable when the 
cooling effect of mannitol occurs in their nasal cavity. Therefore, mannitol was the carrier 
of choice for the subsequent studies in this report.  
Since better treatment for sinuses and reducing nasal irritation is an objective, the use of 
chloroform might not be appropriate, since any unsuccessfully removed solvent residues 
may cause epithelial irritation. Ethanol may comprise an alternative to disperse mannitol 
and dissolve lipids in the preparation of the particulate-based proliposomes. Therefore, 
1:5 lipid to carrier ratio using mannitol as carrier and ethanol as solvent was employed to 
manufacture liposomes, and the resultant vesicles were studied.  
Subsequent changes were made to the ratio of lipid and carrier (1:10 ratio) utilizing 
mannitol with 2.5 mol% BDP. Further investigations were conducted to ascertain whether 
the 1:10 ratio with 5 mol% BDP has exhibited any change.  
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Figure 3-4: Sucrose- and mannitol-based liposomes 1:5 w/w lipid to carrier ratio 
loaded with 2.5 mol% BDP, liposome zeta potential (mV) analysis of BDP-loaded 
liposomes. 
3.3.1.3. Characterization of mannitol-based empty liposomes 1:5 ratio with 
ethanol as a solvent  
Ethanol was compared as a solvent to chloroform. Ethanol is known to be less toxic and 
cheaper than chloroform. Liposomes using a mannitol carrier and BDP were 
characterized. The size analysis (Figure 3-5) of empty liposomes was measured at 
5.52±2.89 µm, compared to liposomes made with chloroform, which gave a mean value 
of 6.82 µm. Liposomes with BDP included showed a size of 6.27±1.51 µm.  
The span was 2.89+0.44 for empty liposomes, which is very similar to the results achieved 
when chloroform was used as a solvent, and size distribution was not affected by the 
change of solvent. Drug-loaded liposomes were observed to have a span of 3.11+0.67. 
No significant difference in the span measurements was seen between empty and drug-
loaded liposomes for ethanol-based formulation.  
The zeta potential of empty liposomes was -1.81±0.101 mV, while drug-loaded liposomes 
had a zeta potential of -2.07±0.59 mV (Figure 3-6). Similar to results achieved previously, 
no significant difference was seen between the results. Since size, span, and zeta potential 
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all correlated with pervious results and especially since the size was slightly smaller when 
ethanol was used, it was decided to continue further research with mannitol as carrier and 
ethanol as solvent to cast the lipid film on the carrier particles.  
 
Figure 3-6: Mannitol liposomes 1:5 w/w lipid to carrier ratio made with ethanol as a 
solvent, loaded with 2.5 mol% BDP. Liposome sizes (µm) and span analysis of empty 
and BDP-loaded liposomes. 
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Figure 3-5:  Mannitol liposomes 1:5 w/w lipid to carrier ratio made with ethanol as a 
solvent, 2.5 mol% BDP, liposome zeta potential (mV) of empty and BDP loaded 
liposomes. 
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3.3.1.4. Characterization of mannitol-based empty liposomes (1:10 ratio) using 
ethanol as a solvent  
Since the research now achieved has served to finalize the thorough results that mannitol 
works best as a carrier and ethanol would be a better solvent, it was decided to change the 
lipid to carrier ratio to explain the comparisons. The size of empty liposomes was 
5.71+0.519 µm correlating with the results obtained by the 1:10 ratio liposomes made 
with chloroform as a solvent; this indicates that ethanol is a suitable solvent to make 
liposomes. Size appeared to increase following entrapment of BDP, being 7.71±0.68 µm 
(Figure 3-7). 
The span was observed to be 4.26±0.89 for empty liposomes and 4.01±0.44 for liposomes 
loaded with the drug for mannitol-based liposomes made using liposomes. The span has 
increased minimally when using chloroform. In addition to its higher safety and lower 
cost, ethanol produced liposomes with a smaller size than chloroform. The zeta potential 
of empty liposomes was seen at -1.72±0.69 mV while liposomes with drug were -
3.02±0.70 mV (Figure 3-8). Liposomes with the drug elicited a trend for a more negative 
charge than empty liposomes (P>0.05).  
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Figure 3-8: Mannitol-based liposomes 1:10 w/w lipid to carrier ratio with 2.5 mol% 
BDP, liposomes zeta potential (mV) of empty and BDP-loaded liposomes.  
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Figure 3-7: Mannitol-based liposomes 1:10 w/w lipid to carrier ratio with 2.5 mol% 
BDP, liposome size (µm) and span analysis of empty and BDP loaded liposomes. 
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3.3.1.5. Characterization of mannitol-based empty and drug-loaded liposomes 
1:10 ratio with ethanol as a solvent with 5% BDP 
Liposome size shown with 2.5 mol% in 1:10 ratio and consequently 1:10 ratio was 
chosen. Liposomes were characterized with 5 mol% BDP in 1:10 lipid to carrier ratio. A 
range of studies have focused on using BDP in 5 mol% as the maximum concentration 
for the drug to be entrapped in liposomes. Earlier experiments were also conducted with 
2.5 mol% in order to reduce drug wastage, if no greater entrapment would be achieved. 
On formulation of effervescent liposomes, it was believed that 1:10 lipid to mannitol 
carrier ratio using ethanol as the solvent for casting the thin film and the drug in 5 mol% 
would possibly be most appropriate for subsequent characterization.   
The size of empty liposomes was 5.27±0.16 µm, whereas after loading the drug it was 
observed that the size was 8.25±0.50 µm (Figure 3-9). A significant difference (P≤0.05) 
was seen when the size of empty and drug-loaded liposomes was compared. There was 
no significant difference observed for the size and span between liposomes 
accommodating 2.5 and 5 mol% BDP.   
The zeta potential for empty liposomes was -1.62±0.42 mV while after loading the drug 
it became -3.72±0.25 mV (Figure 3-10) with a significant difference between empty and 
drug-loaded vesicles.  
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Figure 3-9: Mannitol-based liposomes 1:10 w/w lipid to carrier ratio with 5 mol% 
BDP, liposome size (µm) and span analysis of empty and BDP-loaded liposomes. 
 
 
 
Figure 3-10: Mannitol-based liposomes 1:10 w/w lipid to carrier ratio, with 5 mol% 
BDP, liposome zeta charge (mV) of empty and BDP-loaded liposomes. 
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 Scanning electron microscopy (SEM) for conventional liposome 
3.3.2.1. Surface morphology of sucrose-based proliposomes  
Scanning electron microscopy pictures looked at the surface morphology of sucrose-
based proliposomes. This was observed at x 500 magnification for both sucrose particles 
(Figure 3-11) and drug-loaded proliposomes (Figure 3-12). Both samples showed 
uniform phospholipid coating. The surface of sucrose particles appeared glossy; this may 
be explained by the sticky nature of phospholipid. Particles were irregular but more cubed 
in shape and some of the particles had aggregated. Similar SEM pictures were observed 
for sucrose in a study done by (Wulkersdorfer et al. 2010). There was no difference 
observed between drug-free proliposome particles and BDP-loaded proliposomes.  
 
 
 
 
 
Figure 3-12: Sucrose-based 
proliposomes. A typical observation of 
three different experiments. 
 
Figure 3-11: Sucrose-based proliposomes 
particles with 2.5 mol % BDP drug and 
sucrose-based proliposomes. A typical 
observation of three different experiments.  
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3.3.2.2. Surface morphology of mannitol-based proliposomes  
In comparison to the morphology of sucrose particles (Figure 3-13) that are irregular and 
have cube shapes, mannitol-based proliposomes were cylindrical crystals. Yan-yu et al. 
(2006) compared the difference of mannitol crystal to mannitol-based proliposomes. The 
results shown in Figure 3-14 correlate with their finding, showing a glossy appearance 
when compared to typical mannitol crystals, indicating uniform coating with 
phospholipid was achieved.  
 
 Effervescent BDP proliposome using SPC phospholipid  
3.3.3.1. Investigation of effervescence of formulations  
To the knowledge of the author of this report, no work has been done with BDP 
effervescent proliposomes formulation for targeting the sinuses via aerosolization.  
As mentioned in chapter 2, using 1:10 lipid to carrier ratio (section 2.2.3), and mannitol 
as carrier particles, proliposomes were manufactured. This was achieved without drug or 
with inclusion of BDP (5 mol%) followed by characterization studies (size, span, and zeta 
potential).  
Figure 3-14: Mannitol -based 
proliposomes particles (50 μm) with 2.5 
mol% BDP drug and proliposomes. 
Figure 3-13: Mannitol-based 
proliposomes particles at (200 μm with 2.5 
mol% BDP drug and proliposomes. 
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3.3.3.2. Drug-free effervescent formulations  
Effervescent formulations were prepared without drug to compare conventional 
liposomes to effervescent liposomes loaded with drug. Mannitol-based effervescent 
formulation and liposomes without a carbohydrate-based (effervescent salts alone used 
as carrier) carriers were investigated. Both formulations generated liposomes upon 
liberation of carbon dioxide that was induced by the acid-base reaction in the formulation. 
Mannitol-based liposomes had a size measurement of 5.06+0.12 µm (Figure 3-15); results 
correlated with the previous results showing a similar size to liposomes without 
effervescent. In fact, span was smaller (span = 3.07) compared to normal liposomes, 
indicating slightly less aggregated liposomes (Figure 3-16); hence, effervescence may 
have contributed to disaggregating the liposomes, resulting in narrower size distribution.   
Sodium chloride salt was used as a possible carrier previously by other investigators  
(Payne et al., 1986; Yan-yu et al., 2006). Since salts might be used in formulating 
proliposomes, the possibility of formulating effervescent liposomes using salts as a carrier 
was investigated in this report. Salt-based liposomes generated liposomes having a very 
large size (20.60+3.74 µm) with a relatively high span value of 3.74 (Figure 3-16), 
indicating aggregation of the liposomes. 
The zeta potential values were also different compared to mannitol-based liposomes 
(Figure 3-16). While liposomes generated from mannitol-based proliposomes were 
negatively charged (-1.86+0.60 mV), correlating with non-effervescent liposomes, salt-
based proliposomes generated vesicles with positive zeta potential measurements (+1.19+ 
0.16 mV).  
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Figure 3-15: Liposome size of SPC lipid-based effervescent formulations, 5 mol% 
BDP-loaded. 
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Figure 3-17: Zeta potential (mV) analysis of effervescent liposome formulations of 
SPC lipid-based formulations, 5 mol% BDP-loaded liposomes. 
Figure 3-16: Liposome span analysis of SPC lipid-based effervescent formulations, 5 
mol% BDP-loaded. 
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3.3.3.3. Drug-loaded effervescent formulations  
BDP-loaded effervescent formulations were studied for size, span, and zeta potential. 
Drug-loaded effervescent mannitol-based liposomes had a size of 5.14+0.49 µm while 
effervescent salt-based liposomes had a size of 20.27+6.55 µm. When comparing 
mannitol-based to salt-based formulations a significant difference was observed in terms 
of measured size. Moreover, salt-based liposomes had a span of 2.96+0.77 while 
mannitol-based samples had a span of 4.41+2.72 mV. Zeta potential for mannitol-based 
formulations correlated with all previous mannitol-based formulations, having a 
measurement of -1.86+0.67 mV, while salt liposomes were positively charged 
(+0.89+0.85 mV). Since the size of salt-based liposomes was relatively large, it was 
decided to omit cholesterol from the formulation to investigate if this would affect the 
results. Mannitol-based liposomes showed that the size of 7.33+0.45 µm slightly 
increased with drug when cholesterol was omitted.  The size of vesicles was relatively 
large compared to liposomes with cholesterol (P˂0.05).  
Salt-based proliposomes also showed a drastic difference in size when investigated 
without cholesterol. Size was observed to be 6.04+0.19 µm when cholesterol was omitted. 
Moreover, when cholesterol was excluded from the formulations, there was no significant 
difference between mannitol samples and salt samples. Therefore, it is justified to state 
that the presence of cholesterol as an effervescent ingredient can result in a huge increase 
in the size of liposomes when salt was used as a carrier in preparing proliposomes.  
The span of liposomes using mannitol as a carrier without using cholesterol was 
2.59+0.41, and salt-based liposomes without cholesterol had a span of 2.74+0.16. There 
was no significant difference between the samples with cholesterol and without 
cholesterol when mannitol was used as carrier.  
The zeta potential for mannitol-based proliposomes was -0.68+0.24 while salt-based 
proliposomes generated liposomes having positive surface charge (1.19+0.50 mV) 
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(Figure 17). Omitting cholesterol has not changed the charge of liposomes generated from 
salt-based proliposomes (Kokkona et al., 2000).    
Tseng et al. (2007) found that by increasing cholesterol concentration, liposomal stability 
increased. Liposomes with higher cholesterol concentrations were able to withstand more 
shear stress compared to liposomes with lower cholesterol concentrations. Cholesterol 
has an impact on the integrity of liposomes (Tseng et al., 2007). Cholesterol molecules 
are positioned between the free spaces of the unsaturated lipids of the liposome bilayers, 
leading to decreased flexibility of the surrounding lipid chains (Figure 3-18). Thus, the 
difference of size as a result of cholesterol inclusion might be attributed to the different 
packing profile of the liposome bilayers.   
  
 
 
 
 
 
 
 
 
 
 
Liposomes are usually stable at different pH values, but in pancreatic lipase they rapidly 
lose their entrapped material. Liposomes made with phosphatidylcholine and cholesterol 
immersed in cholate salts were investigated at different concentrations of cholate salts to 
see if any changes would be observed in the size of liposomes.  A decrease of 20% in size 
after immediate addition of the salts was observed for liposomes that are free from 
Figure 3-18: Location of cholesterol molecules within phospholipids 
bilayer. 
(Source: 
http://www.uic.edu/classes/bios/bios100/lectf03am/cholesterol.jpghttp://
www.uic.edu/classes/bios/bios100/lectf03am/cholesterol.jpg) 
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cholesterol (Kokkona et al., 2000). The protective characteristics of cholesterol may help 
in the presence of sodium cholate salt, which is attributed to the rigidity of the bilayers 
upon incorporation of cholesterol, preventing reduction in liposome size (Kokkona et al., 
2000).   
Liposomes exhibit properties similar to that of the biological membrane. One such 
property is the ability of water to pass in and out through the liposome’s semi-permeable 
membranes. Bangham and co-workers (1967) illustrated that liposomes are a good model 
to study the osmotic properties and water permeability of phospholipid liquid crystals. 
When liposomes were immersed in a hypertonic surrounding (e.g. because of the 
effervescent salts) and the inside of the liposomes have more water (hypotonic) than 
outside, this may result in water movement from inside the vesicles to outside, possibly 
causing liposomes to shrink (Hupfeld et al., 2010). Therefore, without the protective 
function of cholesterol in effervescent samples, liposomes may not be able to withstand 
the external osmotic pressure, resulting in a size decrease of liposomes because of 
shrinkage. This was further reported in 2006, when the stability of liposomes was studied 
by introducing a hydrated radius of the adsorbed ions on to the liposome’s surface by 
extending Derjaguin-Landau-Verwey-Overbeek (DLVO) theory. The theory explains 
force changes when interacting between a liquid medium and a charged surface. The 
double layer electrostatic repulsion and Van der Waals attraction combined and resulted 
in the DLVO effect. The presence of ions resulted in a decrease in liposome size when 
certain ions did not pass through the membrane, resulting in an osmotic force leading 
water to pass from inside to outside the liposome vesicles  (Sabın et al., 2006). Ions 
present in effervescent content may also result in a decreased size when the protective 
effect of cholesterol is not present.  
In summary, when only taking into account the characteristics of liposomes in the 
presence of effervesce, it is reasonable to say mannitol-based liposomes with cholesterol 
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would be the best choice of effervescent samples for sugar-based formulations, while salt-
based samples without cholesterol would be more suitable for further investigations in 
terms of size, span, and zeta potential. Physical characterization alone cannot decide if a 
formulation would be suitable for therapeutic use; therefore, further studies are needed in 
the future.  
3.3.3.4. Appearance of effervescent formulations   
A study by (Katare et al., 1990; Katare et al., 1995a) have hypothesized that Ibuprofen 
effervescent proliposomes, upon addition of water,  have generated liposome dispersions 
as a result of shaking provided via the liberation of carbon dioxide.  These results 
correlated with the study in this report using BDP, resulting in the formation of liposomes 
having narrow size distribution.  
Disintegration of proliposome granules was carried out as described earlier (chapter 2; 
section 2.5.3) via the determination of time taken for the sample to disperse in distilled 
water (5 ml; 30 mg/ml). The end point for full disintegration is achieved when no solid 
particles are seen in the bottom of the vial. Three seconds of shaking was provided as 
soon as the proliposomes were added to water. Mannitol non-effervescent proliposome 
formulation was used as a control for comparison with effervescent proliposome 
disintegration.  
Table 3-1: Dispersion time analysis of SPC-based effervescent proliposomes  
 
Mannitol 
with 
cholesterol 
Salt with 
cholesterol 
Mannitol 
without 
cholesterol 
Salt without 
cholesterol 
Mannitol non-
effervescent 
proliposomes 
(control) 
Time 
(min) 
1.21±0.22 0.53±0.04 1.23±0.15 0.4±0.03 56.51±1.87 
 
The non-effervescent formulation took about one hour to fully disperse. Without any 
shaking, solids were observed at the bottom and shaking was necessary for all solids to 
dissolve completely in the control sample. By contrast, the effervescent sample took less 
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than 1.5 min to completely disintegrate, without observing any solids at the bottom of the 
vial.  
Mannitol-based proliposomes with cholesterol was observed to be dispersed after 1.21 
min of water addition. Mannitol-based proliposomes without cholesterol also had a 
similar dispersion time at 1.23 min (Table 3-1). Both mannitol-based samples (Figure 3-
20, Figure 2-22) showed comparatively less form compared to salt-based samples and 
was shown to have less agitation compared to salt-based samples. Both samples showed 
a milky colour after dispersion observed, with very little foam.  
Salt-based samples (Figure 3-20), on the other hand, showed a significant difference in 
disintegration time compared to mannitol-based samples. Less than half the time was 
taken to disperse effervescent salt-based samples. A very large amount of foam was 
observed upon hydration, which immediately diminished (Figure 3--21). 
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Figure 3-19: Appearance of 
mannitol-based effervescent 
liposome sample (more foam), milky 
appearance. 
 
 
 
 
 
 
 
Figure 3-20: Appearance of salt-
based effervescent liposome sample 
(more foam) milky appearance. 
 
 
 
 
 
 
  
Figure 3-21: Appearance of 
mannitol and salt–based 
effervescent liposome samples 
together, foam goes down after a 
while giving both the samples 
similar appearance. 
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 SEM picture of effervescent proliposomes (mannitol- and salt-based)  
As seen in Figure 3-22 and Figure 3-23, effervescent mannitol-based proliposomes had 
needle-like glossy crystals. Effervescent salt-based samples shown in Figure 3-24 and 
Figure 3-25 had less spiky structures compared to mannitol-based formulations, and 
uniformly distributed phospholipid coating was observed.         
 
Figure 3-22: SEM picture salt-based 
sample with cholesterol. 
Figure 3-25: SEM picture of salt-based 
sample without cholesterol  
Figure 3-24: SEM picture of mannitol-
based sample without cholesterol. 
Figure 3-23: SEM picture of mannitol-
based sample with cholesterol. 
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 HPLC results of BDP-loaded effervescent samples  
3.3.5.1. Entrapment studies of BDP for SPC-based formulations  
BDP entrapment of effervescent formulations was tested with water and D2O as described 
in chapter 2, section 2.4. In Figure 3-26, BDP entrapments are determined as a percentage 
in both water and D2O. 
 Table 3-2: Drug entrapment efficiency for BDP-loaded liposomes (%) in water and 
D2O 
 
Mannitol with 
cholesterol 
Salt with 
cholesterol 
Mannitol 
without 
cholesterol 
Salt without 
cholesterol 
Water  98±0.69 97±1.46 86±13.19 81±15.81 
D2O 20.54±12.02 29±13.49 8±1.79 11±3.40 
 
The HPLC study demonstrated that all peaks of BDP were symmetrical and had a 
retention time of 4.5 min. A calibration curve was constructed for BDP using drug 
concentrations of 5-40 µg/ml. The highest level of entrapment was observed for mannitol-
based proliposomes with cholesterol effervescent at 98+0.69%. Salt-based proliposomes 
with cholesterol caused the entrapment to become 97+1.46%. No significant difference 
was observed between these two formulations. However, mannitol-based proliposomes 
without cholesterol demonstrated a lower entrapment of 86+13.19%. Moreover, salt -
based proliposomes without cholesterol also displayed an entrapment of 81+15.81%.   
Entrapment studies using D2O as a separation medium displayed completely different 
results, but cholesterol was still advantageous at enhancing BDP entrapment. In contrast 
to water, samples dispersed using D2O exhibited that salt with cholesterol formulations 
was able to entrap more BDP with an entrapment of 29+13.49%. By contrast, mannitol-
based samples with cholesterol exhibited an entrapment of 20.54+12.02%   
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Liposomes without cholesterol based on mannitol as a carrier in effervescent formulations 
resulted in an entrapment of 8.39+1.79%, while salt-based proliposomes presented a 
slightly higher trend for entrapment of 11.28+3.40%, with no significant difference 
between the two samples. Moreover, lower entrapment in the salt-based formulations in 
the absence of cholesterol was observed. No significant difference was observed when 
comparing mannitol-based samples with and without cholesterol for samples dispersed in 
D2O. Results demonstrated that the presence of cholesterol did not affect BDP 
entrapment. When comparing salt-based samples with and without cholesterol, no 
significant difference in entrapment was observed.   
 Radhakrishnan (1991) stated that achieving 100% encapsulation efficiency is 
challenging due to the encapsulation percentage having dependence on the lipid 
properties and concentration, and on the encapsulation method used. It was further 
discussed that liposomes made without cholesterol have less flexibility to encapsulate the 
drug; only 1–3 mol% of steroidal drugs was seen entrapped in formulations without 
cholesterol (Radhakrishnan, 1991).  This correlates with the results obtained in the present 
study. Formulations without cholesterol demonstrated lower encapsulation efficiency of 
BDP. It was also elaborated that fluffy hydrogenated soy phosphatidylcholine may not be 
the most suitable candidate in the lipid encapsulation of steroidal drugs. Liposomes made 
with egg phosphatidylcholine (EPC) and BDP have shown an entrapment of 75% using 
water as a dispersion medium. However, the experiments undertaken obtained a higher 
entrapment efficiency of BDP with SPC phospholipid.  
BDP entrapment efficiency of 100% was noted when water was the dispersion medium 
for liposomes prepared using the ethanol injection method (Jaafar-Maalej et al., 2010). 
Moreover, the amounts of lipid and cholesterol have affected the size and encapsulation 
efficiency of liposomes. Studies done by Jaafar-Maalej et al. (2011) also reported an 
entrapment efficiency of 98% for BDP.  
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Darwis and Kellaway (2001) have reported that liposomes have a low encapsulation 
efficiency of steroidal drugs, due to the geometric structure of steroidal drug molecules 
which offer a limited interaction with the liposome bilayers. Liposome ability to 
accommodate BDP was reported to be inversely proportional to the transition temperature 
(Tm) of the phospholipid employed. The higher the Tm of the phospholipid the lower the 
entrapment efficiency. The size of liposomes may also affect drug encapsulation, since 
small multilamellar vesicles offered lower drug entrapment compared to larger 
multilamellar vesicles. 
When using D2O to investigate entrapment there is a need to separate the liposomes from 
the suspension. This process may lead to disruption of liposomal bilayers, with 
concomitant leakage of BDP.  Batavia et al. (2001) have reported that using several stages 
of separation may be disadvantageous and the use of D2O can affect the 
partitioning behaviour of the drug between the liposome bilayers and the surrounding 
aqueous environment.  
3.3.5.2. Microscopy investigation of BDP crystal sediment 
Steroids and steroid esters have low solubility in phospholipid formulations (Fildes and 
Oliver, 1978). Batavia et al. (2001) found an alternative method of separating entrapped 
liposomes from BDP crystals. Excess BDP tends to crystallize due to their incompatible 
steric fit with the liposome bilayers. Batavia et al. (2001) investigated the separation of 
liposomes and BDP crystals, stating that BDP crystals have a size and density that are 
comparable to those of liposomes, hence separation is difficult; therefore, density gradient 
centrifugation is necessary for the reliable separation of liposomes (with entrapped drug) 
and free drug that tends to sediment as crystals. The density difference between D2O and 
water facilitates the separation of BDP crystals and liposomes. BDP crystals were 
investigated using light microscopy. Crystalline spots of BDP appeared at the bottom of 
the centrifuge tubes (Figures 3-26 and 3-27, 3:28). This indicates that by using D2O, 
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effective separation of BDP-entrapped liposomes (floating at the surface) from BDP 
crystals (sedimenting at the bottom) was achieved. 
Figures 3-26 and 3-28 represent light microscopy pictures of BDP spot showing the 
presence of BDP crystals alone, with no significant observation of liposomes. Salt-based 
liposome samples and mannitol-based liposomes appeared to have similar types of BDP 
crystals.  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3-26: Microscopy investigation of 
BDP crystal sedimentation of 
effervescent mannitol based with 
cholesterol formulation 40X. 
Figure 3-28: Microscopy investigation of BDP 
crystal sedimentation of effervescent salt 
based with cholesterol 40X. 
 
Figure 3-27: Microscopy investigation 
of BDP crystal sedimentation of 
effervescent mannitol based without 
cholesterol formulation 40X. 
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 Mucoadhesives in SPC formulations  
Formulations with 1:10 w/w lipid to carbohydrate carrier (mannitol) with cholesterol 
formulations and 1:10 w/w lipid to salt without cholesterol formulations were chosen to 
be tested with mucoadhesive. Samples were made according to chapter 2, section 3.3.3 
using the slurry method and were hydrated in alginic acid and chitosan solutions (0.2% 
w/v or 1% w/v). In this part, the effervescent formulations that demonstrated overall 
suitability (size, span, zeta potential, and entrapment) of previous studies for targeting the 
parasinuses were chosen. Mucoadhesive polymers such as alginic acid or chitosan were 
incorporated to improve the bioadhesive properties of the formulations. 
3.3.6.1. Mannitol-based formulation containing alginic acid 
Non-effervescent liposomes with the 1:10 w/w lipid to carrier ratio generated liposomes 
with alginic acid (0.2% w/v), with size (17.99±0.56 μm), while both drug-free 
effervescent liposomes (9.47±0.12 μm) and drug containing effervescent liposomes 
(6.15±0.04 μm) had smaller size. There was no significant difference between drug-
loaded non-effervescent liposomes and effervescent liposomes. Non-effervescent 
liposomes with 1% w/v alginic acid produced smaller liposomes (7.26±0.60 µm) 
compared to non-effervescent liposomes with 0.2% w/v alginic acid. Effervescent 
liposome size generated by alginic acid (0.2% w/v) is smaller compared to 1% w/v alginic 
acid, which produced liposomes with a much larger size (12.25±0.07 μm) in the presence 
of BDP (Table 3-3).  
The span of mannitol-based formulations for alginic acid (0.2% w/v) seem to be more 
suitable compared to non-effervescent liposomes in terms of size distribution (span = 
3.763±0.1), indicating less aggregation. Mannitol-based effervescent formulations with 
alginic acid (1% w/v) have significant span values in comparison to formulations 
hydrated in 0.2% w/v alginic acid (P≤0.05) (Table 3-3). Non-effervescent and 
effervescent formulations with the drug also demonstrated significant differences in span 
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for 0.1% w/v formulation (P≤0.05). Incorporation of alginic acid appears to increase the 
negative charge of the liposomes when compared to samples that did not contain alginic 
acid. Alginic acid with a concentration of 0.2% w/v was deemed to increase the negative 
charge of the effervescent liposomes in general when compared to 1% w/v concentration 
(Table 3-3). The zeta potential in liposome charge was observed for non-effervescent 
liposomes with 0.2% w/v (-17.76±1.05 mV) while 1% w/v formulations had a zeta 
potential of (-42.03±4.0). Formulations of 0.2 w/v seem to be the most suitable for 
mannitol-based formulations in terms of size, span, and zeta potential.  
Table 3-3: Characterization of non-effervescent and effervescent mannitol-based 
liposomes made with SPC, coated with mucoadhesive alginic acid 
 
 
Alginic acid 
concentration  
Size (μm) Span Zeta potential 
(mV)  
0.2% W/V  
(With drug, non-
effervescent 
liposomes)  
 
17.99±0.56 
 
3.87±0.11 
 
-17.76±1.05 
0.2% W/V  
(Empty, effervescent 
liposomes) 
 
9.47±0.12 
 
2.47±0.04 
 
-16.1±0.5 
0.2% W/V (with 
drug, 
effervescent 
liposomes) 
 
6.15±0.04 
 
3.76±0.14 
 
-18.63±0.9 
1% W/V  
non-effervescent 
liposomes (with 
drug) 
 
7.26±0.60 
 
5.35±0.6 
 
-42.03±4.0 
1% W/V  
(empty, effervescent 
liposomes) 
 
11.0±0.07 
 
2.5±0.15 
 
-12.4±0.65 
1% W/V (with drug, 
effervescent 
liposomes) 
 
 
12.25±0.07 
 
2.9±0.15 
 
-12.5±0.5 
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3.3.6.2. Salt-based formulation containing alginic acid 
Liposomes produced with effervescent salts alone, without mannitol and without 
cholesterol, were analyzed after incorporation of mucoadhesive alginic acid. Unlike 
mannitol-based formulations there was no significant size difference between non-
effervescent liposomes loaded with drug and effervescent liposomes loaded with drug 
BDP with 0.2% w/v alginic acid. No size difference was observed between effervescent 
empty and drug-loaded liposomes for 0.2 %w/v alginic acid concentration. A significant 
size difference was observed for effervescent salt-based liposomes without the drug 
(P≤0.05) between 0.2% and 1% concentration of alginic acid. Salt-based formulations 
with 1% w/v formulation demonstrated a significant (P≤0.05) difference between drugs 
loaded and empty (Table 3-4). Size distribution differences between 0.2% w/v empty and 
drug-loaded liposomes were observed to be significant (P≤0.05) (Table 3-4). Liposomes 
hydrated in 0.2% w/v concentration without drug seem to be less aggregated compared 
to 1% w/v formulation (P≤0.05). Both concentrations seem to be giving negative values 
with similar size and span distribution, demonstrating that in salt-based formulations both 
concentrations may be suitable in terms of size, span, and zeta. However, 1% w/v would 
be the most suitable overall due to its smaller size compared to 0.2% w/v formulation.  
 
 
 
 
 
 
 
 
 
121 
 
Table 3-4: Characterization of non-effervescent and salt-based effervescent liposomes 
with alginic acid  
 
3.3.6.3. Entrapment study using HPLC for alginic mucoadhesive  
Entrapment studies were conducted according to chapter 2, section 2.4. Coating the 
liposomes with bioadhesive agents highly affected the entrapment of BDP. Non-
effervescent liposomes were used as a control and coated with alginic acid for 
comparison. Entrapment was very high for conventional liposomes upon coating with 
alginic acid. Alginic acid with 2% w/v concentration for mannitol-based formulations 
demonstrated an entrapment efficiency of 63.53±7.10% while 1% w/v bioadhesive 
demonstrated an entrapment of 66.34±5.43%. However, this was not observed to be the 
same for improved effervescent formulations. 
 
Alginic acid 
concentration  
Size (μm) Span Zeta potential 
(mV)  
0.2% W/V  
(with drug,  
non-effervescent 
liposomes)  
 
-10.11±5.67 
 
3.89±02 
 
-15.32±0.21 
0.2% W/V  
(empty, effervescent 
liposomes) 
 
9.87±0.89 
 
2.44±0.18 
 
-17.63±0.20 
0.2% W/V  
(with drug, 
 effervescent 
liposomes) 
 
9.52±0.88 
 
1.80±0.08 
 
-15.23±0.61 
1% W/V  
non-effervescent 
liposomes (with 
drug) 
 
7.04±0.46 
 
2.87±0.48 
 
-14.56±0.98 
1% W/V (empty, 
effervescent 
liposomes) 
 
8.4±0.07 
 
2.08±0.15 
 
-15.7±0.38 
1% W/V (with drug, 
effervescent 
liposomes) 
 
 
8.90±0.93 
 
3.73±0.16 
 
-25.6±0.30 
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Entrapment results for alginic acid (0.2% w/v) in the mannitol formulation showed a very 
low entrapment efficiency (1.04±1.05%) while 1% showed no drug entrapment at all. 
However, alginic acid did demonstrate an increase in entrapment with salt-based 
formulations, 0.2 w/v alginic acid demonstrated 30.07±31.11% entrapment while salt-
based 1 w/v% concentration demonstrated an entrapment of 46.41±34.33, but both 
concentrations demonstrated high stranded deviations with variable results and the results 
were not reproducible. As a whole this indicates that alginic acid does not improve the 
entrapment of drugs in liposomes. In fact, it reduces the ability to entrap drugs in the 
presence of effervescent salts.  
Alginic acids are naturally occurring polysaccharide polymers (Tønnesen and Karlsen, 
2002). Tønnesen and Karlsen reported that alginates can go through proton-catalyzed 
hydrolysis depending on time, PH, and temperature. Alginates also tend to increase 
solution viscosity due to intermolecular binding upon hydration. Data indicate liposome-
improving entrapment upon coating with alginic acid in conventional non-effervescent 
liposomes; however, this was not observed in effervescent formulations. Effervescent 
mannitol and effervescent salt formulations caused alginic acid to behave differently 
compared to its behaviour in conventional liposome formulations (Tønnesen and Karlsen, 
2002). Another possible reason for reduced entrapment of the drug in the presence of 
alginic acid could be due to alginic acid alone being entrapped in the core of the 
liposomes, causing the liposomes to burst, resulting in leakage of BDP from the bilayers 
(Hong et al., 2008). Alginic acid also forms soluble salts in the presence of monovalent 
metal ions while divalent and multivalent cations (except Mg2+) result in the formation of 
gels. Alginic acid results in swelling, transmittancy, and viscoelasticity depending on its 
M residue and G residue ratio (Tønnesen and Karlsen, 2002). The swelling property is 
usually used in activating the release of drugs trapped in alginic acid gel. However, in this 
case amplified swelling in the presence of salts may possibly have disrupted the 
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liposomes, causing drug leakage. Alginic acid itself could be in competition with the drug 
for entrapment in the liposomes, resulting in reduced drug association with the lipid 
bilayers.  
3.3.6.4. Chitosan as a mucoadhesive used in effervescent mannitol-based 
liposomes and salt-based liposomes  
As drug entrapment in effervescent liposomes was not improved with the addition of 
alginic acid, chitosan was employed as an alternative mucoadhesive polymer. The 
liposome size was different when chitosan was included, with high aggregation being 
observed in comparison to alginic acid. In general, chitosan (0.2%) caused increases in 
liposome size; however, mannitol formulation exhibited smaller size compared to the rest 
of the formulations (21.63±5.57 μm) (Table 3.5). Liposome size was found to be 
significantly larger (P≤0.05) (130.47±15.05 μm) for liposomes coated with 1% chitosan. 
Highly negative zeta potential measurements were observed for all formulations with 
chitosan in comparison to those incorporating alginic acid. Significant differences were 
observed for the zeta potential when the two concentrations of chitosan were compared 
in mannitol- and salt-based formulations (Table 3-5). Literature indicate uncoated 
conventional DPPC liposomes are generally negatively charged (Klein et al., 1987; Law 
et al., 1988; Mady and Darwish, 2010). Studies indicate chitosan  carries a highly positive 
charge; hence, the coating of liposomes with chitosan shift slightly negatively charged 
liposomes to positively charged liposomes (Guo et al., 2003; Mady and Darwish, 2010). 
Liposomes become increasingly positive as chitosan concentration increases; hydrogen 
bonding between polysaccharide and phospholipid head groups results in this positive 
zeta potential (Guo et al., 2003; Perugini et al., 2000). However, in contrast, effervescent 
liposomes coated with chitosan demonstrates the zeta potential of liposomes to be highly 
negative. Studies suggest zeta potential of chitosan was close to zero at alkaline pH of the 
amino group. Researchers further suggests the surface charge of chitosan is related to the 
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chemical groups present in the formulation (Kim, 2013). This could explain the 
unexpected negative charge observed on effervescent proliposomes. Doubling and 
crystalline of chitosan in the presence of effervescent salts may also affect surface charge 
of the liposomes, resulting in negatively charged liposomes.  
Table 3-5: Characterization of BDP-loaded effervescent liposomes coated with 
mucoadhesive chitosan  
 
3.3.6.5. Entrapment studies in liposomes generated from proliposomes using 
chitosan polymer 
For mannitol-based formulations, the entrapment of BDP using chitosan (0.2%) was as 
low as 3.91±6.5.2% while with 1% chitosan it was as high as 37.10±34.38. Chitosan was 
observed to be swelling in the presence of effervescent salts. Salt-based formulations 
demonstrated no entrapment with both concentrations of chitosan. These results indicate 
that the addition of a mucoadhesive results in aggregated liposomes with intense negative 
charge and lower drug entrapment for salt-based effervescent formulation. It can be 
concluded that effervescent formulations, both mannitol- and salt-based formulations, are 
best kept without the addition of a mucoadhesive. Therefore, it was decided to exclude 
mucoadhesives in subsequent investigations.   
  
Chitosan 
concentration 
(w/v)  
Carrier Size (μm) Span 
Zeta 
potential 
(mV)  
0.2%  Mannitol 21.63±5.57 10.78±0.57 -20.9±1.53 
1%  Mannitol 130.47±15.05 2.81±0.11 -28.33±2.63 
0.2%  Salt 42.22±9.51 5.39±0.29 -10.06±7.78 
1%  Salt 114.50±11.68 2.24±0.14 -32.03±1.96 
0% Mannitol 5.14±0.49 4.4±2.72 -1.86±0.67 
0% Salt 6.04±0.19 2.74±0.16 1.19±0.50 
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 Characterization of DPPC-based empty liposomes  
Dipalmitoyl phosphatidylcholine (DPPC) was investigated as a replacement for SPC, and 
the resultant liposomes were characterized. Forty per cent of lung surfactants are made 
from DPPC, which is also an essential component of mammalian membranes (Chono et 
al., 2009; Schmitz and Müller, 1991; Veldhuizen et al., 1998). Schmitz and Müller (1991) 
have reported DPPC to be an essential constituent of the human respiratory system, 
including the nose. DPPC liposomes produced have been previously demonstrated to be 
advantageous in pulmonary drug delivery due to the similarity of this phospholipid to the 
lung surfactants; hence, it was shown to be highly biodegradable and biocompatible 
(Kellaway and Farr, 1990). Therefore, the potential of effervescent formulation for nasal 
delivery was explored in this report using DPPC.  
3.3.7.1. Size of liposomes generated from DPPC-based proliposomes  
These experiments were conducted using DPPC liposomes generated from mannitol-
based proliposomes with 1:10 lipid to carrier ratio. The proliposomes were manufactured 
using ethanol as a lipid solvent, and BDP was included in 5 mol% concentration. Non-
effervescent liposomes were first made with DPPC with or without cholesterol, followed 
by size analysis. Cholesterol containing DPPC liposomes generated from non-
effervescent mannitol-based proliposomes had a size of 11.87±0.4 µm when no drug was 
included and 8.32±0.1 µm when the drug was incorporated. Formulation significantly 
affected the resultant size of liposomes (P≤0.5) (Table 3-6). Mannitol-based effervescent 
liposomes were slightly smaller than non-effervescent liposomes (Figure 3-29). Additions 
of cholesterol in effervescent formulations seem significant when comparing mannitol 
formulations (P≤0.5). Compared to SPC formulations, DPPC liposomes demonstrated a 
significant difference in size. SPC-based mannitol formulations with cholesterol 
demonstrated smaller sized liposomes (5.143±0.50 µm) compared to DPPC-based 
(7.540±0.15 µm). Salt-based formulations demonstrated completely opposite results to 
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SPC-based formulations. Salt formulations, DPPC-based and loaded with drug in the 
presence of cholesterol had smaller size (7.047±0.45 µm) compared to formulations 
without cholesterol (17.81±0.04 µm). SPC-based formulations had large liposome sizes 
when cholesterol was included, 20.27±6.55 µm, while when cholesterol was omitted 
liposome size was reduced. 
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Figure 3-29:  Size (µm), analysis of 5 mol% BDP-loaded effervescent liposomes and non-effervescent liposomes made with DPPC lipid.  
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3.3.7.2. Size distribution (span) of liposomes generated from DPPC-based 
formulations  
These experiments were conducted using DPPC liposomes generated from mannitol-
based proliposomes with 1:10 lipid to carrier ratio. The proliposomes were manufactured 
using ethanol as the lipid solvent, and BDP was included in 5 mol% concentration. DPPC-
based effervescent liposomes tended to form less aggregates, and size distribution was 
more uniform compared to non-effervescent liposomes; hence, the span of effervescent 
vesicles was significantly smaller (P≤0.05). Non-effervescent formulations using 
mannitol as the carrier without the drug had a similar span value to formulations 
containing the drug. However, a significant difference (P≤0.05) was observed between 
the drug-loaded non-effervescent mannitol formulation (span = 1.93±0.04) and 
effervescent mannitol formulations (span = 1.51±0.07) (Figure 3-30). Inclusion of 
cholesterol in the drug-loaded effervescent mannitol-based formulations with the drug 
did not affect the span value.  
Salt-based formulations with cholesterol and drug had a span measurement of 1.56±0.12 
in comparison to those without cholesterol and drug, which demonstrated a significantly 
higher span of 2.65±0.04, possibly indicating vesicle aggregation. However, for drug-
containing mannitol-based formulations, cholesterol did not affect the span value (Table 
3-6).  
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Figure 3-30:  Span value, analysis of 5 mol% BDP-loaded effervescent liposomes and non-effervescent liposomes made with DPPC. 
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Table 3-6: Size, span, and zeta charge of liposomes made with SPC and DPPC as phospholipids prepared with cholesterol and cholesterol-free 
form by slurry method  
Formulation (10 mol%) Soya phosphatidylcholine-based (SPC) Dimyristoyl phosphatidylcholine (DPPC) 
 VMD (µm) Span Zeta charge (mV) 
 
VMD (µm) Span Zeta charge (mV) 
Effervescent liposomes prepared with mannitol, and cholesterol 
Empty  5.065 ± 0.12 3.076 ± 0.71 -1.86 ± 0.60 7.318 ± 0.37 1.657 ± 0.06  -0.78 ± 0.13 
Drug-loaded  5.143 ± 0.50 4.411 ± 2.72 -1.86 ± 0.67 7.540 ± 0.15 1.512 ± 0.07    2.53 ± 0.18 
effervescent liposomes prepared with mannitol, without cholesterol 
Drug-loaded 7.32 ± 0.45  
 
0.451233 
0.451232756 
0.451232756 
2.590 ± 0.41 -0.69 ± 0.24 7.192 ± 0.11 1.683 ± 0.39      2.08 ± 0.22  
effervescent liposomes prepared with effervescent salts alone as carrier, and cholesterol 
Empty  20.60 ± 1.61 2.320 ± 0.38 
 
 1.11 ± 0.16 
 
0.160329 
 
0.160329 
 
8.506 ± 0.18 1.645 ± 0.07     2.63 ± 0.83 
Drug-loaded  20.27 ± 6.55 
 
 
2.969 ± 0.77 
 
0.770804 
 
0.89 ± 0.85 
 
0.850242 
 
7.047 ± 0.45 1.565 ± 0.12     3.83 ± 0.62 
effervescent liposomes prepared with effervescent salts alone as carrier, without cholesterol 
 
0 
Not detected 
Not detected 
 
23.08 ± 0.06 
25.03 ± 1.05 
 
3.88 ± 0.13 
Drug-loaded 6.045 ± 0.19 
 
 
0.192351 
 
2.745 ± 0.16  1.19 ± 0.50 17.812± 0.04 2.652 ± 0.46      1.48 ± 0.35 
non-effervescent (Control) prepared with mannitol and cholesterol 
Empty  5.275 ± 0.16 4.472 ± 0.73 
 
-1.62 ± 0.42 
 
0.160329 
 
11.857 ± 0.48 
 
1.983 ± 0.10     -1.81 ± 0.53 
Drug-loaded  8.254 ± 0.50 4.138 ± 0.19 
 
 
-3.72 ± 0.25 
 
0.160329 
 
0.160329 
  7.047 ± 0.44 1.936 ± 0.04      2.47 ± 0.37  
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3.3.7.3. Zeta potential of liposomes generated from DPPC-based formulations  
These experiments were performed using DPPC liposomes generated from mannitol-
based or salt-based proliposomes with 1:10 lipid to carrier ratio with 5 mol% BDP. The 
zeta potential of DPPC-based liposomes was different to the zeta potential of SPC-based 
liposomes. DPPC liposomes had positive zeta potential measurements, while SPC 
liposomes were negatively charged except for salt-based formulations, while in DPPC 
only mannitol-based non-effervescent and mannitol-based effervescent with cholesterol 
had negative zeta potential measurements (Table 3-6). These findings indicate that 
different lipid composition can lead to different zeta potential values of liposomes. Non-
effervescent mannitol-based formulations with cholesterol demonstrated a significant 
difference in charge between empty and drug-loaded (P≤0.05) (Table 3-6).  However, no 
significance was seen between empty and drug-loaded effervescent mannitol-based 
formulations with cholesterol. In general, the drug seems to have an effect on the surface 
charge of the liposome. A study by Mady and Darwish (2010) demonstrates empty DPPC-
based liposomes were  negatively charged; a similar result was observed with DPPC-
based liposomes from research done by Imura et al. (2003). DPPC liposomes prepared by 
the high pressure homogenizer method was 0.51±0.79 mV slightly positive (Hasanovic 
et al., 2010). DPPC/cholesterol liposomes were observed to be around 5 mV positively 
charged (Szcześ, 2013). Research on ethanol passed proliposomes formulation (drug-
free) prepared with DPPC and SPC demonstrated DPPC-based liposomes were observed 
to have a zeta potential of -2.8 mV while SPC-based formulations were observed at -1.9 
mV. Both lipids produced negatively charged liposomes ( Jain, 2012). It can be observed 
that the preparation method also has an effect on DPPC-based liposomes’ zeta potential.   
SPC-based liposomes made via the thin film hydration method was compared to ethanol-
based proliposomes. Research indicated that regardless of the preparation method, 
liposomes were negatively charged with values between -3.5 to -6.5 mV; however, a 
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significant difference in liposome charge was observed between the two preparation 
methods (P≤0.05). Researchers further state negativity maybe attributed to the presence 
of negatively charged lipids in lipoid S-100 (Jaiswal, 2013). Liposomes made with SPC 
used in a study to deliver curcumin demonstrated a zeta potential of −12.88±1.38 mV 
(Chen et al., 2012). A study comparing tamoxifen citrate demonstrated empty liposomes 
to be highly negative -56.09±4.3 mV compared to liposomes loaded with tamoxifen with 
a zeta potential of −36.88±3.8 mV. Researchers state the reduced negativity of the drug-
loaded formulation is due to the cationic charge present on the drug having neutralized 
the surface charges that existed on the formulation surface (Layek and Mukherjee, 2010). 
Literature indicates SPC is lipid and is mostly negativity charged.  
The zeta potential of cholesterol containing effervescent formulations is affected by 
carrier type (P≤0.05). However, for salt-based DPPC:Chol liposomes, no significant 
differences in the zeta potential were observed as a result of drug inclusion. Furthermore, 
cholesterol did affect the charge of liposomes by making them slightly less positive for 
salt-based formulations (P<0.05) (Figure 3-31). Inclusion or exclusion of cholesterol 
affected the zeta potential of SPC formulations as well. 
Positively charged liposomes were found to have a high entrapment efficiency compared 
to neutral liposomes. Positively charged liposomes were also reported to have prolonged 
circulation and reduced toxicities in the body (Brigham et al., 1989; Bailey and Sullivan, 
2000). Positively charged liposomes tend to behave more like neutral liposomes and 
maintain higher entrapment efficiencies compared to neutral liposomes (Brigham et al., 
1989; Bailey and Sullivan, 2000; Yadav et al., 2011) 
Lipid composition and lipid phase transition temperature can affect the surface charge of 
liposomes (Liu, 2011). Neutral liposomes are mostly based on DPPC, DMPC, Distearoyl 
phosphatidylcholine (DSPC). However, charged liposomes are observed in an electric 
field when they are dispersed in a solution of PH 7.4 (Liu, 2011). The zeta potential in 
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low ionic strength is negative and reduces in magnitude.  Change of zeta potential caused 
by an increase in ionic strength due to a structural change in the head group of liposomes, 
reversal in this charge is observed due to change in direction of the dipole connecting the 
negative charge of liposomes phosphatidyl group and the positive charge of the choline 
group in the head group of the molecule (Liu, 2011).  
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Figure 3-31:  Zeta potential, analysis of 5 mol% BDP-loaded effervescent liposomes and non-effervescent liposomes made with DPPC.  
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 SEM images of DPPC proliposomes 
Non-effervescent DPPC proliposome formulations had similar SEM morphology to 
corresponding SPC formulations (Figure 3-36 and 3.37). Both lipids resulted in particles 
that are irregular in shape, with crystalline structures. SEM images demonstrated a glossy 
appearance, indicating that mannitol was equally coated with phospholipid. SEM pictures 
were similar to those published by Yan-yu et al. (2006). DPPC effervescent formulations 
also demonstrated a similar morphology to corresponding SPC formulations. However, 
non-effervescent and effervescent liposomes for both SPC and DPPC formulations were 
observed to be different due to the needle-like structure protruding outwards from the 
mannitol surface once effervescent salts were incorporated (Figure 3-32 and 3-34). 
Effervescent samples for DPPC were also observed to be glossy and irregular in shape, 
correlating with SPC-based formulation morphology. Salt-based formulations without 
mannitol and without cholesterol with DPPC incorporation had needle-like structures 
(Figure 3-37) while SPC formulations looked smoother (Figure 3-33).  
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Figure 3-33: SEM picture of mannitol-
based effervescent proliposomes with SPC. 
Figure 3-32: SEM picture of mannitol-
based effervescent proliposomes with 
DPPC  
Figure 3-37: SEM picture of mannitol-
based non- effervescent proliposomes 
with DPPC. 
Figure 3-36: SEM picture of mannitol-
based non- effervescent proliposomes with 
SPC. 
Figure 3-34: SEM picture of salt-based 
effervescent proliposomes with DPPC. 
Figure 3-35: SEM picture of salt-based 
effervescent proliposomes with SPC. 
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 Disintegration time of DPPC and SPC effervescent proliposome 
formulations  
DPPC formulations took slightly longer time to disintegrate compared to SPC 
proliposomes. Disintegration of proliposomes without effervescent property took over 50 
min. Non-effervescent DPPC or SPC formulations also failed to fully disintegrate without 
vigorous hand shaking. Effervescent formulations took significantly less time to 
disintegrate (P≤0.05) compared to non-effervescent formulations (Table 3-7). Salt-based 
DPPC in general took slightly more time than mannitol-based formulations, while for 
SPC formulations made with salt carrier only half the time for disintegration to happen 
was needed compared to the corresponding mannitol-based formulations. Formulations 
without cholesterol using mannitol or salt carrier took less time to disintegrate compared 
to the corresponding formulations with cholesterol, indicating that cholesterol may mask 
effervescent ingredients from being in efficient contact with water. However, considering 
the characterization findings, formulations with cholesterol might be generally better 
using DPPC effervescent liposomes. The most appropriate formulation for further studies 
should be decided by considering the properties of liposomes, drug entrapment, 
nebulization performance, etc.  
Table 3-7: Disintegration time for DPPC-based effervescent proliposome 
formulations  
Formulation  Carrier Cholesterol  
Drug 
(BDP) 
Disintegration 
Time (min) 
Non-effervescent  Mannitol Yes - 53.66 ±4.28 
Non-effervescent  Mannitol Yes Yes 61.04 ±5.75 
Effervescent  Mannitol Yes - 2.63 ±0.48 
Effervescent Mannitol Yes Yes 2.65 ±0.41 
Effervescent Mannitol - -             3.69±0.21 
Effervescent Mannitol - Yes 4.10 ±0.58 
Effervescent Salt Yes - 3.70 ±0.36 
Effervescent Salt Yes Yes 4.09 ±0.45 
Effervescent Salt - - 3.5 ±0.53 
Effervescent Salt - Yes 3.74±0.35 
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 HPLC analysis of DPPC formulations 
BDP entrapment in DPPC liposomes tended to be higher than that in SPC liposomes. 
DPPC:Chol non-effervescent formulation using mannitol carrier had a much less 
entrapment efficiency of 51.07±23.5% compared to SPC liposomes, which offered an 
entrapment efficiency of 75.35±1.4%. However, DPPC:Chol effervescent mannitol-
based formulations offered an entrapment of 82.15±8.29 (Table 3-8). DPPC effervescent 
formulations with mannitol carrier have improved the entrapment compared to SPC, 
which offered BDP entrapment of 18.12±12.02 (P≤0.05) (Table 3-8). Cholesterol-free 
DPPC mannitol-based formulations offered a slightly lower trend for drug entrapment but 
that was not statistically significant (Table 3-8). Cholesterol-free DPPC mannitol 
formulation offered higher drug entrapment compared to corresponding SPC liposomes 
(Table 3-8). The use of mannitol as a proliposome carrier had a very mild effect on BDP 
entrapment efficacy, while changing lipid choice from DPPC to SPC greatly improved 
the entrapment.   
These observations were not consistent with salt-based formulations. DPPC:Chol salt-
based formulations offered a high drug entrapment of 90.60±13.51% while entrapment 
using the corresponding cholesterol-free formulations was as low as 36.3±7.0% (P≤0.05).  
SPC:Chol salt-based formulations entrapment was 29.64±12.35% compared to 
11.36±3.41% for the corresponding cholesterol-free preparations (Table 3-8). DPPC 
formulations using salt as carrier and cholesterol as bilayer constituent offered the highest 
drug entrapment, while mannitol-based formulations with cholesterol proved to be second 
best.  
Incorporation of cholesterol may reduce bilayer fluidity (by positioning between the 
phospholipid molecules), and reduce permeability (Alberts et al., 2009; Xiang et al., 
2000). The addition of cholesterol gives liposomes the elasticity to accommodate 1 mol% 
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of steroidal drugs; this is observed for both SPC and DPPC liposomes (Jaafar-Maalej et 
al., 2011).   
It has been reported that entrapment of the drug is dependent on the properties and 
concentration of the lipid used in the liposome formulation, with achievement of 100% 
entrapment efficiency being extremely difficult (Jaafar-Maalej et al., 2011).  The 
entrapment efficiency of BDP in DPPC and SPC liposomes as found in the present study 
contradicts with the results demonstrated previously by Darwis and Kellaway (2001) who 
found that BDP entrapment is inversely propositional to the Tm of phospholipid  used in 
formulation. However, in effervescent formulations this was not observed to be the case, 
possibly due to the difference in liposome size or zeta potential. DPPC liposomes in 
general had a slightly larger size, which may have enhanced the drug entrapment 
compared to SPC liposomes. Darwis and Kellaway (2001) have also shown larger 
liposomes to entrap greater proportions of BDP.  
DPPC and SPC drug entrapment without a coating of mucoadhesives when compared to 
results of SPC-based formulation with the mucoadhesive polymers alginic acid and 
chitosan, demonstrated very low entrapment. Data agree with our previous conclusion 
that effervescent formulations are better at drug entrapment without mucoadhesives. 
Looking at the DPPC results, it can be observed that DPPC is the better lipid, which 
improves drug entrapment when compared to both SPC alone and SPC alone with 
mucoadhesive formulations.  
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Table 3-8: Comparison of entrapment efficacies by HPLC for effervescent 
proliposomes with BDP formulations, with lipids SPC and DPPC  
 
Formulation 
(10 mol %) 
Entrapment efficacies of formulations % 
 
 SPC DPPC  
Effervescent liposomes prepared with mannitol, and cholesterol 
 18.12±12.02 82.15±8.29 
Effervescent liposomes prepared with mannitol, without 
cholesterol 
 8.25±1.75 70.47±10.51 
 Effervescent liposomes prepared with effervescent salts alone as 
carrier, and cholesterol  
 29.64±12.35 90.60±13.51 
Effervescent liposomes prepared with effervescent salts alone 
without addition of cholesterol  
 11.36±3.41 36.3±7.0 
Non-effervescent (control) prepared with mannitol and 
cholesterol 
 75.35±1.4 51.07±23.5 
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3.4. Conclusion for Characterization of BDP-Loaded 
Liposomes With Both SPC and DPPC Liposomes  
The addition of effervescent property to liposomes and improving disintegration time did 
not have a negative impact on the liposomes generated by both SPC-based and DPPC-
based formulations. A model drug (Beclometasone dipropionate: BDP) was used to 
understand the capability of effervescent formulations to carry hydrophobic drugs within 
effervescent liposomes. The comparison of results from formulations based on both lipids 
demonstrated that factors such as carrier choice (mannitol or salt), choice of lipid (DPPC 
or SPC), the addition of cholesterol, and the presence of effervescent ingredients can all 
effect liposome size, span, zeta potential, and drug entrapment efficiency. Mucoadhesives 
such as alginic acid and chitosan in effervescent liposome formulations did not prove to 
be beneficial due to the fact that drug entrapment has decreased.  
SPC and DPPC formulations produced liposomes with similar size and span. However, 
SPC liposomes in general were smaller in size. However, as these novel formulations are 
targeted to be nebulized to the sinus, liposomes from both formulations are proved 
beneficial. Research suggested that nasal drug delivery is done through liposomes that 
are typically large in size (>10 µm), while smaller liposomes particles that are 2 to 10 µm 
can be reached through the trachea and the lungs. Particles less than 1 µm are believed to 
be exhaled (Saari, 2003; Debjit Bhowmik et al., 2010). Therefore, DPPC-based liposomes 
with slightly larger liposome size, smaller span, and better drug entrapment have proved 
to be the better formulation. DPPC would be a better lipid of choice in terms of drug 
entrapment in liposomes. 
Mannitol-based formulations with cholesterol were proven to be the best formulations for 
further research in SPC-based formulations, while salt-based formulations without 
cholesterol proved to be the second best. DPPC-based formulations, on the other hand, 
demonstrated salt-based formulations with cholesterol to have the highest entrapment. 
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Considering the size, span, and zeta charge, mannitol with cholesterol liposomes is also 
proven to be a good candidate formulation for further studies. SPC based with cholesterol 
was excluded from further studies due to its large liposome size; this issue of liposome 
size was by excluding cholesterol, which brought down the liposome size drastically. 
However, this also resulted in reduced drug entrapment.  
Interactions of cholesterol with different lipids (DPPC and SPC) were observed by 
characterization data of liposomes for both SPC- and DPPC-based lipids. Size, span, and 
zeta charge were observed to be different with DPPC when compared to SPC with 
cholesterol due to packaging structure and transition temperature. Mannitol as a sugar-
based carrier demonstrated similar results when used with both SPC and DPPC.  Salt-
based formulations (sugar-free) demonstrated promising results with the DPPC lipid. 
Entrapment of BDP was therefore dependent on choice of lipid and cholesterol. Further 
work is necessary to understand the stability of liposomes in nasal delivery and the 
entrapment of hydrophilic drugs. Effervescent formulations made with SPC lipid based 
on mannitol and cholesterol, SPC-based salt-based formulations without cholesterol, 
DPPC-based mannitol-based formulations with cholesterol, and DPPC-based salt-based 
formulations with cholesterol were chosen for nebulization studies. All formulations of 
SPC were tested with the hydrophilic drug Xylometazoline hydrochloride to understand 
the capacity of effervescent liposomes to entrap hydrophilic drugs. In conclusion of the 
characterization data for BDP drugs with different lipids, effervescent liposomes reduced 
the time taken for disintegration and improves dosing while not having a negative impact 
on size, span, zeta potential, and entrapment of BDP. This suggests that with further 
improvement is required for the effervescent formulations  
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3.5. Effervescent Proliposomes Formulations for 
Xylometazoline hydrochloride (XH) With SPC  
Xylometazoline hydrochloride is a hydrophilic drug that is commonly used as a nasal 
decongestant. In general, hydrophilic drugs have a lower entrapment efficiency in 
liposomes compared to hydrophobic drugs. Hydrophilic molecules are entrapped in the 
aqueous core and spaces of the liposomes, unlike hydrophobic drugs which are entrapped 
within the liposome bilayers. Entrapment of hydrophilic drugs is dependent on the 
preparation method, liposome size, lipid concentration, and liposome lamellarity 
(Bangham et al., 1965; Bangham and Papahadjopoulos, 1966). Various preparation 
methods have been used to maximize the entrapment of hydrophilic molecules in 
liposomes such as reverse phase evaporation, dehydration-rehydration of preformed 
empty liposomes, and freeze-thaw cycles (Xu et al., 2012).   
The difficulty of entrapment of hydrophilic drugs such as Tenofovir and superoxide 
dismutase in liposomes has been previously discussed, with entrapment efficiencies being 
in the range of 20–50% (Xu, 2012). Both of the above researchers indicate the need for 
the improvement of the capacity of liposomes to entrap the hydrophilic drug. To the best 
knowledge of the author of this thesis, no liposome entrapment studies for the drug XH 
have yet been reported. XH was chosen due to its nasal decongestant property and its use 
in the treatment of sinusitis.  In the present investigation, effervescent liposomes were 
prepared using the ethanolic slurry method (1:10 w/w lipid to carrier) using mannitol or 
salt carrier particles, SPC phospholipid, and 5 mol% XH (chapter 2, section 2.2). 
Formulations were tested with mannitol or salt as carriers, with or without cholesterol. 
Characterization of liposomes by size, span, and zeta potential was conducted without 
probe-sonication and following probe-sonication for 20 sec to reduce liposome size 
(Figure 3-38). The drug entrapment (EE) of the resulting liposomes was determined using 
HPLC. 
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Figure 3-36: Preparation of effervescent liposomes with hydrophilic drug. 
Adapted from: http://www.intechopen.com/books/cancer-treatment- conventional-and-innovative-approaches/liposomes-as-
carriers-of-anticancer-drugs 
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 Characterization of mannitol- and salt-based liposomes loaded with XH 
Effervescent liposomes were characterized for size before and after sonication. 
Formulations tested were 1:10 w/w lipid to carrier ratio with 5 mol% XH loaded on 
liposomes manufactured with both carriers, mannitol and salt, with and without addition 
of cholesterol. Formulations tested listed in chapter 2, section 2.3. Non-effervescent 
conventional liposomes were used as control.  
3.5.1.1. Liposomes size before sonication  
Drug-free SPC:Chol liposomes made with mannitol carrier had a measured size of 
7.24±0.15 µm, while the corresponding cholesterol-free formulation had a smaller size 
(5.11±0.09 µm). However, upon inclusion of XH, large size was noted for both non-
effervescent formulations. Mannitol with the cholesterol drug demonstrated a vast 
difference in liposome size upon addition of the drug (18.63±0.17 µm) (Figure 3-39). 
Drug-containing effervescent mannitol formulations with cholesterol had slightly smaller 
size measurements compared to conventional liposomes with drug. Mannitol-based 
formulations with or without cholesterol both had a similar size of around 7.6 and 7.9 µm 
respectively. Salt-based effervescent formulations with cholesterol had a slightly larger 
size (9.53±0.18 µm); however, it was not significantly different in comparison to 
liposomes with mannitol and cholesterol. Furthermore, upon investigation of liposomes 
based on salt without cholesterol, a difference in reduction of size was observed, which 
was also observed to be similar in the case of hydrophobic drug BDP. The Mass Median 
Dimeter (MMD) of Pari Sinus aerosols is noted to be around 3.2 µm. Even though upon 
nebulization liposome size can be reduced, we sonicated the formulations for 20 sec to 
reduce its liposome size in order to improve its size fitness into the nebulizer droplets.  
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Figure 3-37: Size (µm), analysis of XH-loaded effervescent liposomes SPC-based 
formulations before sonication. 
 
 
Figure 3-38: Size (µm), analysis of XH-loaded effervescent liposomes SPC-based 
formulations after sonication. 
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3.5.1.2. Liposome size after sonication  
Non-effervescent liposomes after sonication, mannitol-based formulations with 
cholesterol, conventional liposomes reduced its liposome size drastically before and after 
sonication to (4.10±0.16 µm). Non-effervescent mannitol-based formulations with 
cholesterol liposomes did not seem to have changed liposome size significantly, 
indicating that the addition of cholesterol did not have an impact on liposome size for 
conventional liposomes. However, the addition of a drug into mannitol based with and 
without cholesterol for conventional liposome has significantly increased liposome size 
for both formulations (P≤0.05). Addition of a drug resulted in increases in liposome size 
compared to its empty counterpart. Mannitol effervescent liposomes reduced in size 
drastically before and after sonication (Figure 3-39) (Figure 3-40). Effervescent 
liposomes mannitol with cholesterol, before and after sonication, went from large size 
liposomes (18.63±0.17 µm) to (2.347±1.03 µm) (P≤0.05). Non-effervescent liposomes 
with drug by contrast to effervescent mannitol-based liposomes appeared to have large 
liposome sizes (4.48±0.25 µm) (P<0.05). Mannitol-based formulations without 
cholesterol effervescent formulations were significantly different when compared to 
conventional liposomes (P≤0.05). Salt-based formulations with cholesterol effervescent 
liposomes and drug-loaded were reduced to half the size compared to effervescent 
mannitol-based formulations with cholesterol with drug (P≤0.05). Effervescent salt-based 
formulations, with and without cholesterol, did not seem to have any significant 
difference in liposome size (Figure 3-40). Looking at the results before and after 
sonication it can be concluded that the liposome size with sonication would be more 
appropriate in terms of size for effervescent mannitol- and salt-based with cholesterol 
formulations, which seem to be liposomes with a smaller liposome size. However, 
entrapment studies would be a better indication of the liposome’s capability to entrap 
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drugs for effervescent formulations to understand overall which formulations would best 
suit for the transport of XH.  
 Size distribution of liposomes generated from mannitol- and salt-based 
liposomes  
3.5.2.1. Liposomes span before sonication 
Non-effervescent liposomes before sonication, mannitol-based formulations with and 
without cholesterol both had a similar significance. However, they had a significant 
difference in span comparison for empty and drug-loaded formulations (P≤0.05). 
Mannitol-based effervescent formulations with cholesterol, both empty and drug-loaded, 
were not deemed significant. Mannitol-based formulations without cholesterol, on the 
other hand, did have a significantly different liposome span when drug-free and drug-
loaded formulations were compared (P≤0.05) (Figure 3-41). Drug-free salt-based 
formulations with cholesterol, however, had a larger span compared to the corresponding 
mannitol-based formulations (P≤0.05). No difference in span was observed for salt-based 
formulations with cholesterol, both for empty and drug-loaded liposomes. Both empty 
(4.96±0.10) and drug-loaded (5.63±0.05) and salt-based effervescent formulations 
without cholesterol seemed to have a slightly larger span, indicating aggregation of 
liposomes or a difference in the polydispersity of liposomes (P≤0.05). 
3.5.2.2. Liposome span after sonication  
The span measurements of non-effervescent liposomes with cholesterol were independent 
of drug inclusion. Furthermore, drug incorporation has affected the span of cholesterol 
containing effervescent mannitol formulations (P≤0.05). Non-effervescent drug-loaded 
liposomes with cholesterol and effervescent mannitol-based formulations with 
cholesterol did not have a difference in span values (Figure 3-42). The addition of 
effervescent characteristics to the liposomes has not had an impact on size distribution. 
Mannitol-based effervescent formulations without cholesterol, both empty (10.22±1.05) 
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and drug-loaded (1.72±0.33) demonstrated a significant (P≤0.05) difference in span 
values. Salt-based liposomes with cholesterol, empty and drug-loaded, have similar span 
values. However, results were significantly different (P≤0.05). The same trend of 
significant differences was observed with cholesterol-free, salt-based formulations. 
Comparison of mannitol-based formulations to salt-based formulations with cholesterol 
loaded with drug did not show a significant difference. A general comparison of sonicated 
vs unsonicated formulations indicates that sonicated liposomes tend to have more stable 
span values due to the breakdown of liposome layers making all liposomes similar in size. 
Mannitol-based formulations without cholesterol may not be suitable due to its high span 
value and that without the rigidity provided by cholesterol liposomes they seem to be 
breaking or fusing under the pressure of sonication and may not be suitable for 
nebulization. Considering size and span values, further studies on sonicated liposomes 
would be more appropriate for drug XH since liposomes around 5 µm are expected to fit 
into droplets produced by the Pari Sinus nebulizer.  
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Figure 3-39: Span, analysis of XH-loaded effervescent liposomes SPC-based 
formulations before sonication.  
 
Figure 3-40: Span, analysis of XH-loaded effervescent liposomes SPC-based 
formulations after sonication  
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 Characterization of zeta potential mannitol- and salt-based liposomes  
3.5.3.1. Liposome zeta potential before sonication 
The zeta potential of empty and drug-loaded formulations seems to be very different from 
each other. The addition of the drug for all formulations has given a highly positive charge 
to the liposomes. Non-effervescent liposomes with cholesterol seem to be the only 
formulations that gave liposomes a negative charge. The addition of the drug to the same 
formulations made the liposomes positively charged. Non-effervescent liposomes 
without cholesterol and empty liposomes were around 2.07±0.05 mV. The addition of the 
drug resulted in highly positively charged liposomes of 36.4±0.87 mV. Mannitol-based 
formulations, with or without cholesterol, empty or drug-loaded seem to have similar 
trends, with no significant differences between the formulations (Figure 3-43). Salt-based 
formulations with cholesterol and without cholesterol resulted in positive liposomes. 
Empty and drug-loaded liposomes were not significant for both formulations. All 
formulations with the drug and without cholesterol seem to have a higher positive charge 
when compared to formulations with cholesterol.  
3.5.3.2. Zeta potential analysis after sonication 
Non-effervescent liposome formulations, with cholesterol, without drug and after 
sonication were negatively charged. However, additions of the drug gave it highly 
positively zeta potential (Figure 3-44). The addition of the drug for all formulations 
resulted in highly positive liposomes. The same trend was seen in effervescent mannitol 
formulations regardless of cholesterol incorporation in the liposome formulation. No 
significant difference was observed as a result of drug inclusion in the formulations. 
However, drug-loaded liposomes tended to be more positively charged compared to 
empty liposomes. Drug-free salt-based liposomes with cholesterol had a zeta potential 
measurement of 2.25±0.16 mV and drug-loaded had a value of 7.03±09 mV, and the 
difference was significant (P≤0.05).  
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Mannitol and salt-based formulations with cholesterol and loaded with the drug were not 
significantly different (Figure 3-44). Salt-based formulations without cholesterol, empty 
and drug-loaded, were also similarly positively charged and not significantly different. 
Liposomes before sonication and after sonication for effervescent mannitol-based 
formulations with cholesterol and loaded with the drug were found to be significantly 
different. Cationic liposomes are positivity charged liposomes made with positively 
charged lipids.  
Cationic liposomes have been shown to be promising candidates in targeting negatively 
charged DNA and cell membranes (Krasnici et al., 2003; Simões et al., 2005; Villasmil-
Sánchez et al., 2010). Cationic liposomes have been used to target the angiogenic vesicle 
in tumour sites and sites of chronic inflammation (Thurston et al., 1998). This suggests 
that maybe positively charged liposomes loaded with XH drug can be suitable for 
inflammation of the sinuses. The study found that when comparing (1,2-dioleoyl-3-
trimethyl ammonium propane [DOTAP]/cholesterol or dimethyl dioctadecyl ammonium 
bromide [DDAB]/cholesterol) or liposome-DNA complexes, liposomes-DNA complexes 
were taken up to a greater extent compared to anionic liposomes (Thurston et al., 1998). 
Anionic and cationic liposomes were observed to have similar span values, similar 
encapsulation efficiencies, and reduced cytotoxicity when compared to neutral liposomes. 
Therefore, it can be concluded that charged liposomes (positive or negative), would be 
potentially more appropriate for drug delivery (Nie et al., 2012).   
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Figure 3-41: Zeta potential, analysis of XH-loaded effervescent liposomes SPC-based 
formulations before sonication. 
 
 
Figure 3-42: Zeta potential, analysis of XH-loaded effervescent liposomes SPC-based 
formulations after sonication.
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 HPLC results of effervescent samples for XH drug (sonicated)  
Entrapment efficiency for XH was very high compared to the hydrophobic drug BDP. 
There was only one available method for HPLC analysis of XH, which was time 
consuming (Milojevic et al., 2002). Therefore, a novel HPLC method was developed 
that was demonstrated to be faster, easier, and more specific. Considering size, span, 
and zeta potential data, it was decided to investigate the HPLC results of sonicated 
liposomes for drug entrapment. Non-effervescent liposomes without cholesterol 
(89.43±6.13%) or with cholesterol (69.64±7.88%) demonstrated their entrapment 
efficiency (P≤0.05). Effervescent mannitol with cholesterol formulations seemed to 
have slightly less drug entrapment when compared to conventional non-effervescent 
liposomes (P≤0.05). However, they demonstrated high entrapment when compared 
to the BDP hydrophobic drug. The use of mannitol as carrier did not affect the 
entrapment of XH. Salt-based liposomes with cholesterol demonstrated less ability to 
entrap this hydrophilic drug. On the other hand, salt with cholesterol in DPPC-based 
formulations offered very high entrapment (93%) for the hydrophobic drug BDP. 
Salt-based formulations, with or without cholesterol in comparison did not show any 
significant difference, further proving in effervescent formulations that the addition 
of cholesterol did not have any effect on drug entrapment (Figure 3-45). Even though 
non-effervescent liposome formulations proved to have high entrapment compared to 
effervescent formulations, the non-effervescent formulation has high span value 
(Figure 3-45) and is not suitable in terms of liposome size for drug delivery to the 
sinus. The size of the liposomes of non-effervescent is too large for fitting into the 
aerosol droplets generated by the Pari Sinus nebulizer, indicating that effervescent 
mannitol-based formulations and salt-based formulations are potentially suitable for 
aerosolization to the nasal cavity. Considering the rigidity and reduced permeability 
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given by cholesterols to liposomes bilayers, the formulations with cholesterol may be 
more suitable to withstand the high shear pressure of nebulization.  
Hydrophilic drugs have slightly lower entrapment efficiency in liposomes compared 
to hydrophobic drugs (Uster, 1989). Salbutamol sulphate, a hydrophilic 
bronchodilator, had an entrapment efficiency of 50% and that was further increased 
by using high cholesterol concentrations (Bendas and Tadros, 2007).    
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Figure 3-43: Drug entrapment analysis of XH-loaded effervescent liposomes SPC-based formulations.
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 Conclusion for Xylometazoline hydrochloride (hydrophilic drug)  
Effervescent formulations appeared to be better candidates for the delivery of 
hydrophilic drugs compared to our previous findings on the hydrophobic drug BDP. 
Mannitol-based and salt-based formulations both were promising; however, mannitol 
with cholesterol formulation may be more suitable in terms of liposome size and span 
values after sonication. Overall sonicated liposomes tended to be better candidates 
for delivery via the Pari Sinus nebulizer. The addition of cholesterol did not affect the 
entrapment efficiency for effervescent formulations. However, rigidity provided to 
liposomes may help in protecting the drug from leakage during nebulization. The 
addition of the drug has made all formulations highly positively charged. It can be 
concluded that effervescent formulations could enhance the entrapment of 
hydrophilic drugs such as XH.  
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3.6. Conclusion for Characterization of Effervescent 
Liposomes  
Mannitol was more suitable as a proliposome carrier than sucrose in terms of liposome 
size, span, and zeta potential. Ethanol was a suitable solvent in the preparation of 
proliposomes using the slurry method. The addition of effervescent ingredients to 
conventional proliposomes proved successful with effervescent proliposomes, producing 
stable liposomes similar to conventional liposomes in terms of size, span, and zeta 
potential. The time taken for disintegration was drastically reduced from over 50 min to 
less than 5 min for all formulations prepared with effervescence. SEM images 
demonstrated difference in morphology of conventional liposomes and effervescent 
liposomes; however, effervescent proliposomes had an evenly coated phospholipid layer 
and glossy appearance. 
Effervescent formulations were made with either SPC or DPPC. Mannitol-based 
formulations with cholesterol liposomes made with SPC were found to be more 
appropriate at generating liposomes for sinus delivery in terms of liposome size, span, 
zeta potential, and high BDP entrapment efficiency, while salt with cholesterol 
proliposomes generated liposomes that were relatively large. Mucoadhesive alginic acid 
and chitosan in effervescent formulations did not prove to be beneficial due to reduced 
drug entrapment and interaction and swelling of the mucoadhesive agents in the presence 
of effervescent salts.  
SPC- and DPPC-based formulations both produced liposomes with a similar size and 
span. However, SPC-based formulations in general were comparatively smaller in size. 
However, DPPC liposomes have shown to be beneficial by providing high entrapment 
efficiency of BDP. DPPC proved to be better choice of lipid, while mannitol and salt 
formulations with cholesterol proved to be appropriate in terms of size, span, and zeta 
potential with high BDP entrapment. 
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Cholesterol was found to be interacting differently in the presence of the different lipids 
due to packing structure and difference in the transition temperatures of the lipids. It can 
be concluded that mannitol with cholesterol and salt with cholesterol DPPC formulations 
would be used for further testing. Choice of lipid was the deciding factor for entrapment 
efficiency of BDP. 
Hydrophilic drug Xylometazoline hydrochloride was loaded into SPC-based effervescent 
formulations and demonstrated high entrapment in liposomes. Sonicated XH-loaded 
liposomes were potentially more promising for delivery via the Pari Sinus nebulizer. 
Unlike BDP-loaded SPC liposomes, XH-loaded liposomes did not have an effect on 
entrapment efficiently upon addition of cholesterol. A novel HPLC method that was 
developed to investigate entrapment efficiency of XH within liposomes proved to be 
successful, efficient, highly sensitive, and less time consuming. 
It can be concluded that effervescent liposomes based on SPC or DPPC can produce 
stable liposomes similar to conventional liposomes with improved disintegration times. 
DPPC is a better choice of lipid. Effervescent salts alone without the presence of a sugar-
based carrier were able to produce stable liposomes. The addition of a mucoadhesive 
hampered the entrapment efficiencies in effervescent liposomes. Cholesterol affected the 
entrapment efficiency and stability of liposomes depending on the choice of lipid. 
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CHAPTER 4  
DELIVERY OF 
EFFERVESCENT 
PROLIPOSOMES VIA 
PARI SINUS NEBULIZER
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4.1. Introduction  
Nebulization is a method of transporting medical aerosols for the treatment of respiratory 
diseases. One major drawback of nebulization is drugs being stored in the nebulizer 
ampoules during storage. Ampoules need to be shaken to re-disperse the drug prior to 
performing nebulization. Issues are often observed due to the lack of space for the drug 
to disperse (Iyer and Uster, 2013). Effervescent granules with the drug loaded in the 
liposomes would potentially overcome this drawback and improve drug dosage. 
Conversional liposomes need vortexing and manual shaking to produce liposomes; if not, 
the proliposome particles would not all dissolve, leaving solid in the bottom of the 
ampoules. Effervescent proliposomes, on the other hand, do not need manual shaking or 
vortexing and can disintegrate proliposomes without any solid particles within a matter 
of minutes, generating liposome formulation ready for nebulization. 
Liposomes for aerosol delivery have proven to be advantageous. Liposomes are 
compatible aqueous preparations that provide sustained drug delivery coupled with 
aerosol technology, reduced local irritation, decreased toxicity, increased therapeutic 
benefit, reduced drug clearance, and increased retention with the effective delivery of 
lipophilic or hydrophilic compounds to the site of action (Cullis et al., 1989; Schreier et 
al., 1993; Smola et al., 2008; Taylor and Fan, 1993). 
Little research has been done on the nebulization of sustained release formulations of 
corticosteroid drugs such as Beclometasone dipropionate (BDP). Older patients who used 
nebulization as a method of delivering corticosteroids have been observed to have less 
visits to emergency services when compared to patients who were systemically 
administrating corticosteroids (Marcuos et al, 2006). It is hypothesized that liposomes 
loaded with the drug BDP can be efficiently transported to the parasinuses for the 
treatment of sinusitis using a Pari Sinus nebulizer, improving the treatment of conditions 
such as sinusitis. 
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To understand the suitability of liposomes and their ability to withstand the shearing stress 
during nebulization, the formulations were nebulized using the Pari Sinus nebulizer. 
Nebulization of liposomal formulations will help to recognize change in the behaviour of 
liposomes upon nebulization. Limited research has been done using the Pari Sinus 
technology, and research on the use of this nebulizer with liposomal formulations has not 
yet been conducted. There are no records of studies being conducted on effervescent 
liposome formulations for paranasal sinus targeting. 
Traditional nebulizers, such as jet nebulizers, were initially used with liposomal drug 
formulations (Taylor et al., 1990). However, research indicates that high shear stress from 
the nebulizer causes liposomes to leak their contents. Additionally, in some instances the 
baffles inside the nebulizers damaged the vesicles, resulting in leakage of the liposome 
contents. In this particular part of the study, the ability of effervescent proliposome 
formulation to deliver BDP-loaded liposomes to the nasal cavity through the Pari Sinus 
nebulizer was investigated. The following data are on the performance (nebulization time, 
sputtering time, output, aerosol size) of the Pari Sinus nebulizer with effervescent 
liposomal formulations. 
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4.2. Aims of the Chapter  
The aim of this chapter is to investigate the suitability of effervescent liposome 
formulations made with SPC and DPPC lipids to produce liposomal aerosols suitable for 
drug delivery to the sinuses. 
In this chapter, the Pari Sinus nebulizer with its pulsation technology was employed to 
deliver effervescent nanotechnology-based formulations. 
SPC- and DPPC-based effervescent formulations were nebulized and compared in terms 
of their nebulization time, sputtering time, aerosol size distribution, and aerosol volume 
median diameter (VMD), span, fine particle fraction (FPF), and mass output (%). 
Liposome size, span, and zeta potential of the effervescent formulations upon 
nebulization, and the influence of cholesterol and its impact on the stability of the 
liposomes upon nebulization have also been investigated. 
At the end of this chapter, the most suitable effervescent liposome formulations and most 
suitable lipid for effervescent liposome production were decided and chosen for further 
studies with a nasal cast.  
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4.3. Results and Discussion  
 Nebulization of BDP-loaded SPC liposomes using Pari Sinus nebulizer  
4.3.1.1. Nebulization and sputtering time 
Nebulization times may differ when different nebulizers are used. A study compared the 
corticosteroids BDP, Flunisolide, Fluticasone Propionate and Budesonide. The drugs 
were nebulized via different nebulizers to compare nebulization time, nebulizer output, 
compressor pressure needed, and aerosol characteristics. Research indicated a significant 
difference in drug output and nebulization time between the nebulizers. It was concluded 
that obtaining the best possible characteristics with nebulizers, such as nebulization time, 
adds positively to the resultant clinical benefit (Terzano et al., 2007). There are a number 
of factors affecting efficiency of a nebulizer, such as the design of the device, 
characteristics of the drug solution, cleaning and maintenance procedures of the 
nebulizer, which may all affect the nebulizer performance including the time needed to 
deliver the nebulizer solution (Brun et al., 2000).   
One of the drawbacks of nebulization is the low deposition efficiency of the drug, with 
only 10% of the drug nebulized reaching the target area of the respiratory tract. This is 
considerably low compared to drug deposition using dry powder inhalers (20–30%). 
However, for corticosteroids and β-2 agonists, since the therapeutic dose is less than 1 
mg, the desired drug amount would still reach the targeted site via nebulizers (Selroos et 
al., 1996). Another disadvantage of nebulizers would be the longer time taken for 
nebulization. In clinical practice, 15–30 min of nebulization is considered acceptable 
(Brun et al., 2000). However, the nebulization time could be affected by the solution 
characteristics and nebulizer design. Therefore, different effervescent formulations that 
have been characterized were also nebulized to investigate whether they are appropriate 
for targeting the parasinuses. The nebulization time was investigated by using the Pari 
Sinus nebulizer as previously described (section 4.1).  
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Nebulization times between the samples (mannitol based with or without cholesterol and 
salt-based with or without cholesterol) were insignificant (P≥0.05) with respect to the 
control sample of deionized water. Nebulization of different samples consumed time 
ranging from 21–23 mins to reach ‘dryness’. No significant difference in nebulization 
time was observed between the mannitol- and salt- based formulations, both with and 
without cholesterol. Thus, the inclusion of cholesterol did not affect nebulization time 
when mannitol was used as a proliposome carrier. A similar trend was observed for the 
effervescent salt-based formulations.  
The sputtering duration was significantly different between the control and salt-based 
solutions without cholesterol (P≤0.05). However, other formulations (effervescent 
mannitol with cholesterol, effervescent salt with cholesterol, and effervescent mannitol 
without cholesterol) were not significantly different. The sputtering times between the 
mannitol and salt formulations with cholesterol did not indicate a significant difference. 
However, differences in sputtering times for salt formulations with and without 
cholesterol proved to be significant (P≤0.05). Furthermore, unpublished data by Papanou 
(2011) stated that the Pari Sinus nebulizer demonstrated a sputtering time of 30 sec. In 
contrast, the data collected in the current study indicated a longer sputtering time of 1–2 
min.  
Low patient compliance in nebulization is usually attributed to nebulization time. Most 
children and adults become impatient if the time taken to administer drugs is long, 
resulting in ceasing the administration before the whole dose is delivered. Factors such 
as drug nebulized, concentration, amount of solution to be nebulized, and surface tension 
and viscosity of the solution may affect time the required for nebulization to be completed 
(Iyer and Uster, 2013). Differences in solution physicochemical properties can affect 
nebulization time (Brun et al., 2000). However, preparations used in this study 
demonstrated similarity in nebulization time indicating that effervescence and 
166 
 
incorporation of lipids did not hugely affect the nebulization performance when the Pari 
Sprint nebulizer was used. Air-jet nebulizers are less affected by formulation properties 
compared to other types of nebulizers like vibrating-mesh devices (Ghazanfari et al., 
2007).  
Pari (Jet), Liberty (ultrasonic), and Omron (vibrating-mesh) nebulizers were used to 
deliver liposomes in order to compare efficacy and the impact on the delivery of drugs 
loaded in liposomes via nebulizers (Elhissi and Taylor, 2005). The research demonstrated 
that all nebulizers took approximately 12–30 min to nebulize to ‘dryness’, depending on 
the nebulizer type. Sputtering duration ranged between 2–3 min, showing no significant 
difference between the samples when compared to sputtering time using water, for each 
nebulizer. Elhissi and Taylor (2005) concluded that the nebulization time had some 
influence on the size of liposomes delivered. Moreover, when shearing was applied for a 
longer duration, liposomes were reduced in size within the nebulizer. The findings here 
agree with the results of Elhissi and Taylor (2005).  
Two studies done on improving nebulization time with the AeroEclipse® II breath-
actuated nebulizer by modifying it has improved the time needed for nebulization, leading 
to a 31% reduction in therapy time for administration and a 20% reduction in total costs 
for the year 2008 at Forsyth Medical Centre. Studies done in 2007 further stated that 
breath-actuated nebulizers have reduced nebulization time by 19% and decreased the total 
costs of therapy by 18% (Wilson, 2011). Studies done in 2007 also demonstrated a 
reduction in total cost with shortened nebulization time (St. Dominic Hospital et al., 2007)
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Table 4-1: Nebulization time and aerosol characteristics for effervescent formulations prepared using SPC as a lipid for nebulization via the Pari 
Sinus nebulizer  
Sample 
Nebulization 
time (min) 
Sputtering 
duration 
(min) 
Mass median 
diameter (VMD) of 
droplets (µm) 
Fine particle 
fraction  
(% < 5 µm) 
Span 
Aerosol mass 
output (%) 
Mannitol with 
cholesterol 
22.93+1.68 2.61+0.38 4.65+0.16 59.75+3.58 1.81+0.03 74.28+4.90 
Salt with 
cholesterol 
22.3+0.20 2.71+0.67 3.40+0.12 77.44+3.24 1.64+0.10 85.22+12 
Mannitol without 
cholesterol 
22.67+2.68 2.0+0.73 4.05+0.42 64.75+6.13 2.28+0.25 75.49+3.20 
Salt without 
cholesterol 
21.51+1.80 1.81+0.10 3.485+0.53 80.77+12.15 1.378+0.23 78.24 +1.83 
Water 
 
21.85+0.53 2.61+0.38 4.09+0.78 70.78+14.18 1.40+0.15 66.68+1.58 
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4.3.1.2. Determination of size and size distribution (span) of the generated aerosols 
Aerosol particle size is a fundamental factor in the determination of aerosol suitability for 
nasal delivery. Predominantly, aerosol size influences the deposition on the targeted site 
of the sinus. To ensure aerosols get deposited to the sinus, the aerosols should reach the 
posterior nasal cavity. Aerosols below 5 µm  (aerodynamic diameter) have been found to 
be the most suitable for the deposition in sinuses (ICRP Publication 66, 1994). Current 
nasal sprays have been found to be able to deposit 100% of the administrated drug into 
the nasal cavity; however, only minimal deposition has been observed in the sinuses due 
to the large size emitted from nasal sprays (50–200 µm) (Hwang et al., 2006; Möller et 
al., 2010).  
Möller et al .2009 studied ventilation efficiency of the sinuses of three volunteers using 
dynamic 81mKr-gas imaging along with pulsating air flow. Radiolabel DTPA 
(Diethylenetriaminepentacetic acid) and retention of 99tc-DTPA aerosol particles were 
monitored over a period of four hours (Moeller et al., 2009). No significant difference 
was observed in the central nasal cavity due to pulsating air flow. However, a fivefold 
increase in the proportion deposited was observed in the four sinuses with pulsating air 
flow. A total deposition of 25±16% without pulsation was observed, while a significant 
difference of 58±17% in the nasal cavity was observed with the Pari Sinus nebulizer. A 
value of 4.2±0.3% penetration of the aerosol to the sinuses region was observed with the 
pulsating aerosol technology, while only 1% deposition was observed without pulsation 
(Moeller et al., 2009) 
The supplier manual of the Pari Sinus nebulizer indicates that the VMD of aerosol 
droplets for 0.9% sodium chloride solutions was 3.6 µm in VMD when analysis was 
conducted via laser diffraction (Schuschnig et al., 2008). Therefore, the Pari Sinus 
nebulizer was used for the following part of the study to explore the deposition profile of 
aerosols of containing effervescent liposomes loaded with BDP.  
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The nebulization of liposomes using this nebulizer was performed in vitro using laser 
diffraction. Droplets were generated as a cloud passing through the laser beam, which 
allowed the determination of the VMD. 
The VMD analysis of aerosols showed the droplet size to range from 3–4 µm. Aerosol 
VMD measurements were taken after 2 min of commencing nebulization for each 
formulation and compared with the control sample of deionized water. The VMD was 
observed to be smaller in the salt-based formulation in comparison to the mannitol-based 
formulations. On comparing these formulations to the control, no significant difference 
was observed. However, the mannitol sample in comparison to the salt sample with 
cholesterol demonstrated a large droplet size with a significant difference (p≤0.05). A 
significant size difference was only observed when comparing the two carrier types in the 
presence of cholesterol.  
Span values were significantly larger (p≤0.05) in comparison to the control when using a 
mannitol without cholesterol formulation. These findings may be explained by the ability 
of cholesterol to increase the rigidity of vesicles. The span was higher for aerosols 
generated from cholesterol containing mannitol-based samples compared to the control. 
The size of aerosol droplets generated from all formulations was less than 5 µm, 
demonstrating that liposome formulations could deposit in the sinus. The results are in 
agreement with Möller et al., (2008, 2010) and Schuschnig et al., (2008). SPC-based 
liposome formulations loaded with BDP were found to have a liposome size of 5.14+0.49 
µm. Mannitol-based effervescent formulations with cholesterol were found to be the most 
appropriate formulations in terms of size, span, zeta potential entrapment of liposomes, 
and also aerosol size. Liposomes would be able to fit in the aerosols of the Pari Sinus 
nebulizer. Salt formulations without cholesterol have a vesicle size of 6.04+ 0.19 µm, 
also appropriate in terms of liposome size. However, the salt-based formulation with 
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cholesterol was observed to have a very low entrapment compared to the mannitol with 
cholesterol formulations.  
Investigations conducted using a cadaver nasal cast to collect aerosols generated from the 
pulsating nebulizer revealed that the appropriate aerosol size for deposition in the 
maxillary sinus was 3–10 µm (Saijo et al., 2004). However, only 3% of particles in this 
size range were found to deposit in the maxillary sinus. Effervescent liposomes and 
aerosol VMD of the Pari Sinus nebulizer fall within this size range. A post–ESS nasal 
cast model was also used along with the Pari Sinus nebulizer to investigate the aerosol 
deposition profile. Findings indicated that aerosol droplets with a particle size of 5.63 µm 
were deposited in the maxillary sinus, while larger aerosol droplets (e.g. 16.37 µm) failed 
to deposit in the maxillary sinus. Moreover, the insertion angle of the nose adaptor (45°) 
has been found to influence the deposition profile (Saijo et al., 2004).  
Many investigations (Djupesland et al., 2006b; Frank et al., 2012; Möller et al., 2011, 
2008; Negley et al., 1999; Sato et al., 1981) have indicated a large particle size (>10 µm) 
produced by nasal sprays and plume for deposition in the nose. However, the deposition 
of aerosols via the Pari Sinus have been shown to be more advantages due to the smaller 
particle size of the droplets generated by this device (e.g. < 5 µm) (Moeller et al., 2009). 
Frank et al. (2012) have reported that when nebulizers were compared to nasal sprays 
(generated droplets size >10 µm), findings showed that nasal sprays deposited 100% of 
the sprayed material in the nasal passage while nebulizers had an aerosol size of <6.42 
µm causing more than 50% of the aerosolized material to bypass deposition in the nasal 
passages. Thus, nebulizer particles <10 µm were more likely to be respairable.  
Significant (p≥0.05) differences in aerosol span values were not observed between 
mannitol and salt formulations.  No considerable difference in size between formulations 
and control was found, indicating that the effervescent property did not affect the size 
distribution of aerosols, which might be an indication of a stable liposomal formulation 
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and consistent nebulizer performance when different formulations are used. Unpublished 
data by Papanou (2011) observed a span value of 1.563 using this nebulizer, which is in 
agreement with the present findings in this report.  
Non-effervescent proliposomes were hydrated in situ within the nebulizer and nebulized 
by Elhissi and Taylor ((2005), who compared nebulizers operating at different 
mechanisms such as the Pari Plus (air jet), Liberty (ultrasonic) and Omron (vibrating-
mesh) nebulizers. They found that the Pari Plus nebulizer (similar but not identical to the 
Pari Sinus) produced smaller aerosol droplets (2.50 µm) compared to the other two 
nebulizers. Elhissi and Taylor (2005) stated that rigid liposomes made with cholesterol 
had no effect on aerosol particle size. Furthermore, Elhissi and Taylor (2005) also stated 
that large aerosol particles delivery to the deep lung would be unlikely, whereas smaller 
aerosol particles were delivered to the lower impinger. Even though the focus of this 
research is not on pulmonary delivery, the proposed theory could be extended, i.e. that 
small aerosols may be easier to transport to the sinus, while larger liposomes may deposit 
in the nasal passages. Research by Elhissi et al. (2012) indicate smaller aerosols contain 
smaller liposomes while larger liposomes contain larger aerosols. This suggests that 
smaller aerosol containing smaller liposomes would be delivered to the sinuses and the 
larger aerosol would deposit in the nasal cavity. Larger liposomes could also penetrate to 
nasal epithelium and help with decongestion.  
Darwis and Kellaway, (2001) have investigated BDP liposomes prepared from various 
lipids, dilauryl phosphatidylcholine (DLPC), dimyristoyl phosphatidylcholine (DMPC), 
dipalmitoyl phosphatidylcholine (DPPC), and hydrogenated soy bean 
phosphatidylcholine (HSPC). DLPC liposomes had the smallest VMD aerosol 
measurements (3.31 µm), indicating that formulation may affect the performance of jet 
nebulizers. However, using the Pari Sinus nebulizer, the effervescent property of 
liposomes had no significant effect on the aerosol VMD, suggesting droplet size can be 
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affected by nebulizer type and formulation characteristics. Both mannitol- and salt-based 
liposomes had comparative aerosol sizes when non-effervescent liposomes were 
nebulized. Results indicated that salt-based liposomes with cholesterol were able to 
produce the smallest aerosol droplets with a VMD of 3.40 µm, indicating the effect of 
salt content on aerosol droplet size. 
The Pari Sinus nebulizer (according to the supplier’s manual) when the temperature is 
23 °C, the relative humidity is 50% and the fill volume is 5 ml using 0.9% sodium chloride 
solution, the laser diffraction measured VMD should be around 3.6 µm. This correlates 
with the results obtained in this report. Salt-based effervescent aerosols were only slightly 
smaller in size than sodium chloride aerosols, possibly because of the larger salt 
concentration used in the liposome formulations. Moreover, mannitol-based aerosols 
were slightly larger compared to the result achieved by some other investigators 
(Schuschnig et al., 2008), suggesting that a slight difference in the environmental 
conditions may slightly affect the droplet size of the nebulizer. 
 Hyo et al. (1989) have simulated the deposition of aerosolized particles to paranasal 
sinuses using a nasal cast model. Their research has stated three factors may affect particle 
deposition, with the size of ostia being the most significant factor that had an impact on 
the size of the particles deposited on the maxillary sinus (observed in healthy individuals).  
In summary, mannitol with cholesterol effervescent formulations may be the most 
suitable in terms of particle size and particle distribution (span). Liposomes in this 
formulation also had a smaller size and offered higher drug entrapment, and established 
suitability for delivery by the Pari Sinus nebulizer.  
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4.3.1.3. Aerosol mass output (%)  
Although droplet size is an important factor in nebulization, the amount of drug that is 
put into the nebulizer and the amount that is delivered to the patient, as well as the amount 
of drug that can be delivered at a given time, are all important factors that help evaluate 
nebulization efficiency (Finlay, 2001). The amount of drug released from the nebulizer 
depends on nebulizer output, particle size, and amount of liquid within the nebulizer 
(Wanger, 2011). The simplest way to measure nebulizer output is to study aerosol mass 
output. Given that the Pari Sinus nebulizer has a fixed output rate of 6 l/min with a 
pulsation frequency of 44.5 Hz, the aerosol mass output and output rate can be calculated. 
Higher drug output rates help reduce long treatment times, which may have an effect on 
patient compliance. Mass and drug output rates of a nebulizer can be affected by the 
viscosity increase or decrease in accordance with the nebulizer solution temperature.  
The Pari Sinus brochure indicates that the mass output percentage below 5 µm is 71% 
using 0.9% NaCl (5 ml) solution. Samples (5 ml) of each effervescent formulation were 
nebulized to ‘dryness’; however, complete atomization of the liposome formulation was 
not observed in all formulations and in the control. This indicates that the aerosol mass 
output was less than 100% due to the residual volume remaining in the nebulizer after the 
completed nebulization.  
The aerosol mass output between the control (66.68+1.58%) and mannitol effervescent 
formulations with cholesterol loaded with the drug (74.28+ 4.9%) were significantly 
different to each other. Salt with cholesterol demonstrated a significantly higher aerosol 
mass output rate in comparison. Carriers, mannitol, and salt loaded with the drug, without 
cholesterol, had a significantly higher aerosol mass output rate compared to formulations 
with cholesterol. This indicates that the effervescent ingredients have helped increase the 
aerosol mass output rate. No significant difference of aerosol mass output (%) between 
mannitol and salt formulations with cholesterol was observed. Salt and cholesterol as 
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formulation ingredients gave the highest aerosol mass output (85.22+12.0). Both 
mannitol formulations exhibited similar results for aerosol mass output. For each carrier, 
the incorporation of cholesterol had no effect on the aerosol output.   
Moeller et al. (2009) investigated the aerosol mass output within the sinuses using three 
healthy subjects. Results demonstrated a total aerosol deposition of 25±16% of the 
nebulized dose being deposited within the nasal cavity when no pulsation technology was 
used. However, when pulsation technology was employed the nebulized dose increased 
significantly (p<0.01) to 58±17%. Furthermore, without pulsation only 1% of the 
nebulized dose was found to reach the sinuses, while with pulsation 4.2±0.3% reached 
the sinuses (Table 4-1). It can be hypothesized that a higher percentage of the drug may 
be reached with a large amount of the drug being nebulized to the sinus when the pulsation 
technology is employed. Therefore, with high aerosol mass output (%) and with 
effervescent liposomal formulations, a higher content of drug reaching the sinuses can be 
expected.  
Literature indicates that higher phospholipid concentration in liposome formulations may 
lead to enhanced packing of drug molecules within the liposome bilayers (Manca et al., 
2012). Hence, increased phospholipid and cholesterol content may improve the stability 
of liposomes during nebulization by reducing drug leakage from the liposomes. 
Liposomes with cholesterol tend to have higher nebulization efficiency compared to 
formulations without cholesterol. By contrast, formulations with phosphatidylcholine had 
a nebulization efficiency of 35±2.3%, the same formulations with cholesterol had a 
nebulization efficiently of 48.39%. A similar increase was observed for other the 
formulations tested (Manca et al., 2012). A similar observation was observed for 
effervescent formulations prepared in this study with and without cholesterol. 
Elhissi et al. (2006) investigated the aerosol mass output rate of non-effervescent 
liposomes using the Omron (mesh), Pari (Jet), and Liberty (ultrasonic) nebulizers. 
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Aerosol output was the highest, with the Omron nebulizer exhibiting an output value of 
91%. In comparison to these nebulizers, the Pari Sinus gave an average amount of aerosol 
output, being in the range of 74–85% depending on the formulation. Both salt 
formulations elicited a lower aerosol mass output (Elhissi et al., 2006).  
4.3.1.4. Fine particle fraction (FPF) 
The deposition profile of the drug in the nasal cavity and lung differ drastically depending 
on the nebulizer model used (Hickey et al., 1996; Newman, 1993). In this study, the FPF 
was determined as the aerosol fraction with an aerodynamic diameter less than % <5 µm 
using the Pari Sinus nebulizer. The Pari Sinus nebulizer has been identified as having an 
FPF of 71%, according to the brochure supplied by the manufacturer (PARI Respiratory 
Equipment, Inc., 2012; Schuschnig et al., 2008).  
Sodium chloride trace solution was nebulized with the Pari Sinus to study the in vitro 
effect of the deposition using a silicon nasal cast. The nasal cast consisted of four 
cylindrical chambers representing the sinuses with equal volumes. The ostium diameter 
varied from 0.5 mm to 3 mm in the nasal cast (Boehm et al. 2004, Karn et al., 2011).  
Particles below 5 µm were deposited in the sinus chambers and particles with VMD of 5-
10 µm deposited in the nasal region of the cast. By contrast, particles with a VMD greater 
than 10 µm were deposited in the frontal region of the nasal cast, indicating the influence 
of the aerosol particle size on the deposition profile. Thus, based on the aerosol droplet 
size, it is expected that the majority of the aerosol with effervescent formulation can 
deposit in the sinus region, resulting in the expected therapeutic effect when the drugs are 
administrated. Further investigations are needed to study the validity of this assumption.  
In the present study, nebulization of the effervescent formulations via the Pari Sinus 
nebulizer would generate aerosols with FPF dependent on the carrier type and lipid 
composition of the effervescent formulation. All effervescent formulations in comparison 
to the water control sample did not demonstrate a difference in FPF, except for the 
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cholesterol containing the mannitol-based formulation, which had significantly lower 
FPF by 11.03% when compared to the control water. 
The effervescent formulation made from mannitol and using cholesterol had an FPF of 
59.75% +3.59, whereas the formulation made with salt and cholesterol had a significantly 
higher FPF (77.44% +3.25). The difference in FPF might be attributed to different 
physicochemical properties such as viscosity and surface tension (Ghazanfari et al., 
2007). 
No significant differences in FPF were observed between samples of mannitol and salt 
formulations when cholesterol was omitted from the formulations (Table 4-1). It is 
possible that the rigidity given to the liposome structures owing to the inclusion of 
cholesterol has affected the FPF of the aerosol. Both mannitol formulations with and 
without cholesterol had lower FPF when compared to the relevant counterpart in salt 
formulations (Table 4-1).   
According to a study conducted by Ghazanfari et al. (2007), using the Omron MicroAir 
NE-U22 nebulizer and Aeroneb Pro nebulizer with deionized water, glycerol and NaCl 
solutions, the Omron MicroAir NE-U22 nebulizer had a FPF of 41.00±1.68 for deionized 
water, 30.23±6.36 FPF for the glycerol solution, while sodium chloride solution had a 
FPF of 39.40±0.21. Thus, the formulation may markedly influence the FPF of aerosols. 
Salt-based formulations showed an increase in the FPF compared to the control as in the 
case of using deionized water. Overall, the effervescent formulations using mannitol or 
salt as proliposome carriers nebulized with the Pari Sinus demonstrated higher FPF values 
than those in the literature using the Aeroneb Pro mesh nebulizer. All formulations 
showed that aerosols could potentially be deliverable to the sinuses using the Pari Sinus 
nebulizer. Darwis and Kellaway (2001) worked on liposomal formulations for pulmonary 
delivery. This research states that aerosols produced by the Pari LC Plus nebulizer with 
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sizes >10 μm were deposited in the ‘throat’ of the impinger, and particles having a size 
cut between 10 and 5.8 μm have deposited in stages 0 and 1 (Darwis and Kellaway, 2001). 
4.3.1.5. Determination of drug output from the nebulizer 
The drug output (%) was determined based on the reservoir volume and HPLC analysis 
of the drug in the residual volume left in the reservoir of the nebulizer after nebulization. 
High drug output was observed for all formulations after nebulization. Drug output (%) 
was shown to be 82% for mannitol with cholesterol and 79% for salt with cholesterol 
formulation. Drug output of 76% was found for mannitol without cholesterol and 66% in 
the salt sample without cholesterol. Samples without cholesterol demonstrated lower 
nebulization efficiency (Figure 4-1). There was a significant difference observed (P≤0.05) 
between mannitol with cholesterol samples and salt without cholesterol samples. 
Mannitol without cholesterol gave a high standard deviation, showing inconsistencies in 
the results. From this data it can be concluded that mannitol with cholesterol seems to be 
the most suitable formulation for nebulization.   
Figure 4-1: Determination of drug output (%) of SPC-based liposomes from Pari 
Sinus nebulizer.  
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Slightly higher drug output was noted when compared to aerosol mass output. In contrast 
Papanou (2011) observed that non-effervescent liposomes have excess aerosol mass 
output over drug output (P≤0.05), which is consistent with other findings (Elhissi and 
Taylor, 2005). Thus, it is possible that the influence of effervescent ingredients on 
liposomes have enhanced the drug output, causing it to exceed the aerosol mass output. 
4.3.1.6. Liposome size after nebulization 
Results for VMD, span, and zeta potential, before and after nebulization, were studied 
(Table 4-2). The nebulized aerosols were collected in a flask fitted in front of the nebulizer 
during aerosolization. Compared to the size prior to nebulization, the measurements 
differed upon the release of the aerosols to the flask. When mannitol with cholesterol 
formulation was used, no difference in VMD of liposomes was observed upon 
nebulization (P≥0.05). Similarly, salt with cholesterol samples exhibited no change in 
VMD, span, and zeta potential upon nebulization. Comparison of mannitol and salt with 
cholesterol formulations after nebulization showed no significant difference between the 
two formulations (P≥0.05), indicating that atomization within the nebulizer may not 
affect the physical integrity of the liposomes.   
In the absence of cholesterol, liposomes generated from mannitol proliposomes had 
inconsistent VMD measurements, which might be attributed to inconsistent aggregation. 
The zeta potential was positive for liposomes before nebulization and slightly negative 
after nebulization, without significant difference (P≥0.05). Salt without cholesterol also 
showed aggregation in samples after nebulization with a high VMD measurement, but no 
significant difference (P≥0.05) was observed for both size and span when formulation 
before and after aerosolization were compared. However, the zeta potential showed a 
significant difference (P≤0.05). The zeta potential was positive before nebulization and 
negative after nebulization. A study carried out using the Aeroneb Pro and Omron 
MicroAir vibrating-mesh nebulizers and the Pari LC Sprint air-jet nebulizer demonstrated 
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that nebulization causes fragmentation of the vesicles. This fragmentation as a result of 
nebulization may cause the vesicles to aggregate and may change the charge distribution 
on the vesicle. The side reduction of vesicles change the surface charge of vesicles 
(Elhissi, et al., 2013). 
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Table 4-2: Characterization of SPC-based liposomes before and after nebulization  
 
 
 
Before nebulization 
 
After nebulization 
 
 Size (µm) Span 
Zeta 
potential 
(mV) 
Size (µm) Span 
Zeta 
potential 
(mV) 
Effervescent 
mannitol with 
cholesterol 
6.29±0.45 3.03±0.26 -1.15±1.07 26.4±18.43 2.72±0.85 -1.34±1.48 
Effervescent 
salt with 
cholesterol 
12.07±6.08 3.88±0.90 -0.54±0.51 12.77±11.58 8.25±7.63 -8.89±5.34 
Effervescent 
mannitol 
without 
cholesterol 
6.75±0.71 3.16±1.20 0.18±1.12 49.48±27.68 1.51±0.95 -2.54±1.11 
Effervescent 
salt without 
cholesterol 
4.87±1.09 3.96±2.56 0.53±0.58 39.62±32.92 1.56±0.16 -5.23±1.86 
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4.3.1.7. Conclusions for SPC-based liposome nebulization   
Novel BDP effervescent liposome formulations were able to produce stable liposomes 
for nebulization using the Pari Sinus nebulizer. Effervescent liposome formulations had 
a higher nebulization efficiency compared to water samples, suggesting that the influence 
of liposomes on the nebulizer fluid characteristics was advantageous. Nebulization time 
and sputtering of all the formulations was similar. SPC-based formulations loaded with 
BDP had a size of 5.14+0.49 µm (mean + SD), which was also the most appropriate 
formulation in terms of span, zeta potential, and drug entrapment. This formulation also 
performed very well in terms of aerosol droplet size, and aerosol mass output. However, 
the formulation had less of a FPF rate at 59%.   
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 Nebulization of BDP drug loaded with DPPC-based formulations using 
Pari Sinus nebulizer  
The lipid composition used for the preparation of liposomes has been found to influence 
nebulization efficiency (Niven and Schreier, 1990; Niven et al., 1991;). Furthermore, the 
lipid concentration and liposome preparation method have also been found to influence 
the nebulization efficacy. Liposomes are known to fragment upon application of shear  
forces or as a result of impact on the baffles during nebulization, resulting in drug leakage 
and loss of the controlled release characteristics (Elhissi et al., 2006; Niven et al., 1991; 
Taylor et al., 1990). Therefore, optimization of the effervescent formulations with the 
most suitable lipid composition that would result in more stable liposomes during 
nebulization is needed.  
SPC, Hydrogenated SPC, or Dipalmitoyl Phosphatidylglycerol were made in order to 
understand the effect of lipids on liposome stability during nebulization. 5(6)-
Carboxyfluorescein was used as a model hydrophilic marker which had an entrapment 
dependent on the lipid composition of the liposomes (Niven and Schreier, 1990). 
In a previous study, nine combinations of lipid and cholesterol ratios were used for 
preparing liposomes, in order to understand the effects of lipid composition on drug 
entrapment and nebulization efficiency. The research indicated that retention of 
Rifampicin after nebulization and the entrapment efficiency of the drug was affected by 
lipid composition. Liposomes made from DPPC or DSPC were found to offer a higher 
entrapment efficiency for Rifampicin when compared to liposomes made with a natural 
PC (Zaru et al., 2007). Cholesterol was found to have an effect on the entrapment. DSPC 
with cholesterol (2:1) proved to be the most appropriate for maximizing drug entrapment 
and reducing leakage during nebulization (Zaru et al., 2007). This study correlated with 
the findings using SPC and DPPC effervescent liposomes (chapter 3). Both lipids we used 
acted differently with cholesterol and both lipids were compared in a 2:1 lipid to 
cholesterol ratio. As demonstrated earlier in chapter 3, it was found that effervescent 
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DPPC formulations have offered a higher BDP entrapment compared to effervescent SPC 
formulations. When considering size, span, zeta, and entrapment, mannitol with 
cholesterol and salt with cholesterol effervescent formulations proved to be the most 
appropriate for subsequent studies. This chapter has identified how DPPC-based 
effervescent liposome formulations using mannitol or salt and via incorporation of 
cholesterol may affect nebulization efficiency using the Pari Sinus nebulizer. 
4.3.2.1. Nebulization and Sputtering time for DPPC-based formulations  
Proliposomes were made using DPPC as a lipid and mannitol or salt as carriers and using 
BDP as the model drug. Proliposomes were then disintegrated in deionized water and the 
drug entrapment efficiency was investigated (section 2.3). This was followed by 
performing the nebulization studies as described earlier in section 2.5. 
DPPC formulations using mannitol as the carrier with cholesterol as a lipid ingredient   
had prolonged the time for the completed nebulization (26.72+1.57 min). DPPC-based 
salt-based formulations with cholesterol and a non-effervescent mannitol formulation 
demonstrated a similar nebulization time to SPC-based formulations (22–23 min).  The 
mannitol-based formulation also demonstrated a significantly different (p≤0.05) 
nebulization time compared to the non-effervescent mannitol-based formulation with 
cholesterol and water. The salt-based effervescent formulation demonstrated no 
significant difference when compared to non-effervescent formulations and water (Table 
4-2). It is possible that mannitol had an interaction with DPPC and cholesterol in a 
different manner when compared to other formulations, resulting in different viscosities 
and physiochemical properties. This might be the reason behind the difference in time 
taken for nebulization (McCallion et al., 1995; Steckel and Eskandar, 2003).   
Mannitol and salt formulation with cholesterol had differences in nebulization time. 
Different carriers have affected nebulization in the presence of effervescent ingredients. 
Effervescent mannitol with cholesterol made with DPPC demonstrated a significant 
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difference (p≥0.05). Compared to the DPPC:Chol formulation, the mannitol-based 
SPC:Chol  formulation had a shorter nebulization time.  
The nebulization time of 5 ml of liposome formulation to dryness for all formulations 
using the Pari Sinus for both DPPC and SPC was less than 30 min. This was in agreement 
with the time taken for nebulization using the Pari Plus (air jet) nebulizer (Elhissi et al., 
2007). This indicates that the effervescent properties and the use of DPPC did not 
considerably affect nebulization time.  
Sputtering time differed between the non-effervescent mannitol with cholesterol 
formulation and the corresponding effervescent preparation (p≤0.05).  The effervescent 
salt-based formulation, however, did not show any significant difference compared to the 
control non-effervescent mannitol with cholesterol. The difference in carrier was found 
to affect sputtering time when mannitol- and salt-based effervescent formulations were 
compared. The sputtering time of the DPPC-based formulations were slightly different 
compared to the SPC-based formulations. The sputtering time for effervescent mannitol-
based formulations and effervescent salt-based formulations with cholesterol between 
SPC-based and DPPC-based formulations were similar in time and were not found to be 
significantly different
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Table 4-3: Nebulization data for effervescent formulations prepared using DPPC as a lipid using the Pari Sinus nebulizer  
 
 
Sample 
Nebulization 
time (min) 
Sputtering 
time (min) 
Mass 
median 
diameter 
(VMD) of 
Droplet(µm) 
Fine 
particle 
fraction  
 (% < 5 µm) 
Span 
Aerosol mass 
output rate 
(%), 
Mannitol with 
cholesterol 
26.72 +1.57 2.98+ 0.34 6.37+0.40 50.07+5.60 20.22+5.97 84.47+9.01 
Salt with cholesterol 22.26+1.15 2.22+0.12  6.11+0.68   50.67+6.1 21.60+2.63 82.29+6.34 
Non- effervescent 
liposomes (mannitol 
with cholesterol) 
22.53+1.57 1.96+0.35 5.79+0.41 54.57+0.41 22.43+1.80 76.96+4.53 
Water 21.85+0.53 2.61+0.38 4.09+ 0.78 70.78+14.18 1.40+0.15 66.68+1.582 
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4.3.2.2. Determination of size distribution of the generated aerosols 
The DPPC-based formulations demonstrated an aerodynamic diameter that was slightly 
larger compared to the SPC formulations. However, they were still in the range of 5–6 
µm (Table 4-1 and Table 4-3). The mannitol- and salt-based effervescent formulations 
with cholesterol did not have a significant difference in aerosol size compared to the 
control, or to each other. The effervescent property and carrier type did not affect the 
aerosol size (Table 4-3). 
The data on effervescent formulations with the SPC lipid suggest that the change in lipid 
had a significant effect on aerosol size (p≤0.05) in effervescent mannitol-based 
formulations with cholesterol. The same observation about aerosol size was found to be 
the case for salt with cholesterol formulations using SPC or DPPC formulations (p≤0.05). 
Data also suggest that aerosol size was smaller for the SPC formulations for both mannitol 
and salt effervescent formulations, compared to DPPC. 
A study on an air-jet nebulizer suggested that the size of aerosol droplets was more 
dependent on the type of nebulizer than on the composition of liposomes (Bridges and 
Taylor, 1998). Liposomes were reduced in size during nebulization, resulting in leakage 
of the originally entrapped drug, and greater instability was observed for larger liposomes 
(Elhissi et al., 2007; Niven et al., 1991; Taylor et al., 1990). Even though   DPPC 
formulations produced slightly larger liposomes compared to SPC formulations, these 
liposomes might be fragmented to smaller sizes, so that they may fit into the aerosol 
droplets released by the nebulizer. However, this fragmentation is usually accompanied 
by loss of the drug from the liposomes during nebulization.  
The span of the DPPC formulations was notably high compared to the SPC formulations 
(Table 4-3). The DPPC formulations had a span in the range of 5–7, while the SPC 
formulations had span values in the range of 1–3. The aerosol generated from all 
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effervescent and non-effervescent DPPC formulations demonstrated significantly 
different span values in comparison to water. However, when effervescent formulations 
were compared to non-effervescent formulations no significant difference was observed. 
The difference in aerosol characteristics using liposomes with a range of compositions 
might be attributed to the different fluid physicochemical properties. Fluid properties 
have been previously shown to influence the nebulized aerosol performance (Ghazanfari 
et al., 2007). However, the carrier type (mannitol or salt) had no effect on aerosol size 
distribution.  
4.3.2.3. Fine particle fraction (FPF)  
The effervescent formulation made with DPPC demonstrated FPF values in the range of 
50–55%; this was slightly higher than FPF using the earlier used SPC formulations. The 
FPF of aerosols generated from non-effervescent DPPC:Chol formulations using 
mannitol or salt carriers were similar to FPF generated from water. Non-effervescent 
formulations and effervescent DPPC formulations both had similar FPF values. A change 
of carrier between mannitol and salt did not seem to have any effect on FPF of the 
generated aerosol (Table 4-3). 
Mannitol formulations with SPC:Chol or DPPC:Chol demonstrated similar FPF values. 
The FPF of salt formulations with cholesterol when compared to formulations made with 
two different lipids demonstrated nearly 20% compared to SPC (p≤0.05). Therefore, lipid 
composition may affect FPF only when salt was used as carrier.  
Previous studies have shown that lipid composition may greatly affect the FPF of aerosols 
generated from liposome formulations (Darwis and Kellaway, 2001b). Effervescent 
liposomes made with DPPC had lower FPF than conventional non-effervescent liposomes 
made in this study. However, the FPF of aerosols generated from salt-based effervescent 
formulations with SPC was higher (Table 4-3).  
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4.3.2.4. Mass output for DPPC effervescent formulations  
Effervescent formulations with DPPC when nebulized through the Pari Sinus nebulizer 
to ‘dryness’ did not result in atomization of all the formulation; therefore, some residual 
fluid was left behind within the reservoir of the nebulizer. Hence, aerosol mass output 
and drug output were less than 100% (Table 4-3). The study done by Elhissi et al. (2006) 
indicated formulation differences in liposomes affecting the mass output of several 
liposomes. Therefore, understanding the effect of effervescent formulations on the Pari 
Sinus nebulizer and how changes of effervescent formulations, such as type of carrier and 
lipid used affect the mass output rate, was an interesting part of the investigation.  
Improved aerosol mass output percentages for effervescent formulations were found 
compared to formulations without effervescence (conventional liposomes) and water 
samples (Table 4-3). Effervescent mannitol (84.47+9.01%) and salt formulations 
(82.29+6.34%) with cholesterol were significantly different in aerosol mass output 
compared to deionized water (66.68+1.582%) (p≤0.05). However, no significant 
difference was observed when effervescent formulations of mannitol and salt with 
cholesterol were compared to non-effervescent formulation (mannitol with cholesterol). 
This indicates that the effervescent property of liposomes has not hampered aerosol mass 
output.  Formulations made with either carrier, mannitol or salt, when compared to each 
other did not demonstrate a significant difference in terms of aerosol output. 
Both mannitol formulation and salt formulation with cholesterol made with DPPC as a 
lipid were compared to mannitol and salt formulation with cholesterol made with SPC. 
Both formulations demonstrated no significant differences in results (Table 4-1 and Table 
4-3). This indicates that the type of lipid did not affect aerosol mass output.  
4.3.2.5. Determination of drug entrapment after nebulization  
After nebulization the drug outputs for all formulations were relatively low, both for non-
effervescent and effervescent formulations (Figure 4-2). This can be explained by the 
189 
 
stress liposomes undergo during nebulization. Non-effervescent liposomes demonstrated 
low entrapment before nebulization with high SD, and low entrapment 35.04 + 5.39% 
after nebulization (Figure 4-2). This indicates that non-effervescent liposomes made with 
DPPC:Chol and mannitol were less stable during nebulization compared to effervescent 
liposomes. Effervescent liposomes had greater drug entrapment after nebulization, and 
when salt was used as a carrier and cholesterol as one of the lipid constituents, the 
entrapment was further enhanced.  
When comparing drug entrapment after nebulization between non-effervescent 
(35.04+5.39%) and effervescent (61.27+3.90%) they demonstrated a significant 
difference in drug entrapment (p≥0.05) for mannitol-based formulations with cholesterol. 
The effervescent property has increased the stability of the liposomes towards shear 
stress. Salt-based effervescent formulations were also found to offer significantly 
different entrapment (p≤0.05) compared to non-effervescent liposomes. However, they 
were not found to be significantly different with regard to drug entrapment when 
compared to mannitol-based effervescent formulations. This indicates that the differences 
in carrier did not have any impact on the physical stability of liposomes during 
nebulization.  
The incorporation of cholesterol in liposomes has been found to increase rigidity of the 
liposome membrane, which can reduce drug losses during jet nebulization (Moribe et al., 
1999; Subczynski et al., 1994). 
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Figure 4-2: Entrapment efficiency of DPPC-based formulations loaded with BDP 
before and after nebulization. 
 
It is suggested that including cholesterol and other rigidifying agents increases the 
resistance of conventional liposomes and also reduces leakage of the drug during 
nebulization (Elhissi et al., 2012). Low entrapment of drugs within liposomes of steroid 
drugs is due to the geometric structure of steroid molecules, which reduce interaction of 
the drug with lipid bilayers. Research also indicates that BDP encapsulation is inversely 
proportional to the transition temperature of the phospholipid (Darwis, 2000; Darwis and 
Kellaway, 2001b; Szoka and Papahadjopoulos, 1980). Liposomes made with lipids with 
an increased length of acryl chains were found to have lower entrapment of BDP (Darwis 
and Kellaway, 2001b). The rigidity of liposomes has also been found to increase with 
higher transition temperature lipids. However, this was in contrast to this study, which 
concluded that DPPC was a better choice of lipid for enhancing the entrapment of BDP 
before and after nebulization, compared to SPC. 
BDP forms complexes with the lipid head groups of the liposomes. However, these 
complexes have been observed to break during extrusion and sonication of liposomes 
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through the polycarbonate membranes. Similarly, BDP complexes that could have been 
formed with the lipid head group could be broken during nebulization and that may result 
in the reduction of drug entrapment observed post-nebulization (Darwis and Kellaway, 
2001b; Stamp and Juliano, 1979; Taniguchi et al., 1987). High entrapment observed 
before nebulization could be the result of these complexes between the drug and the lipid 
head group. 
Overall, DPPC:Chol effervescent formulations, made both with mannitol or salt carriers 
were suitable for nebulization. While salt with cholesterol effervescent formulation 
demonstrates high entrapment, mannitol with cholesterol demonstrates itself to be more 
suitable overall for nebulization in terms of entrapment and nebulization performance.  
4.3.2.6. Size of DPPC liposomes after nebulization 
Non-effervescent mannitol-based formulations with cholesterol were observed to 
aggregated upon nebulization since the particle size measured was very high (37.48±0.33 
µm), while effervescent formulations had a smaller size, possibly indicating less liposome 
aggregation (Table 4-4). When mannitol or salt were used as carriers and cholesterol as a 
lipid constituent, effervescent and non-effervescent liposomes did not massively 
aggregate during nebulization (Table 4-4). 
Non-effervescent liposomes before nebulization (8.32±01 µm) drastically increased in 
size and demonstrated high aggregation after nebulization (37.48±0.33 µm). Similar 
increased liposome sizes were observed for both effervescent formulations upon 
nebulization. The effervescent property was not found to have a negative effect on 
liposomes upon nebulization. However, both effervescent formulations, mannitol and salt 
with cholesterol, were observed to be not significantly different in size before and after 
nebulization, even though drastic size differences are observed. A change of carrier in 
effervescent formulation did not seem to affect liposome size after nebulization. SPC-
based formulations were also observed to increase in liposome size and an aggregation of 
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liposomes was found. This indicates that a change of lipid does not have any effect on 
reducing aggregation and the increase in liposome size post-nebulization. 
Research done on the Pari air-jet nebulizer with conventional non-effervescent liposomes 
demonstrates similar results with smaller liposomes before nebulization (Elhissi et al., 
2012). Moreover, smaller liposomes were incorporated into smaller aerosols while larger 
liposomes were incorporated into larger aerosol droplets during nebulization. The 
liposome size of the residual volume was not found to be changed in the Pari Air-jet 
nebulizer (Elhissi et al., 2012). This indicates liposome accumulation and aggregation is 
observed during nebulization (Bridges and Taylor, 2000). Solvent evaporation by 
compressed gas employed during jet nebulization has been found to cause aggregation of 
liposomes. This could also be the case with the Pari Sinus nebulizer, which demonstrates 
that large liposomes aggregate post-nebulization (Clay et al., 1983). 
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                          Table 4-4: Characterization of DPPC-based liposomes before and after nebulization with the Pari Sinus nebulizer  
Before nebulization 
 
After nebulization 
 
 
Size (µm) Span  
Zeta 
potential 
(mV) 
Size (µm)  Span  
Zeta potential 
(mV) 
Non-effervescent 
mannitol with 
cholesterol 
8.32± 0.1 1.93±0.42 2.47±0.36 
 
37.48±0.33 
 
2.54±0.03 
 
-5.39±0.44 
Effervescent mannitol 
with cholesterol  
7.54 0.155 1.51±0.071 2.53±0.18 17.79±0.03 
 
2.65±0.04 
 
7.89±0.36 
 
Effervescent salt with 
cholesterol  
7.19±0.11 1.56±0.12 3.83±0.62 22.12±0.05 
 
1.47±0.03 
 
6.24±0.12 
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However, the result of the effervescent liposomes were in contrast with the results of 
Taylor et al., (1990) in that the increased reduction of liposome size after nebulization 
was a result of the breakage of liposome aggregates during nebulization within the 
reservoir. Darwis and Kellaway (2001b) indicate that it is assumed that liposome size 
within the reservoir is an indication of the liposome size of the nebulized liposomes. 
Literature also indicates that liposomes could aggregate within the nebulizer reservoir due 
to the transition temperature of the lipid being higher than the temperature in the nebulizer 
reservoir (Waldrep et al., 1993). The research indicates BDP-DPPC liposomes 
demonstrated efficient nebulization of liposomal aerosols, with the liposome size before 
nebulization 15.78±1.62 µm increasing in size post-nebulization to 47.51±8.32 µm. 
Effervescent DPPC-BDP liposomes demonstrated much smaller liposomes post-
nebulization, indicating potentially better aerosols and drug output compared to 
liposomes of research by Waldrep et al. (1993). 
The span of liposomes is similar and not significant for non-effervescent liposomes, both 
before and after nebulization. Effervescent mannitol and salt with cholesterol 
formulations demonstrate similar span values. Mannitol with cholesterol effervescent 
formulation demonstrated significant differences (P<0.05), while salt with cholesterol 
does not seem to have significant differences in span value when compared to non-
effervescent liposomes (Table 4-4). No significant differences in span were observed 
between effervescent formulations. Similarly, Waldrep et al.'s (1993) results demonstrate 
DPPC-BDP liposomes (1.76±0.25) and other lipids such as DMPC (1.40±0.26) and 
DLPC (0.85±0.19) demonstrate similar values post-nebulization. Research also indicated 
that span values post-nebulization are slightly smaller compared to pre-nebulization. This 
result correlates with effervescent DPPC-BDP liposomes. 
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Non-effervescent liposomes demonstrated negative zeta potential values post-
nebulization, while effervescent formulations were both charged positively (Table 4-4). 
Positive charges were slightly increased for effervescent formulations after nebulization 
but were not deemed significant. However, both formulations when compared to non-
effervescent formulations demonstrated significantly different changes in charge 
(P<0.05).  
In general, both DPPC-based effervescent and non-effervescent liposomes were stable 
and produced deliverable liposomes. However, the effervescent property seems to have a 
positive effect on the stability of liposomes and their ability to withstand shear stress 
during nebulization. Overall, mannitol with cholesterol seemed to have better 
characteristics more suitable for further research in terms of characterization, entrapment, 
and nebulization, while salt with effervescent seems to be the best formulation when only 
considering the nebulization aspect of the research and entrapment post-nebulization.  
4.4. Conclusion for Nebulization  
Novel BDP effervescent proliposomes for both SPC and DPPC lipids generated 
deliverable and stable liposomes via the Pari Sinus nebulizer. Liposomes produced with 
effervescent properties did not seem to hamper the formulation’s ability to efficiently 
nebulize the drug when compared to BDP loaded into conventional liposomes for both 
SPC and DPPC. 
The nebulization time and sputtering times for all SPC-based formations were similar. 
The VMD of aerosol droplets for SPC-based formulations was around 3–4 µm. The 
droplet size of the aerosol was significantly (P≤0.05) different when mannitol and salt 
effervescent formulations were compared for SPC-based formulations. Furthermore, the 
aerosol mass output did not seem to be affected by the addition of cholesterol; however, 
the omission of cholesterol did seem to affect the span values in mannitol-based 
effervescent formulations compared to mannitol-based formulations with cholesterol 
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(P≤0.05). Formulations without cholesterol demonstrated lower nebulization efficiency. 
The findings of the SPC-based formulations demonstrated that mannitol as a carrier 
increased aerosol droplet size, whereas salt formulations made with SPC reduced aerosol 
droplet size. Furthermore, mannitol with cholesterol was found to produce liposomes with 
a size of 5.14+0.49 µm (mean + SD), with the appropriate liposomal characteristics in 
terms of size, span, and zeta charge. The mannitol with cholesterol formulation also 
performed well in terms of the aerodynamic diameter and aerosol mass output (%), but 
demonstrated a lower FPF rate of 59%.  
DPPC-based formulations of mannitol with cholesterol and salt with cholesterol were 
chosen for nebulization due to their suitability in terms of liposomes size, span, zeta 
potential, and entrapment of BDP. Nebulization of both samples demonstrated a similar 
nebulization time and sputtering time to SPC-based formulations and conventional 
formulations without effervescent property, indicating no negative impact of nebulization 
and sputtering time performance by the effervescent ingredients. However, mannitol and 
salt effervescent formulations demonstrated significant differences in nebulization time 
(P≥0.05). The difference in carriers seems to have an effect on nebulization time. A 
change of lipid also had an impact on nebulization time when SPC took less time and 
DPPC-based mannitol with cholesterol formulations were investigated. However, due to 
the high entrapment of the drug by the DPPC formulations compared to SPC it provided 
an answer for the differences in time and increased patient compliance. 
Drug entrapment post-nebulization of non-effervescent formulations and effervescent 
mannitol with cholesterol, demonstrated significant increases in drug entrapment for 
DPPC-based effervescent formulations (61.27+3.90%). The effervescent property was 
found to improve the liposomes’ ability to withstand shear stress. However, carrier choice 
of mannitol or salt did not seem to have any impact on the mechanical strength of 
liposomes.  
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When looking at both lipids, mannitol with cholesterol effervescent formulations seemed 
to have the greatest potential for drug delivery to the sinus via the Pari Sinus nebulizer. It 
can be concluded that the nebulizer mechanism was the deciding factor affecting aerosol 
mass output compared to other factors in effervescent liposomal formulations. In general, 
the Pari Sinus nebulizer has performed well compared to research done using different 
nebulizers. Mannitol and salt with cholesterol and DPPC would be most appropriate for 
further research. DPPC helped to increase the drug entrapment and both effervescent 
formulations performed very well in all aspects of nebulization. Therefore, it is 
recommended that further work be done on effervescent formulations made with mannitol 
with cholesterol and salt with cholesterol for the drug BDP for delivery to the sinuses via 
the Pari Sinus nebulizer. 
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CHAPTER 5  
DRUG DEPOSITION 
STUDY IN NASAL CAST 
AND IMPINGER 
SYSTEM   
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5.1. Introduction  
Intranasal delivery is a common approach for the administration of peptides, proteins, and 
polar drugs, which have a low oral bioavailability, poor stability, poor intestinal 
absorption, or extensive hepatic first pass degradation (Pires et al., 2009).  Non-
invasiveness, large surface area, permeable/vascularized mucosa, rapid systemic drug 
absorption, quick onset of action, painless administration, and favourable tolerability are 
among the advantages offered by the nasal route of drug administration (Rapoport and 
Winner, 2006).  
Even though nasal drug administration has been used for decades, only a limited amount 
of research has been conducted on factors influencing drug deposition patterns within the 
nasal cavity (Kundoor and Dalby, 2011) let alone sinuses, due to the inaccessible location 
and difficulty in delivery of aerosols to the targeted site. Literature indicates that the 
device used for drug administration, device handling by the patient, inhalation of spray, 
delivered dose, and formulation effects on spray plumb and droplet size are key factors 
affecting drug delivery to the nasal cavity (Newman et al., 1994; Kublik and Vidgren, 
1998; Kundoor and Dalby, 2011). 
Aerosol particles larger than 10 µm are likely to deposit in the nasal cavity while particles 
smaller than 5 µm may reach the lung (Kundoor and Dalby, 2011). However, due to 
limited ventilation and the hidden location of the sinuses, particles larger than 10 µm are 
unlikely to deposit into the sinuses (Sato et al., 1981; Möller et al., 2008; Keller et al., 
2010). The Pari Sinus nebulizer generates a pulsating aerosol that is especially designed 
to deliver aerosols to the sinus through its special ‘snake-like’ aerosols manoeuvre (Keller 
et al., 2010). The Pari Sinus nebulizer brochure describes the ability of this device to 
deliver aerosols directly to the sinus via generating aerosols with a mass median diameter 
of 3.2 µm, hence a lower medication dose is needed and less side effects are elicited 
(Schuschnig et al., 2006). The Pari Sinus nebulizer was also found to deposit more 
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medication in the sinus cavity compared to nasal sprays (Schuschnig et al., 2006). The 
viscosity of formulation may affect aerosol droplet size, plume angles, and angle of the 
device during administration, and all may affect the deposition profile of the spray in the 
nose and generally in the respiratory system (Harris et al., 1988; Cheng et al., 2001; Foo 
et al., 2007). 
Very limited research on aerosol deposition patterns in the sinuses has been conducted, 
due to the anatomical position of the sinuses. Many devices have been used for aerosol 
drug delivery to the nasal cavity. Deposition patterns within the sinus and nasal cavity 
through nebulization has not been thoroughly investigated. 
In this report, a fast, less expensive colour-based method was designed by assembling a 
unique system (Figure 5-1: by using a transparent nasal cast connected to a two-stage 
impinger via a balloon). The nasal cast was coated with water indicating paste Sar-Gel®, 
and the nasal cast impinger system was fixed onto a vacuum system of 60 l/min to comply 
with the inspiration flow rate used in pulmonary delivery studies (Figure 5-1 and Figure 
5-2). This study has investigated the effectiveness of incorporating the effervescent 
ingredients in liposomes along with the drug, to increase drug deposition in parasinuses. 
The Pari Sinus nebulizer (designed for drug delivery to the sinuses) and Pari Sprint 
nebulizer (designed for pulmonary delivery) were compared on the basis of their ability 
to deliver aerosols to the in vitro model of nasal cavity, sinuses, and lower respiratory 
airways using the nasal cast two-stage impinge model.  
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Figure 5.1: Nasal cast coated with water indicating paste Sar-Gel®, to an 
impinger system (vacuum of 60 l/min to mimic normal breathing). 
Figure 5.2 Nasal cast was coated with water indicating paste Sar-Gel®. 
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5.2. Specific Aims  
This study was designed to analyze the delivery of BDP-loaded effervescent liposomes 
and the non-effervescent liposome deposition profile of aerosols in the aforementioned 
nasal cast model using the Pari Sinus (pulsating aerosol system) and Pari Sprint (non-
Pulsating aerosol system) air-jet nebulizers. 
The deposition was also compared between the different effervescent formulations. 
A high-performance liquid chromatography (HPLC) analysis was conducted to quantify 
the deposition profile of the drug BDP within the nasal cast and the impinger (upper stage 
and lower stage) using a range of liposome formulations and by employing the two 
aforementioned jet nebulizers.   
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5.3. Results and Discussion 
The deposition profile of nebulized particles in the nasal cavity is largely dependent on 
airflow through the nose (Giroux et al., 2005). The flow of air in the upper posterior region 
of the nasal cavity is very difficult; this part allows access to the paranasal sinuses (Giroux 
et al., 2005). Nebulizers were originally designed for pulmonary delivery; however, 
targeting the nasal cavity using nebulizers is now an established approach in nasal 
delivery. Targeting the parasinuses via nebulization has been improved by generating 
smaller aerosol particles and particularly by using the pulsating aerosolization 
technology, which generates aerosol clouds having ‘snake-like’ manoeuvres, helping 
access to the hidden sinus pockets (PARI Respiratory Equipment, Inc., 2012). 
Mannitol-based and salt-based DPPC:Chol effervescent formulations have generated 
liposomes potentially suitable for drug delivery to the sinuses, as concluded from HPLC 
analysis. These results are further supported by the previous positive findings of size 
analysis (VMD and span), zeta potential measurements, and BDP entrapment efficiency. 
Therefore, these two formulations were chosen for the last part of the research.  
 Nebulization deposition patterns of BDP-loaded liposomes with DPPC-
based formulations  
5.3.1.1. Deposition analysis of full nasal cavity for Pari Sinus Nebulizer  
In this study, the deposition profiles of the two effervescent formulations, mannitol-based 
and salt-based DPPC:Chol liposomes, were studied and compared with those of deionized 
water and the corresponding non-effervescent liposomes using the two aforementioned 
nebulizers. Investigating deposition areas with different formulations will help to study if 
different viscosities, ingredients, addition of liposomes, and incorporation of the 
effervescent property to liposomes impact deposition area and pattern. Distilled water 
was nebulized through the Pari Sinus nebulizer and the distribution area was compared 
to liposomal formulations nebulized with the Pari Sprint nebulizer. It was observed that 
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control samples (water) had the most deposition area in the nasal cavity when nebulized 
via the Pari Sinus 132.71±47.42 cm2 (Table 5-1). This was the largest deposition area 
observed with both nebulizers and formulations.  
The mannitol-based effervescent formulation had a total deposition area of 107.16±5.50 
cm2 and the salt-based effervescent preparation had a deposition area of 107.94±12.05 
cm2; thus, the carrier type did not affect the deposition profile of the effervescent 
formulations. Furthermore, since there is no difference in deposition between the two 
effervescent formulations it is safe to hypothesize that for patients (e.g. diabetics) who 
need sugar-free medication, DPPC-based salt with cholesterol formulations may be used. 
Incorporation of liposomes showed a trend of lower deposition (P≥0.5) nasal cast 
deposition compared to the control water (Table 5-1). 
The total area of the nasal cast used in this study is 158.99 cm2 , and the total area of the 
respiratory zone of a human nasal cavity has been found to vary in the range of 120–150 
cm2 (Grassin-Delyle et al., 2012) . When analyzing the deposition area as a percentage of 
the total nasal cavity as a whole, it can be observed that water has a deposition of 83.47% 
while non-effervescent formulations demonstrated a deposition of 65.57%. By contrast, 
both effervescent formulations demonstrated a deposition of 67.40% (mannitol with 
cholesterol) and salt demonstrating 67.89% (salt with cholesterol) (Figure 5-4).  Previous 
investigations with nasal sprays having different designs have shown lower deposition 
(Kundoor and Dalby, 2011) compared to the values obtained in the present study. This 
highlights the advantage of using the Pari Sinus nebulizer for nasal delivery.  
The lower deposition of liposomes compared to water might be explained by the different 
physicochemical properties of liposomes. Results from the Pari Sinus Nebulizer were in 
agreement with the nasal cast findings previously published by Kundoor and Dalby 
(2011). Researchers found that Zicam nasal spray with increased viscosity demonstrated 
significantly lower nasal deposition compared to the nasal sprays with lower viscosity 
205 
 
values. Furthermore, they have reported that high viscosity of formulations may produce 
larger droplets, with greater deposition in the anterior part of the nasal cavity.  
Recently, two nebulizers (Atomisor Sonique® and Easynose®) with a droplet size of 5.6 
µm were compared for nasal drug deposition by nebulizing 99mTc-DTPA tagged aerosols 
in healthy volunteers. A human plastinated head model and its replica constructed from 
CT scans was used for this study (Guellec et al., 2014). Deposition was determined in the 
upper nasal cavity and maxillary sinus (MS) regions. Results indicated no significant 
difference between volunteers and human plastinated head model (NC1). However, a 
significant difference in low aerosol deposition was observed in the nasal model made 
from the CT scan compared to volunteers. They concluded that nasal cast models are 
suitable for the prediction of aerosol deposition but the reliability of the model is actually 
dependent on its design. Therefore, further testing of the transparent nasal cast used in the 
present research as compared to different nasal casts used in literature may constitute an 
essential part of the future research of nasal delivery.  
One drawback observed in using a nasal cast in this experiment is the overload on the 
location of the deposition due to the quantity needed for testing (20 ml was nebulized by 
nebulizing 5 ml each, four times). The same drawback was  observed with nasal casts in 
the study of Guellec and co-workers (Guellec et al., 2014). Furthermore, findings 
suggested that the radioactive count gamma images (in vitro) used for deposition 
investigation may have been affected by the materials used for building the two nasal 
casts. Considering this aspect, the colour-based method used with the transparent nasal 
cast could provide a clear advantage, adding to the fact that it is fast, cheap and highly 
convenient to use for analyzing nasal drug deposition in vitro.  
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Table 5-1: Deposition area analysis of effervescent liposomal formulations in the 
nasal cast (overall) and the sinuses region when nebulized via the Pari Sinus and 
Pari Sprint nebulizers, n=3 
 Pari Sinus nebulizer  
Pari Sprint nebulizer  
 
 
Full nasal 
cavity (cm2) 
Sinus alone 
(cm2) 
Full nasal 
cavity (cm2) 
Sinus alone 
(cm2) 
Water  132.71±47.42 43.57±6.39 73.05±4.68 29.71±3.61 
Non-effervescent 
liposomes 
(mannitol with 
cholesterol)  
104.26±7.07 46.43±4.28 95.13±16.07 45.01±7.04 
Effervescent 
mannitol with 
cholesterol  
107.16±5.50 48.45±2.75 82.66±10.29 35.52±11.11 
Effervescent salt 
with cholesterol  
107.94±12.05 47.09±1.92 93.01±29.93 42.17±8.63 
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Figure 5-1: Deposition area of full nasal cavity as a percentage nebulized via Pari 
Sinus and Pari Sprint nebulizers, n=3. 
 
5.3.1.2. Deposition analysis of full nasal cavity for Pari Sprint nebulizer  
The air-jet Pari Sprint nebulizer is typically used to generate aerosols for the treatment of 
lower lung diseases. However, in this study it was used for the nebulization of 
effervescent liposomes to the sinuses and compared with the Pari Sinus nebulizer in order 
to evaluate the influence of pulsating aerosol technology on drug deposition in the nasal 
cavity in general, and access to the parasinuses in particular. A nasal cast deposition study 
using the Pari Sprint nebulizer demonstrated a lower deposition area for all formulations 
compared to the Pari Sinus nebulizer (Table 5-1), indicating that the ‘snake-like’ 
manoeuvre of aerosols generated by the Pari Sinus was advantageous at maximizing 
deposition in the nasal cast. Distilled water was used as the control fluid, which when 
nebulized with the Pari Sprint had a deposition area of 73.05±4.68 cm2, which was 
significantly less that that using the Pari Sinus nebulizer (132.71±47.42 cm2).  
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Non-effervescent liposomes demonstrated higher deposition than distilled water 
(P≤0.05), while effervescent mannitol-based liposome formulations demonstrated a 
similar deposition to water. The salt-based DPPC:Chol liposomes have performed really 
well, with similar deposition (P>0.05) compared to the non-effervescent liposomes 
formulation (Table 5-1). The difference in carrier did not significantly affect the total 
deposition area in the nasal cast for the Pari Sprint nebulizer. Inclusion of the effervescent 
ingredients has reduced the deposition area for the mannitol-based formulation; however, 
the deposition of the salt-based formulation was unaffected.  
The mannitol-based effervescent formulation was observed to have a significantly lower 
deposition area by the Pari Sprint nebulizer (82.66±10.29 cm2) compared to the Pari Sinus 
nebulizer (107.16±5.50 cm2) (P≤0.05). However, for salt-based proliposomes no 
significant difference between the two nebulizers was observed when deposition in the 
whole nasal cast was considered. Results indicate, in general, that the Pari Sprint 
nebulizer was less suitable for liposome delivery to the nasal cast when compared to the 
Pari Sinus nebulizer, which is possibly attributed to the mechanism of aerosol delivery 
rather than the aerosol size produced by the two nebulizers. The Pari Sprint nebulizers 
generate droplets with a size around 3.5 µm, while the Pari Sinus nebulizer generates 
droplets having a median diameter around 3.2 µm (Pari GmbH brochures).  
5.3.1.3. Deposition analysis of aerosols in the sinuses using Pari Sinus nebulizer 
The difficulty of drug delivery to the paranasal sinuses is attributed to their anatomical 
position, resulting in difficulty to access them. Active ventilation is not reported in the 
ostiomeatal complex and sinuses. The ostiomeatal complexes connect nasal passages 
through small orifices called ostia (typically 0.5–2 mm in diameter). Only very limited 
air flows into the ostia during inhalation through the nose and, in fact, most air passes to 
the trachea rather than the sinuses (Keller et al., 2014). However, aerosol deposition in 
the sinuses is possible, even though difficult, due to low ventilated cavities and right of 
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entry to the nose only via narrow ducts. Creation of a pressure gradient between nasal and 
paranasal cavities is the general principle that allows aerosols to access the inactively 
ventilated areas of the paranasal sinuses (Mainz et al., 2011). Mathematical modelling of 
drug deposition into the sinuses is ascribed to three factors: particle size, pressure 
gradient, and size of the ostium (Martin et al., 2007). 
Using the Pari Sinus device, deionized water was found to have the lower area of 
deposition (43.57±6.39 cm2), compared to the liposome formulations (P≤0.05).  
Liposomal formulations had a similar deposition area, while effervescent mannitol-based 
formulations demonstrated the largest deposition area in the paranasal sinuses 
(48.45±2.75 cm2) (Table 5-1).  No significant difference in results was observed between 
the non-effervescent liposomal formulation when compared to both mannitol- and salt-
based effervescent formulations. This indicates that the effervescent property did not have 
a negative effect on the drug deposition area. The carrier type (mannitol or salt) also did 
not affect the drug deposition area for the Pari Sinus nebulizer (Table 5-1). 
Comparatively, a fairly large amount of liposome formulation (48.45±2.75 cm2) (Table 
5-1) has been deposited in the paranasal sinuses, especially the effervescent mannitol 
formulations, suggesting that DPPC liposomes generated from effervescent mannitol-
based proliposomes was highly appropriate for targeting the parasinuses of the nasal cast, 
and hence, future in vivo investigations should consider this particular formulation. The 
effervescent mannitol-based formulation was on the lower side of deposition within the 
nasal cavity; however, results of sinus deposition indicate that this liposome formulation 
has maximized the sinus targeting.  
The pulsating aerosol technology has been studied by Möller et al. (2008), investigating 
sinus deposition by pulsating airflow Kr-gas ventilation. The study indicated that 
pulsating aerosols increase the volume of sinus, which lead to an increase in sinus 
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deposition. The pulsating air flow increased deposition by 8% compared to non-pulsating 
aerosols, which had deposition as low as 0.2%.  
According to the findings of this report, loading the drug into effervescent liposomes 
followed by nebulization using the Pari Sinus nebulizer can be successful for aerosol 
deposition into the parasinuses, and it certainly merits future in vivo investigations 
especially by conducting studies on patients having sinusitis.   
Sinusitis is associated with inflamed nasal linings and infected mucous, reduced mucosal 
drainage, and infections. Disease conditions may make reaching the paranasal hidden 
pockets more difficult compared to patients with healthy sinuses. The hypothesis of 
enhanced drug penetration into the sinuses following drug-loaded liposomes into the 
nasal cavity via nebulization merits investigation.  
A nasal cast model designed by Pari GmbH with four sinus cavities and four front and 
maxillary positions was used for the nebulization of aerosols with the VibrENTTM 
nebulizer. The VibrENTTM system has demonstrated the ability to deposit 10% of the 
aerosol in the sinuses, while 10–15% was expected to travel to the lung (Joseph, 2002). 
Even though this nasal cast model was possibly better designed to suit the investigation 
of deposition in the sinuses, it only represented the upper respiratory airways; thus, 
deposition in the lower airways was not possible to investigate. By contrast, the in vitro 
nasal deposition model used in the present report represents a nasal cast that was attached 
to a widely established in vitro model for quantification of ‘deep lung’ deposition, namely 
the two-stage impinge.  
To the best knowledge of the author of this report, non-effervescent or effervescent 
liposomes have not yet been used as a delivery system for treating sinusitis. Salt-based 
DPPC:Chol proliposomes have actually generated liposomes with highly desirable 
properties for nebulization, since BDP entrapment efficiency was as high as 
90.60±13.51% within the vesicles. Moreover, mannitol-based DPPC:Chol liposomes 
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were also suitable since BDP entrapment was as high as 82.15±8.29% and liposome size, 
span, and zeta potential were in the acceptable ranges and nebulization performance was 
superior. The effervescent properties of DPPC were also found to improve the liposomes’ 
ability to withstand shear stress during nebulization as explained in chapter 4.  
5.3.1.4. Drug deposition analysis in the sinus of the nasal cast using Pari Sprint 
nebulizer 
The Pari Sprint nebulizer was used for delivery of liposomal formulations to the sinuses 
of the nasal cast. Pari LC Sprint nebulizer is a nebulizer designed originally for delivering 
the drug to the ‘deep lung’. In this study, the potential of this nebulizer for targeting the 
parasinuses was explored using the nasal cast model, and the findings were compared 
with those of the Pari Sinus device. The Pari Sprint nebulizer demonstrated different 
results from those observed with the Pari Sinus. With the Pari Sprint, aerosolized water 
covered a surface of 29.71±3.61 cm2, which is half of that shown by the Pari Sinus 
nebulizer (43.57±6.39 cm2). However, non-effervescent liposomes have improved the 
deposition area (P≤0.05) when compared to water (Table 5-1). The deposition area for 
non-effervescent liposomes was similar for both nebulizers (P>0.05). This possibly 
suggests that the influence of the phospholipid on the nebulizer fluid’s physicochemical 
properties (viscosity, surface tension, etc.) has made the conventional Pari Sprint as 
capable as the Pari Sinus for targeting aerosols to the sinuses of the nasal cast.   
Mannitol-based effervescent liposomes demonstrated a trend for a lower deposition area 
but this was not significant; thus, no difference was observed in the deposition area as a 
result of including effervescent ingredients in the liposome formulation. Furthermore, 
when mannitol-based effervescent liposomes were used, a lower sinus deposition was 
observed with the Pari Sprint (35.52±11.11 cm2) compared to the Pari Sinus (48.45±2.75 
cm2). The change of carrier has affected the deposition area only when the Pari Sprint 
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nebulizer was employed; thus, the area for the salt-based effervescent formulations was 
42.17±8.63 cm2 (Table 5-1).  
Due to the poor air flow into the paranasal sinuses, very little or no aerosols can be 
deposited to the sinuses. By contrast, aerosols generated via vibrations of the pulsating 
technology nebulizers may cause periodic transient pressure gradients from ventilated 
nasal cavities through ostia, resulting in deposition into the sinuses by allowing a 
convective flow of air into the sinuses; this achieves equal air pressure in the nasal cavity 
and sinuses (Keller et al., 2014).  
Schuschnig et al. (2008) have compared drug delivery using two human nasal cast 
models. Non-pulsating aerosols were found to have a chance of 85% to be expelled from 
the nostril of the nasal cast with minimal aerosol deposition in the sinus. In the present 
report, the Pari Sinus nebulizer performed better than the Pari Sprint nebulizer in terms 
of drug deposition in the nasal cast as well as the sinuses. Moreover, Schuschnig et al. 
(2008) have reported that pulsating nebulizer technology can localize the deposited 
aerosols in the sinuses for prolonged periods of time compared to non-pulsating aerosols. 
An in vivo study was conducted using the Pari Sinus pulsating system using healthy 
subjects. The nasal cavities of the subjects were ventilated for 10 sec of breath-holding 
through 81mKr-gas in front of a planar gamma camera head. The study has reported that 
without pulsation only the nasal passage was ventilated, while with pulsation the sinuses 
were also ventilated. Moreover, the gamma camera images identified maxillary sinuses 
being ventilated using the pulsating aerosols (Möller et al., 2010). 
 Regional drug deposition analysis of Pari Sinus and Pari Sprint nebulizers  
The efficiency of the Pari Sinus and Pari Sprint nebulizers to deliver mannitol-based 
DPPC:Chol effervescent liposomes or non-effervescent vesicles to the nasal cast and twin 
impinger was investigated. Understanding regional drug deposition within the three 
stages of the cast (nasal cast, upper stage, and lower stage) may help identify which 
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nebulizer and formulation are most suitable in terms of the potential deposition in the 
nasal and sinus region and upper respiratory airways.  
5.3.2.1. Drug remaining within the residual volume of the Nebulizer reservoir   
Figures 5-5 and 5-6 have shown that both nebulizers had a large proportion of drug 
remaining within the nebulizer reservoir for non-effervescent liposomes. Non-
effervescent formulation demonstrated a drug distribution of 63.57±10.5% within the Pari 
Sinus nebulizer, while the Pari Sprint nebulizer had a drug proportion of 53.58±1.5% 
remaining undelivered. This demonstrated that the Pari Sprint nebulizer delivered a 
higher proportion of drug compared to the Pari Sinus nebulizer (Figure 5-5 and Figure 5-
6). In contrast, the effervescent mannitol-based formulation was found to deliver a higher 
percentage of the drug compared to the non-effervescent formulation for both nebulizers. 
The Pari Sinus nebulizer demonstrated a drug distribution of 46.47±7.3%, while the Pari 
Sprint demonstrated 51.15±2.8% remaining undelivered within the nebulizers. Data 
indicate that effervescent formulations are able to entrap a higher amount of drugs within 
vesicles compared to non-effervescent formulations, which also correlates with the HPLC 
entrapment studies done in chapter 3. The addition of effervescent ingredients proved to 
be beneficial in terms of improving the vesicles’ capacity to deliver more drug from the 
nebulizer, to reduce leakage and in its capacity to withstand the high shear pressure of 
nebulization. Comparison of the mannitol-based effervescent formulations to the salt-
based effervescent formulations demonstrated that the salt-based formulations are more 
prone to drug leakage with both nebulizers (Figure 5-2 and 5-3). The result indicates that 
vesicles produced by effervescent formulations delivered higher proportions of drug 
compared to non-effervescent formulations, regardless of the nebulizer. 
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5.3.2.2. Drug deposition in the nasal cast  
The Pari Sinus is a specially designed nebulizer with a pulsating aerosol system that is 
designed to allow aerosols to reach the non-ventilated hollow cavities of the paranasal 
sinuses. Unlike other nebulizers that target the nasal cavity, aerosols nebulized via the 
Pari Sinus nebulizer are smaller, and are similar to the size of liposomes generated from 
the Pari Sprint nebulizer. Nasal cast drug deposition indicated that the Pari Sinus 
nebulizer deposited 7.3±2.9% of the original drug amount with non-effervescent 
liposomes while the Pari Sprint nebulizer deposited as low as 3.62±1.5% BDP to the nasal 
cast. Effervescent liposomes demonstrated promising results of 10.47±2.9%, while the 
Pari Sprint delivered as low as 4.6±1.4% to the nasal cast. Thus, effervescent liposomes 
delivered significantly (P≤0.05) higher drug amounts compared to the non-effervescent 
formulation with the Pari Sinus nebulizer. The degree of drug loss was higher with 
conventional liposomes in the Pari Sinus nebulizer indicating that the degree of bilayers 
disruption was dependent on the formulation (Figure 5-5). The addition of effervescent 
ingredients has increased the ability of liposomes to withstand pressure and increase drug 
entrapment and the liposomes’ ability to retain the drug during nebulization, regardless 
of the nebulizer.  
Effervescent salt formulations had better drug delivery to the nasal region with the Pari 
Sinus (9.43±2.3%) while the Pari Sprint had a nebulization efficiency of 1.7±1.4% 
(P≤0.05). Effervescent mannitol formulation had a better trend of performance with both 
nebulizers compared to effervescent salt formulations (Figure 5-5 and Figure 5-6), but 
with no significant difference.   
A change of carrier from mannitol to salt has hampered its ability to keep drugs entrapped 
without drug leakage during nebulization. Mannitol-based liposomes demonstrated less 
entrapment efficiency prior to nebulization compared to salt-based preparations. 
However, it seems to be able to withstand pressure, making it a better performing 
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formulation in terms of entrapment efficiency post-nebulization within the nasal cavity. 
The addition of effervescent ingredients has increased its ability to withstand pressure 
and increases both drug entrapment and the liposomes’ ability to retain the drug during 
nebulization, regardless of nebulizer type. 
The Pari Sinus nebulizer delivered a higher proportion of drug to the nasal cast with all 
three formulations compared to the Pari Sprint nebulizer. The Pari Sinus nebulizer 
mechanism of aerosol movement (pulsating aerosol technology) proved beneficial 
compared to the Pari Sprint. Mannitol-based effervescent formulations were 
demonstrated to have the highest potential for delivering the drug. Vesicles made with 
mannitol-based effervescent liposomes demonstrated to be more flexible compared to 
liposomes made from salt-based formulations, which suffered from fragmentation during 
nebulization.  
Studies done with nasal casts and vibrating air flow technology conclude that vibration 
technology, apart from helping the aerosol reach paranasal sinuses, also enhances the 
retention of material deposited within the nasal cavity up to a threefold longer time 
compared to aerosols delivered via nasal sprays (Möller et al., 2010).  
A drawback of using a nasal cast to understated deposition and drug entrapment efficiency 
is that it could be hampered by the horizontal position of the nasal cast when the drug was 
nebulized (Möller et al., 2010); thus, patients are informed to observe an appropriate 
inhalation technique. In real life, the patient should administer drugs via the Pari Sinus 
through one nostril, while the other nostril should be closed. This was done with the nasal 
cast impinger system introduced in this study.  
Literature indicates that pulsation increases nasal drug deposition compared to a non-
pulsating drug delivery system by a factor of three (Möller et al., 2008). Möller et al., 
(2008) have stated that Kr-gas ventilation and aerosol deposition has improved drug 
deposition within sinus cavities by 8% while only 0.2% drugs were deposited with non-
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pulsation. The study concluded that topical drug delivery to paranasal sinuses with 
relevant quantities is possible. The results of nasal cavity drug deposition in this study are 
in correlation with the results of Möller et al. (2008). Drug deposition by the Pari Sinus 
has improved, indicating that effervescent liposome technology, coupled with pulsation 
technology, is a very good candidate for further studies to improve drug deposition to the 
sinuses and nasal cavity. 
5.3.2.3. Drug deposition in the upper stage of the twin impinger  
The upper stage of the impinger was demonstrated to have a lower drug distribution 
compared to the nasal region of the system with the Pari Sinus nebulizer. This was 
expected, as larger liposomes and aerosols would be settling within the upper region, 
while smaller liposomes in smaller aerosol droplets would be delivered to the upper stage 
and lower stage of the system. The Pari Sprint nebulizer had a higher drug content 
delivered to the upper stage compared to the Pari Sinus. The Pari Sprint nebulizer targeted 
drug delivery to the lungs while the Pari Sinus nebulizer targeted drug delivery to the 
nasal region, and sinuses to be specific. Non-effervescent liposomes demonstrated a drug 
delivery of 0.86±1.2% while the Pari Sprint was observed to have a drug delivery of 
8.05±2.1% to the impinger’s upper stage. Effervescent mannitol-based formulations and 
salt-based formulations were demonstrated to have a much less drug deposition into the 
upper stage with the Pari Sinus nebulizer compared to the Pari Sprint nebulizer, which 
demonstrated a higher drug deposition in the upper stage. However, results were not 
deemed significant. Adverse effects of BDP deposition in the upper respiratory tract has 
been observed such as hoarseness of voice, oral candiditis, cough, and Dysphonia 
(Barnes, 2007).   
One of the techniques to improve drug delivery is to introduce drug delivery via one 
nostril while the other nostril is tightly closed, via a nose piece sealing it from extra air 
entering. This helps to maintain a high pressure amplitude of pulsating aerosols in the 
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nasal cavity (Keller et al., 2014; patent WO 2004/020029). This was done accordingly in 
our study by closing one nostril of the nasal cast. However, it is advised to keep the soft 
palate of the patient closed to improve drug deposition with the mouth closed, but the 
nasal cast does not have an oral cavity opening. In a situation of drug delivery to a patient, 
if the soft palate is not closed, aerosols may enter the oral cavity, reducing the amount of 
drug that can be deposited within the nasal cavity (Keller et al., 2014). The patient is also 
advised to hold their breath. Therefore, the nasal cast drug delivery system may be 
overlooking this potential loss of drug that may be seen if the patient does not keep the 
soft palate closed. Drug deposition by non-vibrating devices may also improve drug 
delivery by directing the drug via one nostril while the other is closed (Keller et al., 2014).  
A study done on comparisons of BDP-loaded conventional and ultradeformable vesicles 
with drug entrapment of 50.3% and 39.5% respectively (P≤0.05), demonstrated that upon 
nebulization via an Aeroneb Pro nebulizer to a two-stage twin impinger, drug entrapment 
deceased drastically to 10.8% and 15.1% in the upper stage of the impinger (Subramanian 
et al., 2014). A similar study conducted compared liposome drug delivery in an impinger 
via delivery through an air-jet nebulizer (7.57%) and Aeroneb Pro (10.87%) in the upper 
stage of the impinge (Subramanian et al., 2014). This indicates that nebulizer drug 
delivery may also affect the liposomes’ capability to keep the drug entrapped during 
nebulization.  
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Figure 5-2: Regional drug deposition study via Pari Sinus nebulizer. 
 
Figure 5-3: Regional drug deposition study via Pari Sprint nebulizer. 
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5.3.2.4. Drug deposition in the lower stage of the twin impinger  
Higher drug deposition in the lower impinger’s stage was observed, regardless of 
formulation composition and nebulizer type. However, the Pari Sprint nebulizer has a 
higher drug deposition in the lower stage. Non-effervescent formulations offered lower 
drug deposition in the lower impinger using the Pari Sinus nebulizer compared to 
effervescent formulations. Mannitol and salt effervescent formulations demonstrated a 
similar drug delivery to the lower stage with the Pari Sinus nebulizer (Figure 5-5). The 
Pari Sprint nebulizer has a significantly higher proportion of drug delivered to the lower 
stage of the impinger than to the upper stage (P≤0.05) when compared with the Pari Sinus. 
Results correlate with the ‘size fraction’ indication, with smaller liposomes deposited 
within the lower stage while larger liposomes are deposited in the nasal cast and upper 
stage of the impinge (Figure 5-5 and Figure 5-6).  
A study done with liposomes to understand pulmonary drug delivery using a two-stage 
twin impinger (Elhissi et al., 2012) demonstrated larger particles being deposited within 
the upper stage of the impinger, while smaller liposomes deposited in the lower stage of 
the impinger.  
Considering the desired region for drug delivery it can be concluded that the Pari Sinus 
nebulizer is potentially more appropriate for drug delivery using the effervescent 
mannitol formulations. Even though drug delivery was less in the nasal cast compared to 
the lower stage using the Pari Sinus nebulizer, the desired dose for nasal deposition was 
achieved. Furthermore, the continuous air flow using the cast impinger model may have 
overestimated the drug deposition in the lower impinger.  
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5.4. Conclusion  
In conclusion, the unique system of a nasal cast coated with water indicating paste, Sar-
Gel®  fixed onto a two-stage impinger to analyze drug deposition within the nasal cavity 
proved to be efficient, simple, and greatly convenient, to predict drug deposition in the 
respiratory tract. Overall, the Pari Sinus Nebulizer performed better with its pulsating 
aerosol technology compared to the non-pulsating Pari Sprint nebulizer. 
The largest deposition area for the nasal cavity was observed when water was nebulized 
via the Pari Sinus Nebulizer at 132.71±47.42 cm2. Liposome formulations, effervescent 
and non-effervescent, did not show a significant difference in the deposition area 
demonstrated for effervescent property. Also, differences in carrier, mannitol and salts 
alone, were not observed to affect the nebulization deposition area when nebulization 
took place via the Pari Sinus nebulizer. Overall, due to the high standard deviation 
(standard error) observed with salt-based effervescent formulations, even though the 
deposition area is similar to mannitol-based formulation, the latter proved to be a better 
drug carrier in terms of liposome stability. Notably, even though no difference in 
deposition was observed for non-effervescent liposomes and effervescent liposomes 
within the nasal cavity, it was observed that the addition of effervescent liposomes and 
mannitol combination (mannitol-based effervescent formulation) improved targeting of 
the sinuses, bypassing nasal cavity deposition, and resulting in increased deposition 
within the sinuses 48.45±2.75 cm2 via the Pari Sinus nebulizer 
Deposition within the sinuses proved to be better with pulsation 48.45±2.75 cm2 
compared to non-pulsation 35.52±11.11 cm2 for an effervescent mannitol formulation. 
Overall, the nasal cast data demonstrated that the Pari Sinus nebulizer performed better 
overall with all formulations when compared to the Pari Sprint nebulizer.  
Mannitol-based effervescent liposomes were observed to have the highest drug 
distribution in the nasal cast, indicating the maximum drug will be deposited through this 
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formulation when nebulized via the Pari Sinus. It can be concluded that even though drug 
deposition to the sinuses through BDP-loaded liposomes nebulized via a non-pulsating 
Pari Sprint nebulizer was possible, the pulsating technology of the ‘zig zag’ aerosol 
generated by the Pari Sinus improved the drug deposition within the nasal cavity and the 
sinuses.  
A change in viscosity and the addition of liposomes changed the deposition area within 
the nasal cavity of the cast employed in this study. The addition of liposomes did not 
prove to improve deposition within the nasal cavity; however, it did improve depositing 
within the sinuses. The nasal cast Sar-Gel® method, coupled with the impinger, a unique 
and novel system introduced in this project, can be used for further studies as an efficient, 
simple, colour-based method of studying nasal cavity deposition. An improved version 
of the nasal cast to include all sinuses would one day help analyze sinus delivery 
accurately via this simple colour-based method. 
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CHAPTER 6  
GENERAL 
CONCLUSION  
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6.1. General Conclusions   
Effervescent proliposomes formulations using BDP as a model hydrophobic drug have 
demonstrated the capability to disintegrate in water in less than 5 min, compared to 
conventional proliposomes, which took longer than 50 min without manual shaking or 
vortex mixing. Effervescent proliposomes have disintegrated with no solid particles being 
visible in the bottom of the flask. By contrast, conventional (non-effervescent) 
proliposomes had visible solid particles at the bottom of the flask even after 50 min of 
‘stagnant’ hydration.  
 Carrier choice for effervescent proliposomes  
Two different carbohydrate carriers, sucrose and mannitol, were investigated in 1:5 w/w 
and 1:10 w/w lipid to carrier ratio with combinations of chloroform and ethanol. This was 
done in order to find the most suitable type of carrier that produces stable liposomes with 
desirable characteristics such as size, span, zeta potential of liposomes, and morphology 
of the carrier’s particles. Drugs with different percentages from 2.5 mol% to 5 mol% were 
tested with the best formulations using SPC and DPPC as the choice of lipid. Data 
indicated that mannitol is a better carbohydrate carrier than sucrose. Liposomes loaded 
with 2.5 mol% SPC:Chol with mannitol as a carrier was observed to have a VMD of 
6.92±1.05 µm, span (1.09±0.01), and zeta potential (-1.293+ 0.11 mV). Comparatively, 
mannitol seems to be producing better liposomes that can entrap more drug, and also due 
to the cooling effect that is produced through mannitol, which would be beneficial for the 
treatment of hot, inflamed sinuses because of the cooling effect within the nasal cavity.  
 SPC-based effervescent proliposomes (BDP- and XH-loaded)  
6.1.2.1. BDP-loaded effervescent proliposomes 
The liposome formulations are 1:10 lipid to carrier (mannitol) ratio with SPC lipid loaded 
with the BDP formulation, which were further improved with the addition of the 
effervescent property to improve the liposomes disintegration time. The effervescent 
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property was improved with the addition of sodium bicarbonate, citric acid, and sodium 
benzoate. Samples were tested with and without cholesterol to understand how 
disintegration time, size, span, zeta potential, morphology, and drug entrapment were 
investigated. The disintegration time of conventional mannitol-based liposomes with 
cholesterol was improved (56.51±1.87 min), while effervescent mannitol with cholesterol 
formulation disintegrated in (1.21±0.22 min). Cholesterol did not seem to affect 
disintegration time. Salt-based formulations with or without cholesterol also 
demonstrated a superior disintegration property compared to mannitol (P≤0.05).  
Mannitol with cholesterol formulation demonstrated the most ideal liposomes with high 
drug entrapment, size, span, and zeta potential suitable for drug delivery to the sinuses. 
Effervescent mannitol with SPC:Chol liposomes had a size of 5.14+0.49 µm. The 
addition of cholesterol did not seem to have a major impact on mannitol formulations. 
Effervescent salt-based liposomes with cholesterol appeared to have large size liposomes 
that were unsuitable for drug delivery to the sinuses. However, upon excluding 
cholesterol, liposome size decreased to 6.04+0.19, and a significant difference was seen 
between the size of liposomes with cholesterol and without cholesterol. The zeta potential 
of mannitol-based proliposomes were mostly negative, while salt-based proliposome 
formulations were positively charged. Cholesterol did not affect the charge of liposomes 
in salt-based formulations. Therefore, considering size, span, and zeta potential, 
effervescent mannitol formulations with cholesterol were more suitable for further 
studies.   
Jaafar-Maalej et al. (2010) stated that archiving 100% BDP drug entrapment efficiency 
was difficult, and lipid composition may have an effect on size and encapsulation 
efficiency of BDP in liposomes, which was further proved to be true with novel 
effervescent liposomes in the present report. Drug entrapment in mannitol-based 
liposomes with SPC:Chol was found to be 20.54+12.02%. However, cholesterol-free 
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formulations offered lower BDP entrapment efficiency compared to samples containing 
cholesterol. Cholesterol may increase stability, improve rigidity of liposomes, reduce 
drug leakage and affect osmosis (Sabın et al., 2006; Tseng, 2007). 
It can be concluded that mannitol may help stabilize the liposomes and reduce drug 
leakage. The salt-based formulation without cholesterol had a lower drug entrapment of 
11.28+3.40%, but was still suitable in terms of liposome size; therefore, it was decided to 
use mannitol with cholesterol and salt without cholesterol formulations for further studies. 
Thus, novel effervescent formulations able to entrap BDP with improved disintegration 
property were successfully produced. In the second stage of the study, the addition of 
mucoadhesives and changing the lipid from SPC to DPPC was done to improve drug 
entrapment efficiency.  
6.1.2.2. Mucoadhesive-coated effervescent proliposomes   
Alginic acid and chitosan mucoadhesives were used for the coating of effervescent 
liposomes. The best formulations, mannitol with cholesterol and salt without cholesterol, 
were coated by hydrating proliposomes with alginic acid and chitosan solutions (0.2% 
w/v or 1% w/v). The liposome size of non-effervescent liposomes was increased to 
17.99±0.56 μm, while effervescent mannitol-based formulations with cholesterol were 
noted at 6.15±0.04 μm (P≥0.05). Alginic acid 1% w/v formulations have produced much 
larger effervescent mannitol-based liposomes. Liposomes were seen to be less aggregated 
with 0.2/v% formulations. Chitosan-based formulations in the presence of cholesterol 
increased the liposome size, with the smallest liposome size noted at 21.63±5.57 μm. 
Similar liposome size increases were observed for both mannitol- and salt-based 
formulations and 1% w/v concentration had high polydispersity compared to 0.2% w/v 
for chitosan-coated formulations.  
Drug entrapment with alginic acid or chitosan proved to be unsuccessful, with very low 
drug entrapment when compared to mucoadhesive-free formulations. Effervescent 
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mannitol coated with chitosan (0.2% w/v) was observed to have an entrapment efficiency 
of 1.04±1.05%, while 1% showed no entrapment of the drug at all. Results indicated that 
alginic acid did improve drug entrapment in non-effervescent liposomes; therefore, it was 
concluded in the presence of effervescent salts the alginic acid did not improve drug 
entrapment. Possible reasons for this could be proton-catalyzed hydrolysis, and the 
alginic acid itself being deposited within the liposomes core, while BDP is being 
deposited within bilayers resulting in bursting of liposomes (Tønnesen and Karlsen, 
2002). Alginic acid was also seen to be swelling in the presence of effervescent salts, 
leading to drug leakage. It is also possible that carbon dioxide liberation during 
effervescence may promote the swelling of alginic acid. Chitosan also acted similarly to 
the alginic acid by swelling in the presence of effervescent salts. Therefore, the addition 
of a mucoadhesive was not deemed successful to improve drug entrapment. Effervescent 
liposomes, regardless of carrier type, had higher drug entrapment in the absence of the 
mucoadhesive agent.  
 DPPC lipid-based effervescent proliposomes (BDP-loaded)  
Effervescent formulations made with a DPPC lipid were able to generate stable and 
similar liposomes to conversional liposomes (non-effervescent) and SPC-based 
effervescent liposomes. The presence of effervescence improved the DPPC liposomes’ 
disintegration time when compared to conversional (i.e. non-effervescent) liposomes.  
Mannitol-based formulations with cholesterol had a size of 8.32±0.1, which was 
significantly different (P≤0.5) compared to formulations without cholesterol. Unlike 
SPC-based formulations, salt formulations with cholesterol had smaller liposomes. Salt 
formulations made using DPPC loaded with drug in the presence of cholesterol had 
smaller size liposomes 7.047±0.45 µm in comparison to formulations without cholesterol 
17.81±0.04 µm. Cholesterol affected packing density by reducing the area per 
phospholipid in DPPC, reduced surface tension, and increased mechanical strength (New, 
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1990; Ohvo-Rekilä et al., 2002; Choi et al., 2013;). Liposome size was also seen to be 
dependent on the transition temperature of the lipid. The zeta potential of DPPC-based 
liposomes had positive surface charge, while SPC formulations mostly had negative 
surface charge. The size and zeta potential of effervescent formulations were affected by 
lipid type and drug inclusion. Salt-based effervescent formulations with DPPC lipid 
demonstrated the possibility of having stable liposomes with high drug entrapment 
without the presence of a carbohydrate carrier.  
Drug entrapment in DPPC formulations was quite high compared to SPC formulations.  
Effervescent mannitol with cholesterol formulations using a DPPC lipid offered a drug 
entrapment of 82.15±8.29% while SPC-based formulations had a much lower entrapment 
of 20.54+12.02 (P≤0.05). Addition of cholesterol did not create a significant difference 
for mannitol. However, salt-based formulations had a high entrapment of 90.60±13.51 
with cholesterol, while salt-based formulations without cholesterol had entrapment of 
36.3±7.0 (P≤0.05). A change of lipid did have an impact on entrapment for both mannitol 
and salt formulations, while the addition of cholesterol made a difference in the 
effervescent salt formulations only.  
Using mannitol as a carrier was important with SPC-based liposomes. DPPC-based 
formulations produce better liposomes with higher entrapment and stability. Cholesterol 
acts differently towards the packing structure of the two different lipids, producing 
liposomes with different characteristics when lipids where changed. The inclusion of 
cholesterol was beneficial for enhancing the stability and entrapment of effervescent 
formulations made with DPPC. Effervescent liposomes with both DPPC and SPC seemed 
to improve disintegration time when compared to conversional liposomes. 
 Xylometazoline hydrochloride-loaded effervescent proliposomes   
Xylometazoline hydrochloride is a hydrophilic drug used as a nasal decongestant. 
Hydrophilic drugs generally have low entrapment in liposomes. Liposomes made with an 
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SPC lipid were used for investigation. Formulations were made with mannitol and salt 
with and without cholesterol to understand liposome characteristics and capacity to entrap 
5 mol% XH. Liposomes were tested with or without sonication prior to characterization.  
Before sonication, the addition of XH to mannitol-based, non-effervescent liposomes 
without cholesterol, produced large liposomes (18.63±0.17 µm) compared to 
conventional liposomes with cholesterol (7.24±0.15 µm). However, effervescent 
mannitol-based liposomes, with cholesterol, had smaller liposome size measurements 
with cholesterol compared to the corresponding formulations containing no cholesterol. 
Salt-based effervescent liposomes with cholesterol had slightly larger liposomes 
(9.53±0.18 µm) compared to those free from cholesterol. Effervescent liposomes were 
capable of producing stable liposomes loaded with XH for both mannitol and salt 
formulations. Sonication was done to the same formulations to reduce liposome size.  
Upon sonication, mannitol with cholesterol effervescent liposomes were drastically 
reduced in size (2.347±1.03 µm) (P≤0.05) compared to the non-sonicated liposomes.  
Mannitol formulations without cholesterol were also found to differ significantly 
(P≤0.05) in size compared to mannitol with cholesterol upon sonication. Salt-based 
formulations produced liposomes that were reduced by half in size after sonication 
compared to mannitol-based samples. The zeta potential of liposomes upon addition of 
the drug was highly positive. The addition of cholesterol has slightly reduced the positive 
zeta potential.  
Drug entrapment in sonicated liposomes was studied. The entrapment efficiency of the 
hydrophilic drug was surprisingly very high. SPC-based liposomes had a low entrapment 
of BDP compared to DPPC-based liposomes. However, in the case of XH, this 
hydrophilic drug had very high drug entrapment. Non-effervescent liposomes with 
cholesterol and mannitol-based had an entrapment of 89.43±6.13%, while without 
cholesterol the entrapment efficiency was 69.64±7.88%.  
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Effervescent formulations had slightly lower entrapment of XH but the values were 
actually higher than BDP entrapment. Cholesterol was beneficial for enhancing the 
entrapment of the hydrophilic drug in mannitol formulations but did not show an effect 
with the salt formulations. Unlike BDP, for XH, mannitol or cholesterol did not make a 
significant difference in entrapment. The effervescent formulation proved to be beneficial 
for enhancing XH entrapment and lowering the span values compared to conventional 
liposomes. The size of non-effervescent liposomes was not suitable for drug delivery via 
the Pari Sinus nebulizer due to the large size of liposomes. Thus, formulations using 
mannitol or salt as carriers with cholesterol would be more suitable due to the rigidity 
provided by the liposomes when high shear pressure of nebulization is applied. 
Effervescent liposomes produced stable liposomes with a high entrapment of XH that 
could be potentially suitable for nasal drug delivery. 
 Nebulization of BDP-loaded effervescent liposomes with Pari Sinus 
nebulizer 
The nebulization of BDP-loaded effervescent liposomes made with two different lipids 
based liposomes (SPC or DPPC) and nebulized via the Pari Sinus or the Pari Sprint 
nebulizers to target sinuses, was evaluated in vitro using a nasal cast attached to a twin 
impinger.  
6.1.5.1. Nebulization of SPC-based formulations 
Effervescent liposomes made with SPC and loaded with BDP produced stable liposomes, 
with an improved disintegration time compared to conventional non-effervescent 
proliposomes. Effervescent formulations using mannitol or salt carriers with or without 
cholesterol were investigated for their suitability for nebulization. The nebulization time 
to dryness ranged from 21–23 min. The nebulization time was not affected by cholesterol 
regardless of carrier type. Sputtering time ranged from 1–2 min for all formulations.   
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The VMD of aerosols ranged from 3–4 µm. The VMD of salt formulations were smaller 
when compared to mannitol formulations. Mannitol-based formulations with cholesterol 
compared to salt formulations with cholesterol were significantly different (P≤0.05). The 
aerosol mass output for control water was (66.68+1.582) while for effervescent mannitol 
with cholesterol formulations it was (74.28+ 4.90) (P≤0.05).  Salt with cholesterol gave 
the highest aerosol mass output. The effervescent property was observed to improve 
aerosol mass output rate. Cholesterol did not seem to have any impact on aerosol mass 
output. Effervescent mannitol with cholesterol liposomes loaded with BDP with liposome 
size of 5.14+ 0.49 µm, was the most appropriate in terms of the liposome’s zeta potential, 
span, aerosol size, and liposome entrapment. However, it had less FPF of 59%, while salt 
with cholesterol showed an FPF of 77.44+3.25 (P≤0.05). Therefore, it can be concluded 
that SPC-based effervescent proliposomes produce liposomes and aerosols suitable for 
drug delivery to the sinuses via a Pari Sinus nebulizer and does not show any negative 
impact compared to conversional liposomes.  
6.1.5.2. Nebulization of DPPC-based formulations   
BDP effervescent liposomes made with a DPPC lipid also produced stable liposomes 
suitable for delivery via a Pari Sinus nebulizer. The effervescent property and improved 
disintegration property did not hamper liposomal formulation to produce aerosols with 
characteristics to deliver drug to the sinuses of the cast. DPPC-based liposomal 
formulations made with mannitol and salt incorporating cholesterol were used due to high 
drug entrapment and a suitable liposome size to compare with liposomes and aerosols 
produced by SPC-based formulations.  
The nebulization time of DPPC-based mannitol with cholesterol effervescent liposomes 
formulation took slightly longer to nebulize compared to a salt-based formulation and 
control water. Effervescent mannitol with cholesterol formulation compared to mannitol 
with cholesterol conversional formulation demonstrated a significant difference in 
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nebulization time (p≤0.05). A change in lipid from SPC to DPPC affected nebulization 
time, with the DPPC sample taking a longer time to dry. 
The aerosol size of liposomes was between 5–6 µm and not hampered by effervescent 
property or choice of carrier. However, the aerosol size was slightly higher than SPC-
based formulations. The span of DPPC-based formulations was notably high compared 
to SPC-based formulations.  
Choice of carrier, mannitol or salt, did not affect the fine particle fractionation of DPPC-
based liposomal formulations aerosols. However, a change of lipid from SPC to DPPC 
caused a lowering in FPF of DPPC to 50–55%. A difference in carrier did not affect the 
aerosol mass output (%). SPC-based formulations performed better in terms of aerosol 
mass output (%) compared to SPC formulations. However, SPC liposomes had less drug 
entrapment compared to DPPC liposomes; thus, DPPC formulations, owing to the high 
drug entrapment, would be more appropriate for drug delivery to the sinuses.  
Effervescent proliposomes of mannitol with cholesterol retained a higher entrapment of 
61.27+3.90%, when compared to non-effervescent liposomal formulations. This indicates 
that the effervescent property can improve the ability of liposomes to withstand shear 
stress. The choice of carrier did not affect the liposome’s ability to withstand shearing. 
The mass output rate was mainly affected by nebulizer type. Both mannitol with 
cholesterol and salt with cholesterol made with a DPPC lipid were chosen for further 
studies with the nasal cast, due to high performance in drug entrapment and aerosol 
characteristics. DPPC was overall a better choice of lipid for novel effervescent BDP-
loaded formulations, while the SPC lipid performed well with the hydrophilic drug XH. 
Data from salt-based effervescent liposomes made with DPPC indicate the possibility of 
a sugar-free, stable liposome formulation with high drug entrapment for further work. 
The Pari Sinus nebulizer produced aerosols for drug delivery with effervescent liposomal 
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formulations; therefore, nasal cast work would help identify if the deposition area was 
affected by carrier type, cholesterol inclusion and nebulizer type. 
 Nasal cast and impinger studies using Pari Sinus and Pari Sprint nebulizer  
Chapter 5 of this thesis focused on factors affecting nasal drug deposition patterns within 
the nasal cavity and sinuses. The Pari Sinus pulsating aerosol system’s snake-like 
movement was compared to a nebulizer with the non-pulsating aerosol system of the Pari 
Sprint nebulizer. A novel system of a Sar-Gel® (water indicating paste) coated clear nasal 
cast fixed to a two-stage impinger system was set up to analyze drug deposition within 
the nasal cavity. This system proved to be simple, effective, and a cheap colour-based 
method to help identify deposition patterns in a matter of minutes. DPPC lipid-based 
mannitol with cholesterol and salt with cholesterol effervescent liposomes were nebulized 
via both nebulizers to compare drug deposition within the nasal cavity as a whole and the 
sinuses.  
Data indicate that drug deposition with the Pari Sinus nebulizer indicates a large nasal 
cavity deposition area of 132.71±47.42 cm2 while both non-effervescent and effervescent 
formulations demonstrated less drug deposition area. Effervescent liposomal 
formulations based on mannitol (107.16±5.50 cm2) and salt (107.94±12.05 cm2) 
demonstrated similar drug deposition areas within the nasal cavity, indicating that the 
choice of carrier did not affect the deposition patterns. The effervescent property tended 
to improve nasal drug deposition when compared to non-effervescent formulations using 
the nasal cast model. However, mannitol with cholesterol effervescent formulation was 
observed to increase drug deposition within sinuses to 48.45±2.75 cm2 via the Pari Sinus 
nebulizer.   
Similarly, the difference in carrier, mannitol or salt, did not affect drug deposition within 
the nasal cavity via the non-pulsating aerosol system Pari Sprint nebulizer. By contrast, 
the Pari Sprint nebulizer had a lower drug deposition than the control water and had a 
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significant increase in drug deposition when a non-effervescent mannitol with cholesterol 
formulation was nebulized (P≤0.05). Effervescent formulations based on salt and 
cholesterol were noted to have a higher drug deposition with the Pari Sprint nebulizer. 
Sinus drug deposition was observed to be highest at 48.45±2.75 cm2 with pulsation in the 
Pari Sinus nebulizer, compared to a drug deposition of 35.52±11.11 cm2 for effervescent 
mannitol with cholesterol formulation for the Pari Sprint nebulizer. This indicates that 
even though the drug deposition within the nasal cavity was possible with the non-
pulsating system of the Pari Sprint nebulizer, the “zigzag” movement of the Pari Sinus 
nebulizer improves drug deposition within the sinuses compared to the Pari Sprint 
nebulizer. It can be concluded that the Pari Sinus nebulizer with pulsating aerosol system 
had a higher drug deposition when compared to the non-pulsating nebulizer Pari Sprint. 
Drug entrapment studies within the nasal cast and two-stage impinger study demonstrated 
that the effervescent mannitol with cholesterol liposome formulation had a high 
entrapment efficiency of 47.6±6.60% compared to the non-effervescent liposome 
formulations with entrapment efficiency of 33.06±2.06 % (P≤0.05).  
The addition of effervescent liposomes and mannitol as a carrier improved drug 
deposition in the sinuses when nebulization took place via the Pari Sinus nebulizer; 
however, drug deposition in the nasal cavity as a whole was not improved. Liposomes 
may improve drug deposition overall by penetration through the nasal cavity; this cannot 
be shown using the in vitro cast model. A nasal cast with the addition of sinus cavities in 
all areas will improve demonstrations of sinus drug deposition as a fast, efficient, and 
cheap alternative to existing technologies; this should constitute part of the future studies  
Overall, the whole study demonstrated that mannitol was a better choice as a proliposome 
carrier compared to salt. Novel effervescent liposome formulations were made with 
mannitol or salt effervescent to generate stable deliverable liposomes. Effervescence did 
not have a negative effect on liposome size, drug entrapment, or aerosol characteristics 
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compared to non-effervescent liposomes. In fact, effervescence greatly shortened the 
disintegration time of the formulation with no need for shaking or vortex mixing to 
generate liposomes. DPPC demonstrated to be a better phospholipid for effervescent 
proliposomes loaded with BDP. Cholesterol improved liposomes’ stability, physical 
strength of liposome bilayers, and drug deposition profile in vitro. Inclusion of the 
mucoadhesive agent’s alginic acid or chitosan hampered drug entrapment of effervescent 
liposomes; thus, effervescent liposome formulations performed better when no 
mucoadhesive was included. Effervescent liposomes made with SPC proved able to 
entrap hydrophilic drugs such as Xylometazoline hydrochloride. A colour-based, simple, 
cheap, efficient, and unique system was developed for investigations of drug deposition 
within the nasal cavity and sinuses by incorporating a transparent nasal cast coated with 
Sar-Gel® (water indicating paste) attached to a two-stage impinger. Proliposome 
technology was established for drug delivery to the nasal cavity and sinuses of the nasal 
cast used. The pulsation aerosol system of the Pari Sinus nebulizer proved to be more 
appropriate for drug deposition within the sinuses compared to the non-pulsating Pari 
Sprint nebulizer. Effervescent liposomes made with mannitol and cholesterol with DPPC 
performed best overall, out of all formulations tested in this study.  
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6.2. Future Studies  
Effervescent liposomes made with SPC or DPPC lipids were analyzed upon 
disintegration for liposomes size, span, zeta potential, and drug entrapment of BDP. The 
physical and chemical stability of liposomes should be evaluated in three different 
temperatures over a duration of three months (Panwar et al., 2010). 
Isotonicity of a solution is an important indicator to understand its suitability within the 
body for drug delivery. Osmole concentration of a solution should ideally be the same as 
the solute concentration of a cell; if not, the cells could either swell or shrink.  
Formulations, therefore, should be tested with a haemolysis test as described in Das 
(1980). 
Investigation of the effervescent liposome behaviour in vivo is necessary to understand 
its capacity to deliver drugs to the sinuses. Fluorescent tagging or 81mKr-gas inhalation 
imaging could be used to understand the deposition within the nasal and sinuses cavity 
with effervescent liposomes similar to the study done by Moeller et al. (2009). 
A drug release study of effervescent liposomes in vitro with dialysis method or any other 
method should be conducted (Hua, 2014). A drug release study could help identify if rate 
of drug release is affected by the presence of salts, and if addition of cholesterol is 
favourable for sustaining the drug release from liposomes in the presence of salt or 
mannitol. 
Finally, the nasal cast impinger system could be further improved by the addition of all 
sinuses to the nasal cast and coating of sinuses alone, to understand drug deposition within 
the sinus more accurately. Drug deposition could further be tested in different head tilting 
positions to understand if nebulization and drug delivery to the sinuses might be affected 
by position of the head when nebulization is performed.   
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